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Summary 
Human Immunodeficiency Virus type 1 (HIV-1) is the major causative agent of the 
AIDS epidemic. Several independent transmission events from monkeys to humans 
gave rise to different viral lineages that differ with respect to their ability to encode 
for accessory gene products that facilitate virus replication in the infected host. In 
particular, the vpu gene is unique to the HIV-1/SIVcpz lineage and not present in 
HIV-2 and most SIV isolates. Vpu is not essential for HIV-1 replication but 
intensively modulaties host immune components such as the HIV-1 primary entry 
receptor CD4, whose cell surface levels are reduced by Vpu. Uniquely, Vpu promotes 
the release of mature viral particle from infected cells by antagonizing the host 
restriction factor CD317/tetherin. Moreover, Vpu interferes with NF-ƙB signalling 
triggered by CD317/tetherin and reduces the cell surface exposure of MHC class I 
(MHC-I) and natural killer cells ligand NTB-A. While these Vpu activities have been 
established ex vivo, their relevance for HIV pathogenesis in the infected host remains 
unclear.  
In an attempt to correlate Vpu function with the clinical outcome of HIV-1 infection, 
we assessed here the functions of vpu alleles derived from two distinct clinical groups 
of treatment-naïve HIV-1 infected patients. While HIV-1 elite controllers (ECs) 
naturally control virus replication and keep the viral load below detectable level (<50 
copies/ml), chronic progressors (CPs) display viral loads of more than 2 000 
copies/ml. Both EC and CP Vpu alleles showed conserved and potent capacities to 
reduce cell surface levels of CD4 and CD317 molecules and to promote viral particle 
release. In contrast, EC Vpu alleles were less activitive in MHC-I and NTB-A 
downregulation than CP Vpu alleles and the antagonism of NF-kB signalling was not 
conserved in both patient groups. Sequence analysis of our Vpu alleles revealed the 
enrichment of killer-cell immunoglobulin-like receptor (KIR) KIR2DL2-associated 
footprints in EC Vpus, this polymorphism however did not explain the functional 
difference between EC and CP Vpus. 
These results suggest downregulation of cell surface CD4 and antagonism of the 
particle release restriction by CD317 as important in vivo functions of Vpu. Since 
attenuated Vpu alleles were more frequent in ECs than in CPs, at least a subgroup of 
EC Vpu alleles may be under selection pressure resulting in adaptation of Vpu that is 
associated with a mild fitness cost. Whether the functional constrains of EC Vpu 
alleles contribute to the suppression of HIV-1 in these patients warrants further 
investigation.  
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Zusammenfassung 
Das humane Immundefizienz-Virus 1(HIV-1) ist der Haupterreger der 
AIDS-Epidemie. Mehrere unabhängige Übertragungsereignisse von Affen zum 
Menschen sind der Ursprung verschiedener viraler Stämme, die sich in Bezug auf ihre 
Fähigkeit, für akzessorische Genprodukte zu kodieren, welche die virale Replikation 
im infizierten Wirt erleichtern, unterscheiden. Insbesondere das vpu Gen ist ein 
spezielles Charakteristikum der HIV-1/SIV cpz Linie, und ist nicht in HIV-2 und den 
meisten SIV Isolaten vorhanden. Vpu ist zwar für die HIV-1 Replikation nicht 
essentiell, aber es moduliert intensiv Immunkomponenten des Wirts, wie den 
Haupteingangsrezeptor CD4, dessen Zelloberflächenlevel durch Vpu reduziert 
werden. Vpu fördert auf einzigartige Weise die Freisetzung von reifen viralen 
Partikeln von infizierten Zellen, indem es dem wirtseigenen Restriktionsfaktor 
CD317/Tetherin entgegenwirkt. Darüber hinaus interferiert Vpu mit CD317/Tetherin 
vermittelter Signaltransduktion und reduziert die Zelloberflächenexposition von MHC 
Klasse I (MHC-I) und dem natürliche Killerzellliganden NTB-A. Da diese Aktivitäten 
von Vpu ex vivo etabliert wurden, bleibt ihre Relevanz für die HIV Pathogenese im 
infizierten Wirt ungeklärt. In einem Versuch, Vpu Funktion mit dem klinischen 
Verlauf der HIV Infektion zu korrelieren, untersuchten wir hier die Funktion von vpu 
Allelen, welche aus zwei unterschiedlichen klinischen Gruppen von 
behandlungsnaiven HIV-1 infizierten Patienten stammten. Während sogenannte HIV-1 
Elite Controller (EC) die Virusvermehrung auf natürliche Weise kontrollieren und 
dabei die Viruslast unterhalb der Nachweisgrenze halten (<50 Kopien/ml), zeigen 
chronische Progressoren (CP) eine Viruslast von mehr als 2000 Kopien/ml. Sowohl 
EC als auch CP Vpu Allele zeigten ein konserviertes wirkungsvolles Vermögen, die 
Oberflächenexpression von CD4 und CD317 Molekülen zu modulieren und die 
Freilassung von Viruspartikeln zu fördern. Im Gegensatz dazu waren EC Vpu Allele 
im Vergleich zu CP Allelen weniger aktiv in der Herabregulierung von MHC-I und 
NTB-A von der Zelloberfläche und der Antagonismus der NF-ƙB Signalkaskade war 
in beiden Patientengruppen nicht konserviert. Sequenzanalysen unserer Vpu Allele 
zeigten eine Anreicherung von Killerzell Immunglobulin-ähnlichen Rezeptoren (KIR) 
KIR2DL2-assoziierten Footprints, was jedoch nicht die Funktionsunterschiede 
zwischen den EC und CP Vpu Allelen erklärt. 
Diese Ergebnisse weisen darauf hin, dass die Herunterregulierung von 
Zelloberflächen-CD4 und der Antagonismus der CD317-vermittelten Hemmung von 
Partikelfreisetzung eine bedeutsame in vivo Funktionen von Vpu darstellen. Dass 
abgeschwächte Vpu Allele in EC häufiger auftraten als in CP, deutet darauf hin, dass 
zumindest eine Untergruppe von EC Vpu Allelen unter Selektionsdruck steht, was in 
einer Anpassung von Vpu auf Kosten von leicht abgeschwächter Fitness resultiert. Es 
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benötigt weiterer Untersuchungen, ob die funktionellen Einschränkungen von EC Vpu 
Allelen zur Unterdrückung von HIV-1 in diesen Patienten beiträgt. 
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1 Introduction of HIV/AIDS 
The human immunodeficiency virus (HIV) is a retrovirus that specifically infects cells 
of the human immune system (Maddon, Dalgleish et al. 1986) (Koenig, Gendelman et 
al. 1986) (Koppensteiner, Brack-Werner et al. 2012). The most deteriorative stage of 
the HIV infection constitutes the acquired immunodeficiency syndrome (AIDS). Both 
HIV-1 and HIV-2 are the causative agents of AIDS. More than 35 million people are 
living with HIV, and over 1.5 million have died from AIDS within the WHO region 
by the year of 2012 (WHO HIV/AIDS data and statistics, 2014). HIV/AIDS is 
considered as one of the major global public health issues (WHO media centre) 
because of its devastating effect on the human immune system, while still no 
therapeutic and prophylactic vaccines are currently available (Cohen and Dolin 2013). 
Since HIV-1 is the leading cause of the global HIV/AIDS pandemic (WHO, health 
topics HIV/AIDS), the scope of this introduction remains directed toward HIV-1. 
1.1 HIV-1 Virology  
1.1.1 Genome and structure of HIV-1 
HIV-1 is classified in the genus Lentivirus of the family Retroviridae based on its 
morphological, genetic and biological properties (Karlsson Hedestam, Fouchier et al. 
2008). It specifically infects human immune cells including CD4+ T cells, 
macrophages, and dendritic cells (Maddon, Dalgleish et al. 1986) (Cunningham, 
Donaghy et al. 2010) (Koppensteiner, Brack-Werner et al. 2012). HIV-1 is an 
enveloped virus possessing two identical copies of positive sense RNA genome. Each 
copy contains nine open reading frames encoding fifteen proteins, as well as two long 
terminal repeats (LTR) 5’-LTR and 3’-LTR serving as regulatory elements for the 
expression of viral RNA and proteins (Frankel and Young 1998) (Sierra, Kupfer et al. 
2005) (Watts, Dang et al. 2009). The three largest reading frames of the HIV-1 
genome encode three poly-proteins, which can be processed into viral structural 
constituents. The group specific antigen (Gag) is cleaved by the viral protease into the 
viral matrix (p17, MA), the capsid (p24, CA) and the nucleocapsid (p7, NC), which  
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Figure 1: Genome organization and structure of HIV-1. A: Organization of the 
HIV-1 genome (strain HXB2). HIV-1 RNA contains 9719 base pair nucleic acids 
(Accession number K03455.1). Nine open reading frames are shown as rectangles and 
the cleavage sites of Gag, Pol and Env polyproteins are shown as dash lines in each 
rectangle. Tat has two isoforms and rev gene is located in two exons. The numbers in 
the upper left corner represent the starting position of the gene and the numbers in the 
lower right corner record the ending position of the genes. B: Graphical depiction of a 
mature HIV-1 virion organization. HIV-1 virion consists of a virion core and an 
envelop membrane. The core is shelled by HIV-1capsid proteins. Two positive RNA 
strands in association with nucleocapsid proteins, as well as reverse transcriptase, 
integrase, and protease are encapisudated into the core. And the core is further shelled 
by HIV-1 matrix proteins, which is located in the interface of host-cell-derived 
membrane with the insertion of viral spikes composed by Env (SU and gp120) 
proteins. 
(A: adapted from Los Alamos National Laboratory database; B: adapted from 
Harriet L. Robinson, Nature reviews. Immunology, 2002(Robinson 2002) ) 
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are the major structural components of the virion core (Figure 1B). The processing of 
polymerase (Pol) polyprotein produces the enzymatic proteins including protease 
(p11, PR), reverse transcriptase (p66/p51, RT) and integrase (p31, IN), all of which 
remain encapsulated in the virion core, together with the viral RNA genome (Freed 
2001) (Robinson 2002). Cleavage of the envelop (Env) protein by cellular protease 
generates the transmembrane protein (TM, gp40) and the surface glycoprotein protein 
(SU, gp120), which are required for the formation of the surface spike (Freed 2001). 
The Env spikes are inserted into the host cell-derived lipidprotein-rich membrane 
which surrounds the virion core (Brugger, Glass et al. 2006) (Robinson 2002). 
Beyond the genes common to all retroviruses, HIV-1 possesses two regulatory genes 
tat and rev essential for the HIV-1 gene expression, as well as four multifunctional 
accessory genes vpr, vif, vpu, and nef being mainly responsible for antagonizing host 
restriction factors (Strebel 2013). Except for Vpu, the rest are incorporated to HIV-1 
particles (Sherman, de Noronha et al. 2003). All HIV-1 gene products have elaborate 
functions in the proceeding of the HIV-1 replication cycle and in circumventing 
restriction factors in the host environment. 
 
1.1.2 Replication Cycle of HIV-1 
The replication of HIV-1 can be arbitrarily divided into successive steps which are 
deeply networked. HIV-1 exploits not only the viral components but also a great 
number of host cellular factors for its own replication. The major events in a step of 
the replication cycle, together with the critical viral and accompanying cellular factors 
involved, are briefly summarized on the basis of the relevant literatures and reviews, 
and rendered in graphic form as shown in Figure 2. 
Viral Entry 
The entry of HIV-1 into a susceptible target cell is the first step toward a new 
infection. It is a coordinated multi-step process. Initially the HIV-1 attaches itself to 
the target cell via specific interactions of Env with adhesion factors such as α4β7 
integrin, and non-integrin DC-SIGN, or via unspecific interactions of positively 
7 
 
charged Env with negatively charged cell surface proteoglycans (Kuritzkes 2009) 
(Friedrich, Dziuba et al. 2011). The attachment is followed by the high-affinity 
binding of Env protruding protein gp 120 with its specific primary receptor CD4, 
which leads to the exposure of the chemokine receptor binding sites of gp120. And the 
binding of gp 120 with chemokine receptor then triggers the membrane fusion 
machinery in the gp41 subunit which pulls the viral and cellular membranes together 
termed as fusion (Wilen, Tilton et al. 2012). The main chemokine receptors that HIV-1 
utilizes are CCR5 and CXCR4 (Deng, Liu et al. 1996) (Feng, Broder et al. 1996), and 
HIV-1 can be classified into R5 HIV, X4 HIV and R5X4 HIV based on the chemokine 
receptor usage (Berger, Doms et al. 1998) (Berger 1997) (Bleul, Wu et al. 1997). In 
addition to the receptor-mediated fusion at the plasma membrane, HIV-1 could also 
infect cells via endocytosis and fuse with intracellular compartments (Miyauchi, Kim 
et al. 2009) (Pritschet, Donhauser et al. 2012). At the site of fusion occurs, a virion 
core is released into the host cell cytoplasm and then proceeds into the next step of its 
life cycle. 
Reverse Transcription  
After the viral core is released into the cytoplasm, the viral capsid first needs to be 
dissociated, a process termed as uncoating. It is known that uncoating is a dynamic 
process and is critical for the reverse transcription of viral RNA, while the timing and 
cellular factors remain poorly understood mainly due to the lack of available methods 
to label capsid molecules without perturbing the function of the viral capsid (Arhel 
2010) (Hulme, Perez et al. 2011). Uncoating ultimately results in the rearrangement of 
the virion core to form the reverse transcription complex (RTC), which contains 
genomic RNA, viral proteins MA and Vpr and various host factors such as 
tRNA(Lys)3 primers (incorporated into the virion during assembling) and the 
cAMP-dependent protein kinase (Lanchy, Isel et al. 2000) (Arhel 2010) (Karn and 
Stoltzfus 2012) (Giroud, Chazal et al. 2013). RTC is associated with actin 
microfilaments of the host cell cytoskeleton where the reverse transcription mainly 
occurs (Bukrinskaya, Brichacek et al. 1998). The reverse transcription is initiated with 
the binding of denatured primer tRNA(Lys)3 and the viral RNA (Wakefield, Wolf et al. 
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1995) (Mak and Kleiman 1997), then followed by a transcription of the viral RNA 
from the binding site to the LTR into a small fraction of DNA, while simultaneously the 
transcribed region of the template RNA is degraded by the RNase H activity of HIV-1 
RT. Then the resulting DNA fraction is transferred to the complementary region of the 
other RNA template thereby completing the synthesis. This RNA template is again 
degraded once it is copied by RNase H, but as the RNA polypurine tract (PPT) is 
resistant to the degradation it primes the other DNA synthesis by using the first strand 
of RNA as the template. All the remaining RNA is removed by RNase H. The double 
strands of DNA are then processed to be integrated into the host chromosomal DNA or 
form stable DNA circles that are not integrated into the host genome (reviewed in 
(Warren, Warrilow et al. 2009; Warrilow, Tachedjian et al. 2009; Arhel 2010) (Sloan 
and Wainberg 2011)). 
Integration 
Once the viral DNA is synthesized in the cytoplasm, it stably associates with the 
integrase (IN), which form the pre-integration complex (PIC) together with other viral 
and cellular proteins (Turlure, Devroe et al. 2004) (Suzuki and Craigie 2007). It is a 
prerequisite for the integration that PIC is transported into the nucleus to encounter 
the cellular DNA (Marchand, Johnson et al. 2006) (Craigie and Bushman 2012) The 
nuclear envelope lamina together with the associated proteins such as the well 
characterized emerin and barrier-to-auto-integration factor (BAF) mediate the entry of 
PIC into the nucleus and the proper localization within the nucleus (Jacque and 
Stevenson 2006) (Li and Craigie 2006). The integration of viral DNA into the host 
chromosomal DNA occurs precisely at the termini of the viral DNA but can also take 
place at many other locations in the host genome (Di Nunzio 2013). The linkage of 
viral integrase (IN) with the host chromatin via the co-activator lens epithelium 
derived growth factor (LEDGF) is essential for the integration (Llano, Saenz et al. 
2006) (Shun, Raghavendra et al. 2007). Two main actions are involved in this process. 
Firstly, IN catalyzes the removal of two nucleotides from each of the 3′ ends of the 
viral DNA in the region of LTR and generates the CAOH 3’-hydroxyl, and this 
provides the nucleophiles to the 5′-phosphates of the chromosomal DNA which is 
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then captured and cut by IN as well (Suzuki, Chew et al. 2012). Subsequently each 
junction with the un-ligated nucleotides is repaired by the cellular DNA repair 
machinery, which is considered as being a limiting step for integration (Van 
Cor-Hosmer, Kim et al. 2013) (Brady, Kelly et al. 2013). 
Transcription 
The proviral DNA can be transcribed into RNA by using the host cellular machineries 
during cycles of cell division along with the chromosomal DNA (Karn and Stoltzfus 
2012). The transcription is initiated by the binding of HIV-1 LTR with the host RNA 
polymerase II (RNAP II). HIV-1 Tat and the cellular transcriptional elongation factor 
P-TEFb play a critical role in enhancing the transcription efficiency via a mechanism, 
in which Tat binds with the transactivation responsive region (TAR) located 
downstream of LTR and directs P-TEFb to the nascent RNA polymerases for the 
transcription elongation (Frankel 1992) (Marshall and Price 1995). The transcription 
efficiency is tightly regulated via the interaction of the various binding sites 
embedded in LTR with corresponding cellular factors such as NF-ƙB (Burnett, 
Miller-Jensen et al. 2009) (Krishnan and Engelman 2012).  
mRNA Processing and Nucleus Export 
Along with the generation of nascent HIV-1 pre-mRNA transcripts, they are modified 
by capping 5’LTR with 7meGpppG and adding poly-adenyl at 3’LTR which are 
mediated by cellular enzymes and HIV-1 Tat (Chiu, Ho et al. 2002) (Wilusz 2013). 
Further, the modified pre-mRNA transcripts undergo extensive and complex 
alternative splicing to convert the premature mRNAs into the full range of mature 
multiple-spliced RNA species which include three major classes: 1) unspliced RNAs 
functioning as genomic RNA packaged into virions and the mRNAs for the Gag and 
Gag/Pol polyprotein precursors; 2) partially spliced mRNAs encoding Env/Vpu, Vif, 
Vpr and a truncated 72 aa form of Tat; 3) completely spliced mRNAs translating into 
the HIV-1 regulatory proteins Tat, Rev, and Nef (Purcell and Martin 1993; Stoltzfus 
and Madsen 2006) (Karn and Stoltzfus 2012). The processing and regulation of HIV-1 
mature mRNAs are dependent on a number of cis-acting elements within the HIV-1 
transcript and complex cellular factors referred to as the spliceosome (Kim and Yin 
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2005) (Chen and Manley 2009). The splicing patterns are distinct among different 
HIV-1 strains and clinical isolates, so the mRNAs splicing has a critical role in HIV-1 
infectivity (Purcell and Martin 1993; Ocwieja, Sherrill-Mix et al. 2012).  
 
 
 
 
Figure 2 Schematic view of HIV-1 replication cycle, critical accompanying 
cellular factors and host restriction factor of HIV-1 replication and HIV-1 drugs. 
This graph contains four sets of information: 1) Each step of the HIV-1 replication 
cycle is marked as numbers in order; 2) The critical accompanying cellular factors for 
the HIV-1 replication are indicated: CD4 and CCR5 for viral entry, LEDGF for 
integration, RNA Pol II for transcription, and ESCRT for viral protein transport; 3) 
Host restriction factors: TRIM5, APOBEC3G, SAMHD1, CD317 and SLFN11. 4) 
Drugs against HIV-1: inhibitors for fusion and CCR5, revers transcription inhibitors 
(NRTIs and NNRTIs), integrase inhibitor (INSTIs) and protease inhibitors. 
(Adapted from Alan Engelman & Peter Cherepanov, Nature reviews. 
Microbiology, 2012 (Engelman and Cherepanov 2012)) 
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To translate the mature mRNA into viral proteins, they need to be transported from the 
nucleus to cytoplasm. The completely spliced mRNAs are first exported constitutively 
to the cytoplasm via the endogenous cellular pathway used by host cellular mRNAs as 
well. However, the transport of HIV-1 unspliced and partially spliced mRNA species 
relies on the HIV-1 Rev by interacting with the Rev-responsive element (RRE) 
located in the env gene (Sodroski, Goh et al. 1986). This transport pathway is 
regulated by the level of Rev and the unspliced and incompletely spliced mRNAs in 
the nucleus (Malim, Hauber et al. 1989). Overall the maturation of HIV-1 mRNA 
transcripts and the following transport are dynamically and tightly regulated. 
Translation of HIV-1 mRNAs 
After entering the cytoplasm, HIV-1 exploits the cellular machineries to translate 
mRNAs to viral proteins (Freed 2001) (Friedrich, Dziuba et al. 2011). This process 
basically includes three phases: initiation, elongation and termination, which require 
the concerted interactions of the three classes of RNA (ribosomal RNA, transfer RNA 
and messenger RNA) with cellular translation factors in a timely manner (Chamond, 
Locker et al. 2010). The initiation is considered as the rate-limiting step, and there are 
distinct pathways according to the ribosome scanning model (Bolinger and 
Boris-Lawrie 2009). The conventional way is dependent on the recognition of the 
5’cap structure by the eukaryotic initiation factor 4E (eIF4E) and the recruitment of 
43S pre-initation complex which is consisting of the 40S ribosomal subunit, eIF3 and 
the ternary complex (eIF2, GTP, Met-tRNA)(Kozak 1989; Merrick 2004). The 
alternative initiation pathways involve the internal ribosome entry segment (IRES) 
and posttranscriptional elements (PCEs) in the viral gene sequence (Pelletier, Kaplan 
et al. 1988; Hellen and Sarnow 2001) (Chamond, Locker et al. 2010). The ratio of 
translated proteins needs to be regulated for the successful HIV-1 virion production. 
HIV-1 utilizes the ribosomal frame shifting program to produce the balanced ratio of 
Gag/ Pol polyproteins, which is generated when translating the ribosome shift into the 
-1 reading frame at a site near the 3′ end of the gag open reading frame, and then go 
on to translate the pol gene (Parkin, Chamorro et al. 1992) (Brakier-Gingras, 
Charbonneau et al. 2012). 
12 
 
Assembly, Budding, and Maturation  
The viral proteins, together with the viral genome RNA, must be directed to the site of 
virion assembly. HIV-1 virion assembly occurs at the plasma membrane and is 
fundamentally mediated by the HIV-1Gag/Pol polyprotein precursor (Gheysen, Jacobs 
et al. 1989) (Adamson and Freed 2007). The main events involved during this process 
are as follows: Gag N-terminal MA region binds the plasma membrane and recruits 
the viral Env protein. The central CA domain mediates the protein–protein 
interactions for the creation of the conical shell of the viral core. NC captures the viral 
genome via direct interactions with the RNA packaging sequence. The Gag p6 region 
recruits the late assembly motifs which could recognize the endosomal sorting 
complexes required for the transport machinery (ESCRT) of the host cell and 
therefore facilitates the budding of the immature assembled virion from the lipid 
membrane (Morita, Sandrin et al. 2007) (Bieniasz 2006) (Van Engelenburg, Shtengel 
et al. 2014). Along with the budding, the viral protease embedded in the Gag/Pol 
polyproteins is activated and cleaves Gag/pol into their own constituents. The 
proteolysis of Gag/Pol triggers conformational changes of both the virion structure 
and the RNA genome, which therefore leads to viral maturation (Adamson and Freed 
2007) (Ganser-Pornillos, Yeager et al. 2008) (Ivanchenko, Godinez et al. 2009; 
Sundquist and Krausslich 2012). To this point, the virus completes its replication 
cycle and new infectious viruses are generated. 
 
1.1.3 Host restriction factors of HIV-1 replication 
In contrast to the accompanying cellular machineries adding HIV-1 replication, five 
host cellular proteins were identified as the HIV-1 restriction factors which can 
intrinsically suppress HIV-1production and can be antagonized by HIV-1 proteins, as 
shown in Figure 2. The first identified one is the tripartite-motif-containing 5α 
(TRIM5α), a component of cytoplasmic body, has an effect on the uncoating of viral 
capsid and reverse transcription (Stremlau, Owens et al. 2004). HIV-1 employs its MA 
to overcome this restriction (Stremlau, Owens et al. 2004) (Huthoff and Towers 2008). 
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APOBEC3, one of the apolipoprotein B mRNA-editing enzyme catalytic 
polypeptide-like family proteins, could be encapsidated into viral particles and restrict 
reverse transcription by editing sense-stranded DNA in the absence of HIV-1 Vif 
(Sheehy, Gaddis et al. 2002) (Goila-Gaur and Strebel 2008). The membrane protein 
CD317 acts on the release of mature virions, which is counteracted by the accessory 
protein Vpu. Another two host restriction factors are recently identified. SAMHD1 
restricts the ability of HIV-1 to infect the dendritic and other myeloid cells and this 
restriction can be counteracted by SIVsmm/HIV-2 lineage which encodes the 
accessory protein Vpx (Lahouassa, Daddacha et al. 2012). The target step is again the 
reverse transcription by lowering the concentrations of intracellular deoxynucleoside 
triphosphates (dNTPs) to below the threshold needed for the synthesis of the viral 
DNA by reverse transcriptase (RT) (Lahouassa, Daddacha et al. 2012) (Ayinde, 
Casartelli et al. 2012). Last but not least, SLFN11, whose viral antagonist is not 
identified yet, acts at the point of virus protein synthesis by exploiting the unique viral 
codon bias towards A/T nucleotides (Razzak 2012).  
 
1.1.4 HIV-1 Latency 
One striking feature of HIV-1 infection is that it can fall into the latency stage during 
the life cycle. There are two situations of latency depending on the afferent or the 
efferent stage of the replication cycle. The afferent one exists as the pre-integration 
complex which is generated after transcription in the cytoplasm and mainly locates in 
the resting CD4+ T lymphocytes. Once the CD4+ T lymphocytes become activated, the 
latent pre-integration complex produces infectious viruses and so they are considered 
as the major HIV-1 reservoir. The efferent one refers to the integrated HIV-1 provirus 
of which the transcription is ceased regardless of the activation status of the infected 
cell (Butera 2000) (Jordan, Bisgrove et al. 2003). HIV-1 latency limits the benefits 
from the highly active antiretroviral therapy (HAART) and therefore puts a 
formidable obstacle for eradiation of HIV-1 in resting T cells. However, the 
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mechanisms behind need to be further elucidated for developing the therapeutic 
strategies. 
 
1.1.5 HIV-1 Genetic Diversity and Subtypes 
Clinical HIV-1 isolates represent great genetic diversity which is up to 30%, and this 
sets a formidable obstacle to control HIV/AIDS (Spira, Wainberg et al. 2003) (Santoro 
and Perno 2013). There are four types of HIV-1: main (M), outliner (O), non-M and 
non-O (N), and proposed (P), which have different geographic distributions but show 
similar symptoms (Robertson, Anderson et al. 2000) (Vallari, Holzmayer et al. 2011) 
(Santoro and Perno 2013). The M group which is responsible for the globe HIV/AIDS 
epidemic can be split further into nine clades (A-J) (Perrin, Kaiser et al. 2003) 
(Wainberg and Brenner 2012). Besides, over 58 HIV-1 circulation recombinant forms 
(CRF) have been identified (HIV lanl data base; 
http://www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html). Several factors 
contribute to the high variability. First of all, HIV-1 RT is an error-prone enzyme lack 
of proofreading functions. It generates much mutation in the HIV-1 genome at a rate 
of 1:2 000-10 000 (Mansky 1998). And further, the recombination of the mutated 
genome increases the genetic variability (Hu and Temin 1990) (Moutouh, Corbeil et 
al. 1996). Last but not least, the rate of HIV-1 replication being high, this gives rise to 
the immune escape mutations due to selection pressure from the host. However, the 
rate of genetic diversity varies among the different regions of HIV with a relatively 
low level in pol but a much higher level within the region of vpu/env (Santoro and 
Perno 2013). Overall, the genetic diversities between HIV-1 isolates, especially 
specific regions, lead to changes of antigenicity with impediments for the 
development of HIV-1 vaccines (Santoro and Perno 2013). 
 
1.2 HIV/AIDS Epidemics 
Since the recognition of AIDS in 1981 and the identification of its causative agents 
HIV-1 and HIV-2 in 1983, HIV/AIDS becomes a worldwide HIV/AIDS pandemic. 
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According to the latest data the world health organization (WHO) released by 2012, 
approximately 36 million people live with HIV, including about 2.0 million 
adolescents. 1.6 million people died of HIV/AIDS related diseases worldwide by 
2012. Currently the global prevalence is around 0.8%, with the highest ratio in Africa 
reaching up to 4.8% (WHO, http://www.who.int/topics/hiv_aids/en/). More than four 
decades of intensive basic and translational research make the treatments against 
HIV/AIDS available. However, the development of vaccines remains confined mainly 
due to the complicated properties of HIV-1. With an increase of preventive 
interventions and HIV-1 testing and counselling, as well as the global cooperation 
between nations, the new HIV-1 incidents have declined with the result, that the 
quality of life for people with contracted HV-1 is seen to improve.  
 
 
 
Figure 3: HIV/AIDS distribution in WHO region. The number of people living 
with HIV is recorded corresponding to different regions marked with different colours 
in the map (The colours do not apply into any opinion.) (Adapted from WHO, 2013) 
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1.3 HIV-1 Pathogenesis  
1.3.1 Acquisition of HIV-1 Infection 
HIV-1 can be transmitted from an infected person to another via several channels: 1) 
mucosal surfaces of the oropharynx, rectum, and genital. They can trap antigens and 
virus particles for they are rich in langerhans cells; 2) accidental blood transfusion 
from HIV infected donors; 3) mother-to-infant. A number of factors contribute to the 
risk of HIV infection. The risk of infection via the blood transfusion approaches 
100%. Trans-mucosal infection risks vary according to the site of exposure, with the 
highest risk through the rectum and the lowest risk across the oral mucosa. Beyond 
that, the high levels of plasma HIV RNA enhance mother-to-infant transmission of 
HIV. The acquisition of HIV infection is also influenced by the viral load of infected 
donor individual. The viral load is defined as the viral titres in the blood and described 
as the number of copies of HIV genetic RNA or DNA per millilitre (copies/ml) (CDC, 
HIV/AIDS; http://www.cdc.gov/hiv/default.html). Especially, the viral set point, 
defined as the stable level of viral loads after acute phage of HIV-1 infection, is good 
marker to predict the probability of transmission and the disease progression (Fraser, 
Hollingsworth et al. 2007).  
 
1.3.2 General Clinical Courses of Untreated HIV-1 Infection  
HIV infection is typically classified as a three-stage process ranging from an initial 
infection to the development of AIDS based on the criteria put forward by the Centers 
for Disease Control and Prevention (CDC).  
Acute Stage  
The acute stage of HIV-1 infection is defined as the time period from the initial 
acquisition of HIV-1 to the development of an antibody response detectable by 
standard tests (McMichael, Borrow et al. 2010). This stage may last from a few days 
to several weeks, with the mild or severe flu-like symptoms of fever fatigue, 
lymphadenopathy, headache, and rash. During the early period of the stage, the 
viruses replicate extensively in activated CD4+ T lymphocytes which are then 
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destructed, and this leads to high viral load and a widespread dissemination of HIV-1 
to the lymphoid organs and other sites including the dramatic fall of CD4+ T 
lymphocytes counts in the blood. Meanwhile, a reservoir of HIV-1 infected resting 
CD4+ lymphocytes is established. During the later stage, the virus titer in the blood 
falls and CD4+ lymphocyte counts begin to increase, with the development of 
HIV-1-specific CD8+ cytotoxic T cells (CTLs). After this stage, the HIV-1 set point is 
reached. This value varies widely between patients and is reversely correlated with the 
breadth and strength of HIV-1-specific CTL response. Therefore, it serves as a 
significant mark for predicting the progression of the disease and the probability of 
HIV-1transmission (Mellors, Munoz et al. 1997) (Fraser, Hollingsworth et al. 2007) 
(Huang, Chen et al. 2012). 
Asymptomatic Stage 
After the acute stage of HIV-1 infection, there is usually a relatively long period that 
is characterized by little or no clinical manifestations, and we refer it as the 
asymptomatic stage or clinical latency (Ford, Puronen et al. 2009). The time duration 
varies among infected individuals, averaging around about 10 years, even in the 
absence of treatments. This stage is characterized as the persistent immune activation 
which is fueled by the translocation of microbial products because of the CD4+ T 
lymphocytes loss resulted from the acute HIV-1 infection at the gut sites (Ford, 
Puronen et al. 2009). The immune activation has profound influences on HIV-1 
replication and the host immune system because it speeds up HIV-1 production by 
stimulating the tremendous naïve and central memory CD4+ T cell repertoire (Zhang, 
Wietgrefe et al. 2004) (Klatt, Villinger et al. 2008). The enormous HIV-1 replication, 
with its high viral mutation propensity, leads to the accelerated viral evolution, which 
is mainly responsible for the alterations in the target cellular trophism from 
CCR5-trophic to dual trophic or dominantly CXCR4 trophic strains with increased 
virulence and broader target cell trophism (Grossman, Meier-Schellersheim et al. 
2006) (Mogensen, Melchjorsen et al. 2010). From another aspect, the immune 
activation is disadvantageous to the host because of the damage to the adaptive 
immune system and the dysregulated innate immune defence. HIV-1 infection induces 
18 
 
resting T cells into increased T-cell turnover because of the enhanced immune 
activation by antigens and inflammation (Ho, Neumann et al. 1995) (Sachsenberg, 
Perelson et al. 1998) (Grossman, Meier-Schellersheim et al. 2002), as well as 
abnormalities of B-cell activation and immunoregulation (Lane, Masur et al. 1983) 
(Moir, Malaspina et al. 2001). HIV-1 infection could also causes the hyperactivation 
of innate immune system, hence leading to the production of a range of cytokines and 
chemokines, which in turn contributes to the persistent immune activation (Boasso, 
Hardy et al. 2008) (Boasso and Shearer 2008). All of these contribute to the 
progressive loss and ultimate depletion of CD4+ T lymphocytes. As summarized in the 
review of Ford, "The asymptomatic chronic phase of HIV infection is a dynamic 
balance between host and virus, the outcome of which determines an individual's 
course of disease" (Ford, Puronen et al. 2009). 
AIDS 
AIDS is the final and most deteriorate stage of the HIV-1 infection. The median time 
from initial infection to the development of AIDS among untreated patients ranges 
from 8 to 10 years (Vergis and Mellors 2000). This clinical stage is defined primarily 
on the CD4+ T lymphocytes count of below 200 cells/mm3 (CDC criteria). In the 
absence of anti-retroviral treatments (ART) to fight off the opportunistic infections 
and neoplasms the patients would die because of the HIV-induced immune deficiency. 
The initiation of ART is highly recommended to start when CD4+ T lymphocyte- 
counts remain lower than 350 cells/mm3. 
 
1.3.3 Variable Disease Progression of HIV-1 Infection 
In the absence of antiretroviral therapy, various patterns of HIV-1 related disease 
progression are recognized among HIV-1 infected individuals (Langford, 
Ananworanich et al. 2007) (Hogg, Yip et al. 2001). A variety of viral and host factors 
are associated with the rate at which the disease progresses (Shankarappa, Margolick 
et al. 1999) (Bello, Casado et al. 2005) (Fellay, Shianna et al. 2007) (Pereyra, Addo et 
al. 2008). Because of the variations of the related factors, the plasma viral load (VL)  
19 
 
CP   Asymptomatic phase duration up to 10 years  Viral set point above 2000 copies/ml in the absence of ART 
RP  CD4+ T lymphocytes below 350/mm3 within 3 years  AIDS-related symptoms within 3 years 
LTNP-EC  Asymptomatic phase duration up to 10 years  Plasma VL below 50 copies by ultrasensitive PCR in the 
absence of ART 
LTNP-VC  Asymptomatic phase duration up to 10 years  Plasma VL below 2000 copies/ml by ultrasensitive PCR in the 
absence of ART 
LTNP-NC  Asymptomatic phase duration up to 10 years   Plasma VL above 2000 copies/ml by ultrasensitive PCR in the 
absence of ART 
 
Table 1: Categories of HIV-1 infected clinical groups and the major parameter(s) 
CP: chronic progressors; RP: rapid progressors; LTNP-EC: long-term nonprogressors, 
elite controllers; LTNP-VC: long-term nonprogressors, viremic controllers; 
LTNP-NC: long-term nonprogressors, viremic non-controllers. (Adapted from 
Concepcion Casado et al. PLoS ONE, 2010) 
 
 
and CD4+ T lymphocytes count are the most widely used ones for predicting the stage 
of disease and initiating anti-retroviral treatments, which are well established 
(Langford, Ananworanich et al. 2007) (Hessol, Lifson et al. 1989) (Goujard, Bonarek 
et al. 2006). Based on the asymptomatic duration, the measurement of vial load and 
CD4+ T lymphocyte counts, HIV-1 infection is categorized into five classes as shown 
in table 1: rapid progressors (RP), chronic progressors (CP) and long-term 
nonprogressors which can be further divided into elite controllers (LTNP-EC), 
viremic controllers (LTNP-VC) and viremic non-controllers (LTNP-NC) (Casado, 
Colombo et al. 2010) (Hunt 2009). CPs progress toward AIDS within 10 years and a 
maintained viral set point above 2000 copies/ml in the absence of ART, a portion of 
around 70-80% of patients is affected. RP indicates a dramatic decline of CD4+ T 
lymphocytes below to 350/mm3 and the occurrence of AIDS-related events within a 
few years after infection. The LTNP are rare, especially for the LTNP-EC, which are 
found around 0.1% of the patients. They could naturally suppress HIV-1 replication to 
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a level below standard detection (< 50 copies/ml by ultrasensitive PCR), and therefore 
do not ultimately progress toward AIDS (Deeks and Walker 2007) (Hubert, Burgard et 
al. 2000). Shown below are the clinical evidences for CP and EC patients (Figure 4). 
The HIV-1 Vpu alleles are derived from the HIV-1 isolates circulating in these two 
clinic groups. 
 
 
 
Figure 4: Clinical records of chronic progressors and elite controllers. Viral loads 
(in red) and CD4+ T cells count (in blue) are shown. (a) Chronic progressors. three 
typical clinical stages including acute phase, clinical latency and AIDS. (b) Elite 
controllers. Following the acute phase, the natural suppression of HIV-1 takes place. 
(Adapted from Karen A. O’Connell et al. Trends in Pharmacological Sciences, 
2009) 
 
 
1.3.4 Treatments of HIV/AIDS 
No prophylactic and therapeutic vaccines against HIV are on the horizon due to its 
inherent plasticity and capacity for mutation to escape the host immune clearance and 
surveillance (Cohen and Dolin 2013). In the course of the discovery of the association 
between HIV-1 plasma viral RNA level and the progression of the disease together 
with the unmasking of the molecular mechanisms of HIV-1 replication, the 
development of drug interventions, targeting different steps of its life cycle as shown 
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in Figure 2, have been advancing. To date, an arsenal of 24 Food and Drug 
Administration (FDA)-approved small molecule anti-retroviral drugs are used for 
HIV-1 treatment regimes, which have evolved into cocktail therapies from the 
mono-therapy in the early 1900s (Arts and Hazuda 2012). The drugs target different 
steps of HIV-1 replication cycle (Figure 2), they are categorized into six classes 
according to the different interactions they target: 1) CCR5 inhibitors; 2) fusion 
inhibitors; 3) nucleotide reverse transcriptase inhibitors, NRTIs; 4) non-nucleotide 
inhibitors reverse transcriptase inhibitors, NNRTI; 5) integrase inhibitors; 6) protease 
inhibitors (PIs) (Arts and Hazuda 2012). The drug-based treatments can, in the best 
cases, control the HIV viral loads down to undetectable levels, however, not all people 
can bear the side effects and afford the high cost and, moreover, ART cannot undo the 
HIV infection and eliminate the risk of transmission. Efforts to decipher and fight 
HIV are still on the way. 
 
1.4 Natural Control of HIV/AIDS: Elite Controllers 
A rare and striking phenotype of HIV-1 infection is the natural control of HIV-1 
replication by around 0.1% of infected individuals, referred to as HIV-1 Elite 
controllers (EC) (Deeks and Walker 2007) (Hubert, Burgard et al. 2000). ECs are 
different from other patients because of three parameters: 1) Their plasma viral RNA 
load is lower than 50 copies/mm3 in the absence of anti-retroviral therapy (ART), a 
range below the detectable level of traditional PCR; 2) The CD4 counts remain 
normal and stay at a stable level with respect to these infected individuals; 3) They do 
not progress toward AIDS for at least 10 years and typically there is no need to apply 
the antiviral therapies for them (Deeks and Walker 2007) (Hubert, Burgard et al. 
2000) (O'Connell, Bailey et al. 2009). 
ECs bring the hope that HIV-1 can be controlled without antiviral therapies, which are 
expensive and require a life-time commitment. Understanding the mechanisms of 
natural HIV-1 control could contribute to the development of the vaccine design. 
Based on different cohort studies, no single virological or immunological factor is 
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defined to explain the virus control status. It’s universally admitted that heterogeneous 
factors are responsible for the natural suppression of HIV-1, including viral elements, 
host genetic backgrounds, and host immune-system properties.  
 
1.4.1 Viral Genetics in Different EC cohorts 
One possibility to cause asymptomatic HIV-1 infection and thus EC status is of 
infection with less pathogenic and attenuated viruses. Indeed, nef-deficient HIV-1 
isolates were found and the infected individual do not progress or progress very 
slowly to AIDS (Brambilla, Turchetto et al. 1999) (Casartelli, Di Matteo et al. 2003) 
(Geffin, Wolf et al. 2000). While the infection with less fit HIV-1 could not explain all 
the ECs. HIV-1 isolates from our cohorts and other groups showed there are no 
common mutations or significant deletions in the plasma RNA sequences compared 
with the HIV-1 isolates from chronic progressors (CPs) (Miura, Brockman et al. 2008). 
Very recently, a paper proposed that 33% of the variation in disease progression is 
attributed from the viral genetic by summarizing the published literatures. They 
proposed that the evolutionary capacity of HIV-1 had an underscored impact in its 
virulence and pathogenesis which is critical for the set point in the early stage of 
infection (Fraser, Lythgoe et al. 2014). 
 
1.4.2 Heterogeneous Host genetic Factors Determine the Spontaneous Control 
Host genetics strongly influences the susceptibility and resistance of an individual to 
HIV-1. The scanning of single-nucleotide polymorphisms (SNPs) on whole genome 
scale dissected two major genetic determinants for the viral set point level in a 
consortium of nine cohorts including hundreds of patients with a clear background. 
The polymorphisms located at the HLA-B and HLA-C loci could explain around 15% 
of the variation in HIV-1 set point (Fellay, Shianna et al. 2007). The following 
large-scale epidemiological studies confirmed the enrichment of HLA-B*57, 
HLA-B*27, HLA-B*13 and HLA-B*58:01 in HIV-1 elite controllers compared with 
HIV-1 progressors (International, Pereyra et al. 2010) (Limou, Le Clerc et al. 2009). 
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By contrast, certain HLA alleles, particularly subtypes of HLA-B*35 and HLA-B*07, 
are highly enriched in HIV-1 rapid progressors (Carrington, Nelson et al. 1999) (Gao, 
Nelson et al. 2001) (International, Pereyra et al. 2010). Not only the special HLA 
genotype but also its epistatic interactions with killer immunoglobulin-like receptors 
(KIRs) on natural killer (NK) cells are also correlated to disease progression. The 
combined pairs including KIR3DS1&HLA-Bw4-80I, KIR3DL1&HLA-Bw4-80I, 
KIR3DL1&HLA-B*57 were shown to have effects on the HIV-1 plasma RNA level 
(Flores-Villanueva, Yunis et al. 2001) (Martin, Gao et al. 2002). In addition to the 
special protective genotypes, the high expression level of HLA-C is independently 
associated with low viral set points and control of HIV-1 (Fellay, Shianna et al. 2007) 
(Thomas, Apps et al. 2009). The spontaneous control of HIV-1 can also result from 
the reduced susceptibility of the infection for new target cells in the population of a 
mutant chemokine receptor CCR5 with a 32-basepair (bp) deletion (Martinson, 
Chapman et al. 1997). 
 
1.4.3 Adaptive Immune Responses in ECs 
Strong and effective HIV-1-specific CD4+ and CD8+ T cell responses are generally 
regarded as the best weapons of antiviral immune activity, and they might define the 
biological characteristics of an effective T cell response against HIV-1 (Ogg, Jin et al. 
1998) (Oxenius, Price et al. 2004). Currently available data suggest stronger CD8+ T 
cell-mediated antiviral response is the backbone for the EC status because CD8+ T 
cells from ECs have higher capacity to proliferate and synthesize greater amounts of 
cytotoxic granule components (Migueles, Osborne et al. 2008) (Hersperger, Pereyra et 
al. 2010) (Chen, Ndhlovu et al. 2012). Moreover, HIV-1-specific CD4+ T cells from 
ECs seem to have higher functional avidities and they secrete multiple cytokines, such 
as IL-2 and IL-21 that increase the antiviral activities of HIV-1-specific CD8+ T cells 
(Chevalier, Julg et al. 2011). It’s generally recognized, although controversial with 
respect to early studies, that neutralizing antibody (NAb) has no obvious role in viral 
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suppression (Pereyra, Addo et al. 2008) (Doria-Rose, Klein et al. 2010) (Bailey, 
Lassen et al. 2006) (Lambotte, Ferrari et al. 2009). 
 
1.4.4 Role of Innate Immunity in ECs 
Natural Killer Cells  
In addition to the effectiveness of CD8+ T cell-mediated responses, the relevance of 
natural killer (NK) cells was reported to have an impact on the control of HIV-1 
disease progression. There are two major phenotypes of NK cells in the peripheral 
circulation. The majority are CD56dim NK cells which can directly lyseHIV-1 infected 
cells via cytolytic granules. The less population are poorly cytotoxic CD56bright NK 
cells which secrete cytokines and shape the adaptive immune responses. The 
functions of NK cells are delicately regulated by the in interaction of its activating or 
inhibitory receptors on the surface with ligands on target cells or (Fauci, Mavilio et al. 
2005) (Alter and Altfeld 2009). NK cells can also be activated directly through 
binding of specific antibody to particular Fc-receptors on NK cells, a process known 
as antibody dependent cellular cytotoxicity (ADCC). The role of NK cells in HIV-1 
disease control has been observed. One cohorts study showed that NK cells from ECs 
displayed higher levels of interferon-gamma, activation markers, and cytolytic activity 
than NK cells from CPs (Lichtfuss, Cheng et al. 2012). Another group displayed NK 
cells from ECs had increased level of activating receptor NKG2D which is critical for 
the lytic function. Very strikingly, these NK cells had higher capacity to maintain the 
stable level of one receptor NKp44 which is related to CD4 maintenance (Marras, 
Nicco et al. 2013). Further another group characterized the CD38 expression in the 
cytolytic CD56dim NK cells, and its association with HIV-1 disease progression in 
treatment naïve ECs, CPs and AIDS subjects, and they claimed that the activation of 
NK cells was reversely associated with HIV-1 disease progression (Kuri-Cervantes, 
de Oca et al. 2014). This is inherent with a former study showing the the strong NK 
cell-mediated inhibition of viral replication is not necessary for the immunological 
control of HIV-1 in all ECs (O'Connell, Han et al. 2009). The results about NK cells 
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role in suppress HIV-1 infection so far are quite conflicting in different cohorts. In 
some studies, ECs had the trend to maintain higher cytolytic effects via higher 
activation level, while in some ECs, they maintain the similar activation level as 
healthy donors. These facts just reflect that the mechanism to suppress the viral 
replication in ECs can be different among each individual. 
 
Antibody Dependent Cellular Cytotoxicity (ADCC)  
ADCC is carried out by the effector cells of innate immune system bearing Fc 
receptors, such as NK cells and macrophages, through their interaction with antibody 
coated cells. ADCC is considered as one of the efficient protective mechanisms and 
regains the attraction in the HIV-1 field mainly because its level inversely correlates 
with infection risk in the ALVAC-HIV/AIDSVAX-B/E RV144 vaccine trial (Haynes, 
Gilbert et al. 2012). Higher levels of ADCC antibodies were found in ECs, especially 
in HLA-B57 positive controllers (Lambotte, Ferrari et al. 2009). Other cohort studies 
also showed that the broader ADCC response was correlated with disease progression 
(Baum, Cassutt et al. 1996) (Wren, Chung et al. 2013). Very strikingly, the 
Vpu-derived epitopes could stimulate ADCC, and moreover, they were only 
recognized by long term slow progressors but not CP patients (Wren, Chung et al. 
2013).  
 
Overall, the spontaneous control of HIV-1 in ECs could be established via virological, 
genetic and immunologic factors. The mechanisms for the natural control of HIV-1 
replication among all patients are heterogeneous. Nevertheless, research of this rare 
group could provide valuable implications for the control of HIV-1(Fraser, Lythgoe et 
al. 2014). 
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2 Review of HIV-1 Vpu 
2.1 General Properties of HIV-1 Vpu 
2.1.1 Vpu Gene and its Role in HIV-1 Pathogenesis  
HIV-1 has a set of accessary genes including vpu, vif, vpr, and nef that are dispensable 
for the replication in the cell culture system but are required for optimal infectivity in 
vivo (Malim and Emerman 2008). The gene of vpu is only present in HIV-1/SIVcpz 
lineages but absent in HIV-2 and the most of SIV such as isolated rhesus macaque and 
sooty mangabeys (Cohen, Terwilliger et al. 1988) (Strebel, Klimkait et al. 1988) 
(Dazza, Ekwalanga et al. 2005) (Jia, Serra-Moreno et al. 2009). Vpu gene is 
overlapped at its3’end with the env gene, and so Vpu is encoded from the bicistronic 
env mRNAs that contains the Rev-responsive element. And the expression level of 
Vpu is regulated by the abundance of different isoforms of env mRNAs (Schwartz, 
Felber et al. 1990) (Karn and Stoltzfus 2012). 
 
 
 
 
Figure 5: Gene maps of HIV-1 and HIV-2/SIV. The genes to encode prototypical 
proteins (Gag, Pol Env) for retroviruses are present in HIV-1 and HIV-2/SIV. HIV-1 
dese not possess vpx. Vpu gene is unique to HIV-1, marked in red. (Adaped from 
Stephan Bour and Klaus Strebel, Microbes and Infection, 2003) 
 
 
Vpu is not incorporated into the mature viral particles, and it is not required for the 
viral replication in the cell culture system as other accessory proteins. It has two 
classic two functions: down-regulating the primary HIV-1 receptor CD4 molecules  
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and enhancing the viral particle release (Willey, Maldarelli et al. 1992) (Bour, Perrin 
et al. 1999) (Strebel, Klimkait et al. 1989) (Neil, Eastman et al. 2006). The 
contribution of Vpu to HIV-1 pathogenesis is a central issue which is not elucidated 
yet. The main obstacle is due to the lack of a suitable animal model because the vpu 
gene is not present in most SIV viruses especially SIVmac which could infect the 
widely used animal model for HIV-1 study-rhesus macaque. Nevertheless, the animal 
model researches using the HIV-1/SIV chimeric virus strongly suggest that Vpu plays 
a role in HIV-1 pathogenesis. It was shown that macaques infected with vpu-negative 
simian-human immunodeficiency virus chimeras (SHIV) had lower virus loads than 
vpu-positive virus (Li, Halloran et al. 1995). Another group demonstrated that deletion 
of Vpu significantly affects virus infectivity of HIV-1 by using severe combined 
immunodeficient mouse (SCID) model (Jamieson, Aldrovandi et al. 1996).  
 
2.1.2 Molecular Aspects of HIV-1Vpu 
Vpu is composed of around 80 amino acids, with the molecular weight around 16kDa 
(Cohen, Terwilliger et al. 1988) (Strebel, Klimkait et al. 1988). Is a type I integral 
trans-membrane protein capable of homooligomerization (Hussain, Das et al. 2007), 
consisting of a short luminal N-terminal hydrophobic domain (NTD), a 
trans-membrane domain (TMD) serves as the membrane anchor and a hydrophilic 
C-terminal domain (CTD) protruding into the cytoplasm. The CTD contains two 
amphipathic helixes (α-helix) opposite polarity, and they are separated by an 
unstructured region containing two conserved serine residues at the sites of 52 and 56 
amino acids (DSGxxS), which are phosphorylated by protein kinase CK-II and 
essential for its basic functions which will be introduced in the next sections (Cohen, 
Terwilliger et al. 1988) (Strebel, Klimkait et al. 1988) (Schubert, Henklein et al. 1994) 
(Marassi, Ma et al. 1999).  
The localization of HIV-1 varies among different subtypes. The subtype B Vpu is 
accumulated in the and trans-golgi-net (TGN), and this is critical for enhancing the 
virion release. However, the subtype C Vpu was found to localize at the plasma 
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membrane and TGN (Dube, Roy et al. 2009) (Pacyniak, Gomez et al. 2005). The 
determinants for raft association and TGN localization (R30 and K31) are embedded 
in the region of TMD (Fritz, Tibroni et al. 2012) (Dube, Roy et al. 2009; Bruce, 
Abbink et al. 2012). The conservation of TMD, especially the alanine residues, 
together with the subcellular trafficking motif ExxxLV present in the second α-helix 
and the tryptophan (W) in the end of CTD are critical for the virion release 
enhancement (Petit, Blondeau et al. 2011). (Vigan and Neil 2010) (Kueck and Neil 
2012) (Jafari, Guatelli et al. 2014). The determinants for multifaceted functions of 
Vpu are spanned from its N- to C-terminus. 
 
 
 
 
Figure 6: Schematic presentation of HIV-1 NL4.3 Vpu. A: Secondary structure and 
predicted tertiary fold of Vpu. Vpu is composed of a short N terminal domain (1-4 
amino acids), a transmembrane domain spanning from the 4 to 27 amino acid residue, 
and a relatively long cytoplasmic domain containing two α-helixes. The two 
phosphorylation sites for recruiting β-TrCP are marked in yellow. B: Sequence 
presentation of Vpu and important motifs. The prototypic NL4.3 Vpu consists of 81 
amino acids. The functional motifs for antagonizing CD317 (or tetherin), raft 
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association, trans-Golgi localization, β-TrCP binding, KIR-2DL2 recognition and two 
major CTL epitopes are indicted. (A: adapted from Mathieu Dube, et al. 
Retrovirology, 2010) 
 
 
2.2 Vpu-Mediated Removal of the HIV-1 Receptor CD4  
Vpu is not required for the replication of HIV-1 in the cell culture system, but it 
modulates a broad array of cellular factors. Strikingly it is one of proteins HIV-1 
exploits to reduce the surface level of the primary receptor CD4 molecules in infected 
cells. The modulation of CD4 seems critical for HIV-1 because it utilizes three of its 
proteins (Vpu, Nef and Env) to interfere with the surface level of CD4 via distinct 
mechanisms. Vpu retains newly synthesized CD4 molecules at endoplasmic reticulum 
(ER) and consequently induces proteasomal degradation (Buonocore and Rose 1990) 
(Willey, Maldarelli et al. 1992) (Piguet, Chen et al. 1998) (Crise, Buonocore et al. 
1990). Vpu-mediated CD4 downregulation starts with the interaction of the cytosolic 
domains of both proteins and relies on the phosphorylation of Vpu at the two serine of 
the DSGxxS motif (Bour, Schubert et al. 1995) (Schubert, Henklein et al. 1994). The 
phosphorylated Vpu binds with β-TrCP, leading to the recruitment of the cytosolic 
SCFβ-TrCP E3 ubiquitin ligase complex, which then results in the poly-ubiquitination of 
CD4 at its cytosolic tail (Margottin, Bour et al. 1998). The ubiquitinated CD4 is 
directed for degradation by cytosolic proteasomes (Schubert, Anton et al. 1998).  
The physiological relevance of CD4 down-modulation is partially understood. One 
benefit for HIV-1 is to prevent super-infection and premature cell death in order to 
expand the period of effective virus production (Benson, Sanfridson et al. 1993). 
Another benefit was proposed based on the propensity of Vpu in that it targets 
newly-made CD4 and therefore results the release of HIV-1 Env protein to enhance 
viral production (Lama, Mangasarian et al. 1999). More recently study revealed a role 
of Vpu in the evasion of killing by NK cells via removing CD4 molecules from the 
HIV-1 infected cells (Pham, Lukhele et al. 2014). 
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2.3 HIV-1 M Vpu: Competent Antagonist of CD317/tetherin 
2.3.1 Dual-faced CD317/tetherin: Viral Restriction Factor and Viral Sensor 
The initial biological phenotype of vpu-deficient HIV-1 was that the virion particles 
were retained on the plasma membrane of infected cells (Strebel, Klimkait et al. 1988) 
(Bour, Perrin et al. 1999). This phenotype was only observed in some cell lines such 
as human T cell lines but not in African green monkey cell line COS-7 (Geraghty, 
Talbot et al. 1994), which raised the searching and identification of the specific 
cellular factor. Finally in 2008 the IFN-stimulated BST-2 gene product (known as 
bone marrow antigen 2) was identified as the factor for the cell type dependent 
phenotype, designated as CD317/tetherin (Neil, Zang et al. 2008). CD317/tetherin is a 
lipid raft-associated type II integral membrane glycoprotein, consisting of 180 amino 
acids with the molecular weight of 30-36 kDa (Chiang, Wang et al. 2010) (Kawai, 
Azuma et al. 2008) (Kupzig, Korolchuk et al. 2003). It is of an unusual topology 
containing an N-terminal cytoplasmic tail, a conventional trans-membrane helix and a 
C-terminal glycosylphosphatidylinositol (GPI) membrane anchor connected by a 
coiled-coil extracellular domain. It further forms stable parallel dimers in the 
extracellular domain (Kupzig, Korolchuk et al. 2003) (Andrew, Miyagi et al. 2009) 
(Evans, Serra-Moreno et al. 2010). CD317/tetherin is constitutively expressed on 
various cells of the immune system including T lymphocytes, macrophages, and 
plasmacytoid dendritic cells (pDCs) at low level. Its expression can be strongly 
increased upon the stimulation of type I IFNs (Erikson, Adam et al. 2011). Since its 
identification as a restriction factor for HIV-1 release, CD317/tetherin was found to 
block the release of a variety of enveloped viruses (Jouvenet, Neil et al. 2009). And 
also various viral antagonists to counteract CD317 were identified, such as HIV-1 
Vpu, HIV-2 Env and SIV Nef (Neil, Eastman et al. 2006) (Hauser, Lopez et al. 2010) 
(Gupta, Mlcochova et al. 2009) (Jia, Serra-Moreno et al. 2009) (Sauter, Schindler et 
al. 2009).  
CD317/tetherin functions not only as an intrinsic restriction factor to block the release 
of viral particles but also as a viral sensor to stimulate innate immune responses. The 
gene encoding CD317/tetherin was early reported as a potential activator of the 
31 
 
transcription factor NF-κB in a cDNA screening before the identification of its 
restriction activity (Matsuda, Suzuki et al. 2003). The subsequent researches 
demonstrated the role of CD317 as a pattern-recognition receptor to stimulate the 
activation of NF-κB via a mechanism independent of its restriction of virion release 
(Galao, Le Tortorec et al. 2012) (Tokarev, Suarez et al. 2013). NF-κB is the major 
transcriptional control factor which plays a pivotal role in immune and inflammatory 
responses. It is sequestered in cell cytoplasm by its inhibitor IƙB as an inactive form 
in the cell cytosol. Upon various stimulations such as TNFα, bacterial 
lipopolysaccharide (LPS) and the growth factors, NF-κB is free of IƙB sequester and 
then transported to the nucleus where it regulates a list of gene expression including 
immunoregulatory proteins and cytokines (Gilmore 2006) (Oeckinghaus and Ghosh 
2009). The motif studies showed that the restriction of virus release and induction of 
NF-κB by CD317/tetherin are uncoupled activities. Activation of NF-κB by 
CD317/tetherin is dependent on the YxY motif in the CTD but not the GPI anchor of 
CD317/tetherin, while the GPI anchor but not the YxY motif is essential for the 
restriction of virion release (Galao, Le Tortorec et al. 2012) (Tokarev, Suarez et al. 
2013). How HIV-1 Vpu counteracts these two antiviral activities of CD317/tetherin 
and what HIV-1 could benefit from the antagonism of CD317/tetherin are unsolved 
issues. 
 
2.3.2 Antagonism of CD317 by HIV-1 Vpu 
Vpu-mediated Virion Release Enhancement and CD317 Surface Downregulation 
HIV-1 utilizes Vpu to antagonize CD317/tetherin and facilitate virion particle release. 
The molecular mechanism of how CD317/tetherin tethers mature virions at the plasma 
membrane of infected cells and how Vpu counteracts the restriction are partially 
determined. It’s clear that the membrane anchor GPI and extracellular coiled-coil 
domain of CD317/tetherin are involved in crosslinking the virions on the cell 
membrane, and also Vpu TMD domain is essential for facilitating the virion release. 
The Paul D. Bieniasz group demonstrated that HIV-1 Vpu directly bind with 
32 
 
CD317/tetherin via TM domains of both proteins and displaced CD317/tetherin from 
the sites of viral assembly, leading to the failure of CD317/tetherin tethering into the 
viral envelop and the decreased surface level of CD317/tetherin (Venkatesh and 
Bieniasz 2013) (McNatt, Zang et al. 2013).The required molecule determinants of 
Vpu were identified. The highly conserved AxxxAxxxA motif embedded in the TM 
domain, together with the its β-TrCP binding motif DSGxxS and a trafficking motif 
ExxxLV located in the CTD domain, as well as a tryptophan (W) residue in the end of 
Vpu CTD are essential for the optimal virion release enhancement (Vigan and Neil 
2010) (Kueck and Neil 2012) (Jafari, Guatelli et al. 2014). Apart from its capacity to 
antagonize the virion restriction activity of CD317/tetherin, Vpu could reduce the 
level of CD317/tetherin from the cell surface. The proposed mechanism is that Vpu 
interacts with CD317/tetherin and targets it to TGN for lysosomal degradation, or 
traps CD317/tetherin molecules in TGN and blocks the anterograde trafficking 
(Schmidt, Fritz et al. 2011). Ambiguously, surface down-modulation and total 
intracellular depletion of CD317/tetherin are not essential for neutralizing 
CD317/tetherin-restricted release of viral particles, which indicates that the 
antagonism of CD317/tetherin restriction and downregulation of CD317 are separable 
activities of Vpu (Goffinet, Homann et al. 2010). 
Inhibition of NF-ƙB Signalling in the Presence or Absence of CD317/tetherin by 
Vpu 
In addition to counteract the restriction of virion particle release imposed by 
CD317/tetherin, Vpu could also inhibit CD317/tetherin-induced NF-ƙB signalling. 
NF-ƙB can be activated by the presence of CD317, whose expression level is 
increased due to the enhanced type I interferon upon the infection of HIV-1. Vpu has a 
negative effect on the stimulation of NF-ƙB in this pathway due to its effect on 
CD317/tetherin. This inhibitory activity requires the β-TrCP binding motif DSGxxS 
of Vpu (Tokarev, Suarez et al. 2013). A former study also observed Vpu interfered the 
NF-ƙB signalling independent of CD317/tetherin. And this capacity of Vpu is 
attributed to its affinity with β-TrCP which is required for the degradation of NF-ƙB 
inhibitor-IƙB. In the presence of Vpu, the degradation of IƙB is suppressed, because 
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the phosphorylated Vpu has high affinity with the adaptor protein β-TrCP of SCFβ-TrCP 
E3 ubiquitin ligase complex which is needed for marking the phosphorylated IƙB to 
degradation (Perkins 2007), and thus the activation of NF-ƙB is inhibited (Bour, 
Perrin et al. 2001; Gilmore 2006). 
 
2.4 Surface Down-modulation of Antigen Presenting Molecule: MHC-I 
In addition to the enhancement of viral particle release and the inhibition of NF-ƙB 
signalling, Vpu may disturb the presentation of HIV-1-derived peptides to CD8+ 
cytotoxic T lymphocytes (CTL) by down-regulating the surface expression of major 
histocompatibility complex I (MHC-I) (Kerkau, Bacik et al. 1997). One of the 
primary antiviral functions of MHC-I is to present pathogen-derived peptides to the 
specific CTLs (Yewdell and Bennink 1992), which consequently induces the killing of 
pathogen-invaded cells. MHC-I plays a critical role in eradication of virus infected 
cells and viruses have evolved strategies to interfere the MHC-I mediated immune 
responses (Yewdell and Hill 2002). One of the strategies is to decrease the surface 
expression level of mature MHC-I molecules. HIV-1 utilizes three of its proteins Vpu, 
Nef and Tat to down-modulate MHC-I (Petersen, Morris et al. 2003). The accessory 
protein Nef blocks the transport of MHC-I and leads to the surface level reduction and 
by doing so, Nef enables HIV-1 to evade CTL killing and contributes to the 
pathogenicity of HIV-1 (Collins, Chen et al. 1998) (Swann, Williams et al. 2001) 
(DeGottardi, Specht et al. 2008). However, the mechanism and functional relevance 
of Vpu-mediated downregulation of MHC-I has not been investigated since its effect 
on the surface expression level of MHC-I was observed (Kerkau, Bacik et al. 1997). 
One group proposed that Nef and/or Vpu played the major role on the surface 
reduction of MHC-I during HIV-1 infection to evade the CTLs (Schmokel, Sauter et 
al. 2011). In this scenario, Vpu may have a positive effect on viral survival during the 
HIV-1 infection if not directly on the HIV-1 replication, as the pathogenic factor Nef. 
It is worthwhile to mention that Vpu could target MHC-I, but Vpu-derived peptides 
are very rarely presented to CTLs (Addo, Altfeld et al. 2002) (Addo, Yu et al. 2002) 
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(Hasan, Carlson et al. 2012). 
 
2.5 Vpu-mediated Interceptions of NK cells Antiviral Activity 
Not only the adaptive immune responses dysfunction during HIV-1 infection, but also 
the innate immune system is perturbed, as increasing evidences have showed (Alter, 
Teigen et al. 2005) (Fogli, Costa et al. 2004). As a major component of innate 
immunity, the phenotypes of NK cells was altered by HIV-1 infection (Iannello, 
Debbeche et al. 2008). The surface levels of membrane markers such as CD56, as 
well as members from killer-cell immunoglobulin-like receptors (KIR), present on the 
surface of NK cells, can be dysregualted during the infection of HIV-1 (Mavilio, 
Benjamin et al. 2003) (Naranbhai, Altfeld et al. 2013) (Milush, Lopez-Verges et al. 
2013). All these evidences attract the researchers to decipher the mechanisms how 
HIV-1 could escape the first line of host antiviral the surveillance-innate immunity. 
The Vpu-mediated evasion of NK cells immunity is described as follows. 
 
2.5.1 Vpu Impedes NK cells Killing via NTB-A and PVR Downregulation 
NK cells express a repertoire of activating and inhibitory receptors which regulate the 
functions of NK cells by interacting with their corresponding ligands. In normal 
conditions, a delicate balance is maintained by the interactions of NK cell receptors 
and their ligands (Lanier 2008). Upon infection or other stimuli, NK cells could 
initiate the cytolytic activity by sensing the surface level changes of NK cell ligands 
on target cells such as tumours and virus-infected cells via the interactions with 
specific NK cell receptors (Alter and Altfeld 2009). HIV-1 could shape these 
interactions and thus evade the killing by NK cells. One target is NK-T-B antigen 
(NTB-A) which is a co-activating receptor required for NK cell degranulation. 
NTB-A can be downregulated from HIV-1 infected cells specifically by Vpu, which 
leads to the failure of NK cell degranulation and consequently inability of killing 
HIV-1 infected cells (Shah, Sowrirajan et al. 2010). Another NK cell ligand PVR 
(CD155) for the activating receptor DNAM-1 (CD226) expressed by all NK cell, is 
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also modulated in HIV-1 infection and therefore contributes to the evasion of the 
cytolytic effect imposed by NK cells. The major viral component responsible for this 
downregulation activity is HIV-1 Nef, while the optimal downregulation needs the 
presence of HIV-1 Vpu (Matusali, Potesta et al. 2012). Overall, Vpu is not strictly 
required for the HIV-1 replication, but it modulates the expression level of the ligands 
for NK cells functioning and thus leads to the inability of innate immune responses, 
which adds the strength of HIV-1 to persist in the complicated host cell immune 
surveillance. 
 
 
 
 
Figure 7: Biological functions of HIV-1 Vpu. ① Vpu enhances HIV-1 particle 
release HIV-1 particle release by antagonizing CD317. ② Vpu inhibits the NK 
cell-mediated ADCC response. ③ Vpu traps CD317 at TGN and reduces the surfacel 
level of CD317. ④ Vpu inhibits CD317-induced NF-ƙB signalling. ⑤ Vpu induces 
the degradation of newly sythesized CD4. ⑥, ⑦ Vpu disables NK cell killing by 
36 
 
down-regulating NK cell ligands NTB-A and PVR. ⑧ Vpu inhibits NF-ƙB signalling 
via the inhibition of IƙB. ⑨, ⑩ Vpu decrease the surface expression level of MHC-I 
or CD1d. 
 
 
2.5.2 Vpu Modulates NK cell function via its KIR-associated Footprints 
In addition to regulate the expression level of NK cells ligands, Vpu was shown to 
directly adapt to the receptors on NK cells during the co-evolution of HIV-1 and the 
host. One epidemiology study showed evidences that HIV-1 evolved under the NK 
cell mediated selection pressure and adapted to KIR receptors present on the surface 
of NK cells and thus neutralize the lytic effects imposed by NK cells. Two amino 
acids at the C-terminal of Vpu 71M/74H were found to be associated with one of the 
inhibitory KIR receptors KIR2DL2. The specific Vpu footprints, together with the 
corresponding KIR genotype, enable HIV-1 to escape the recognition and killing by 
NK cells (Alter, Heckerman et al. 2011).  
 
2.5.3 Vpu Protects HIV-1 Infected Cells from NK cell-mediated ADCC  
As introduced in 1.4.4, ADCC is increasingly recognized as a potentially powerful 
anti-HIV response. Recently, two groups observed that Vpu could circumvent the 
effects of NK cell-mediated ADCC. The Cohen group showed that Vpu, 
synergistically with HIV-1 Nef, decreased NK cell-mediated ADCC by antagonizing 
CD317/ tetherin and preventing CD4 accumulation from the infected cells, which may 
contribute to the persistence of HIV-1 in vivo (Pham, Lukhele et al. 2014). The other 
study showed that Vpu protected infected cells from ADCC via the antagonism of 
CD317/tetherin. They proposed that CD317/tetherin retains virions on the infected 
cells surface and therefore enhances the chances of recognition and binding of HIV-1 
particles with HIV-1 specific ADCC antibodies in the absence of Vpu, which makes 
the infected cells more susceptible to NK cells (Arias, Heyer et al. 2014).  
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2.6 Functional Discrepancy of Primary Vpu from Different HIV-1 Groups 
Only the HIV-1 M group, which is responsible for the global pandemic, has evolved 
the full functional Vpu to modulate the immune components or pathways described in 
previous sections. The rare HIV-1 N group Vpu alleles could counteract 
CD317/tetherin to a very limited extent, but they are inactive to reduce the cell surface 
level of CD4 due to the lack of determinants in cytoplasmic domain (Sauter, 
Unterweger et al. 2012). HIV-1 O and P group Vpu alleles are active for CD4 
downregulation but deficient to enhance vial particle release (Vigan and Neil 2011). 
All these evidences suggest that Vpu could be one of the factors to promote the spread 
in the population level and contribute to the HIV-1 pathogenesis. However, the central 
issue about the role of Vpu in HIV-1 pathogenicity is not defined yet, which motivates 
us to give more insights into this issue. 
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3 Aims of This Study 
Vpu is not essential for HIV-1 replication but intensively modulates host immune 
components including the HIV-1 primary entry receptor CD4, whose cell surface 
levels are reduced by Vpu. Uniquely, Vpu promotes the release of mature viral 
particle from infected cells by antagonizing the host restriction factor CD317/tetherin. 
Moreover, Vpu interferes with NF-ƙB signalling triggered by CD317/tetherin and 
reduces the cell surface exposure of MHC class I (MHC-I) and natural killer cells 
ligand NTB-A. While these Vpu activities have been established ex vivo, their 
relevance for HIV pathogenesis in the infected host remains unclear.  
In an attempt to correlate Vpu function with the clinical outcome of HIV-1 infection, 
we designed to generate the vpu alleles derived from two distinct clinical groups of 
treatment-naïve HIV-1 infected patients. While HIV-1 elite controllers (ECs) naturally 
control virus replication and keep the viral load below detectable level (<50 
copies/ml), chronic progressors (CPs) display viral loads of more than 2 000 
copies/ml. Several aspects concerning these two groups of Vpu alleles were to be 
addressed in the course of this study: 
1) Sequence diversity of patient-derived Vpu alleles. 
2) If the activities of CD4, CD317, MHC-I, and NTB-A downregulation are 
conserved among EC and CP Vpus? 
3) Whether the Vpu alleles still possess the activities to enhance virion release 
and inhibit NF-ƙB signalling or not?  
4) Is there any systematic difference regarding these functions between EC and 
CP Vpus? If these functions of Vpu are correlated with each other? 
5) Is any activity correlated with disease outcomes? 
6) Based on the natural Vpu alleles, define novel functional motifs for the listed 
activities. 
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4 Materials and Methods 
4.1 Materials 
4.1.1 Study Subjects 
Fifteen HIV-1 ECs (pVL< 50 RNA copies/ml; median [interquartile range, IQR] CD4 
counts 843 [654–955]cells/mm3) and sixteen CPs (median [IQR] CD4 count 284 
[36.75–433] cells/mm3) were selected from two cohorts described previously 
(Pereyra, Addo et al. 2008) (Miura, Brockman et al. 2008) (Miura, Brockman et al. 
2009) (Brumme, Li et al. 2011) (Mwimanzi, Markle et al. 2013). Briefly, all 
participants were recruited on the basis of viral load from outpatient clinics at local 
Boston hospitals and also referred from provides throughout the United States, after 
institutional review board approval and written informed consent. At the time of 
plasma sample collection, all patients were treatment naïve. HIV-1 ECs were defined 
as having plasma HIV RNA levels below the level of detection for the available 
ultrasensitive assays (< 75 copies/mL by multiple branched DNA (bDNA) or < 50 
RNA copies/mL by ultrasensitive PCR) without ART. HIV-1 CPs were defined as 
having plasma HIV RNA levels above 10,000 copies/mL without ART (Pereyra, Addo 
et al. 2008).  
4.1.2 Viral RNA Isolation and RT-PCR Amplification 
Prior to the vpu gene amplification, plasma collection, viral RNA isolation and 
RT-PCR amplification were performed by the researcher from the group of Bruce D. 
Walker (Ragon Institute of Massachusetts General Hospital, Massachusetts Institute 
of Technology and Harvard University, Boston, MA, USA) (Pereyra, Addo et al. 
2008) (Miura, Brockman et al. 2009). The RT-PCR products for our research project 
were kindly provided by Takamasa Ueno (Center for AIDS Research, Kumamoto 
University, Japan) who was authorized to have the patients’ samples as described 
below. The plasma collection and viral RNA isolation were described previously 
(Pereyra, Addo et al. 2008) (Miura, Brockman et al. 2009). Briefly, HIV-1 plasma 
virus from EC and CP was isolated by ultracentrifugation. Viral RNA was extracted 
by using the Qiagen viral RNA mini kit with the treatment of RNase-free DNase set 
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and was eluted in DNase- and RNase-free water and stored at -80°C. HIV-1 gene 
regions were amplified using nested reverse transcriptase PCR (RT-PCR) followed by 
the treatment of DNase, as described (Miura, Brockman et al. 2008). Genbank 
accession numbers for primary vpu sequences are EU517721-EU873004 (EC) and 
FJ469688-FJ469764 (CP). 
 
4.1.3 Oligonucleotide Primers for Vpu Sequences Amplification 
Based on the primary vpu sequences, forward and reverse primers were designed by 
tracking the nucleotide sequences for editing the first and the last four amino acids 
respectively. All the primers were listed in Table 2-1 and 2-2. 
Table 2-1: List of forward primers for vpu gene amplification. 
Eco-MQSL 5'-CGCGGAATTCATGCAATCCTTA- 3' 
Eco-MQPL 5'-GCCGGAATTCATGCAACCTTTA- 3' 
Eco-MQSI 5'-GCCGGAATTCATGCA ATCTATA- 3' 
Eco-MQTL 5'-GCCGGAATTCATGCAAACTTTA- 3' 
Eco-MQSV 5'-GCCGGAATTCATGCA ATCTGTA- 3' 
Eco-MQAL 5'-GCCGGAATTCATGCAAGCTTTA- 3' 
Eco-MQTT 5'-GCCGGAATTCATCA AACCA A- 3' 
Eco-MIPL 5'-GCCGGAATTCATGATACCTTT A- 3' 
Eco-MPSL 5'-GCCGGAATTCATGCCATCTTTA- 3' 
Eco-MSPL 5'-GCCGGAATTCATGTCACCTTTA- 3' 
Eco-MQLL 5'-GCCGGAATTCATGCAATTGTTA- 3' 
Eco-MNSL 5'-GCCGGAATTCATGAACTCTCTA- 3' 
Eco-MNAL 5'-GCCGGAATTCATGAATGCCTTA- 3' 
Eco-MQYL 5'-GCCGGAATTCATGCAATATTTA- 3' 
Eco-MQPI 5'-CGCGGAATTCATGCAACCAATC- 3' 
Eco-MQPIQI 5'-CGCGGAATTCATGCAACCTATACAAATA- 3' 
Eco-MHVS 5'-GCCGGAATTCATGCATGTATG- 3' 
Eco-MYSL  5'-GCCGGAATTCATGTACTCTTTA- 3' 
Eco-MLSL 5'-GCCGGAATTCATGCTCTCTTTA- 3' 
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Table 2-2: List of reverse primers for vpu gene amplification. 
VDDL BamRev 5'-GCGCGGATCCAGATCATCAAC- 3' 
WDVDDL BamRev 5'-GCTCGGATCCAGATCATCAACATCCCA- 3' 
WDIDDL BamRev 5'-GCGCGGATCCAGATCATCAATATCCCA- 3' 
IDDL BamRev 5'-GCGCGGATCCAGATCATCAAT- 3' 
VNDL BamRev 5'-GCGCGGATCCAGAT ATTAAC- 3' 
INDL BamRev 5'-GCGCGGAT CAGATCATTAAT- 3' 
NDNL BamRev 5'-GCGCGGATC CAGATTATCATT- 3' 
INNM BamRev 5'-GCGCGGATCCATATTATTAAT- 3' 
GDDIG BamRev 5'-GCGCGGATCCCCTATATCATCACC- 3' 
INDM BamRev 5'-GCGCGGATCCATATCATTAAT- 3' 
VDNL BamRev 5'-GCGCGGATCCAGATTATCAAC- 3' 
TDDL BamRev 5'-GCGCGG ATCCAGATCATCAGT- 3' 
IDDQ BamRev 5'-GCGCGGATCCTGATCATCAAT- 3' 
DINDM BamRev 5'-GCGCGGATCCATATCATTAATATC- 3' 
 
4.1.4 Specific Primers for Site-directed Mutagenesis 
All the primers used for searching novel molecular determinants of Vpu are listed in 
Table 3. They were designed for site-directed mutagenesis under these conditions: 1) 
The primer length is in the range of 25-45 bases of nucleotides; 2) The primer 
contains at least 40% cytosine (C) and guanine (G), starting with a C or G; 3) Melting 
temperature (Tm) should be above 78°C; 4) The target sequence for mutation should 
be in the middle of the primer (Laible and Boonrod 2009). 
Table 3-1: List of forward primers for mutagenesis from NL4.3 Vpu to MEF 
NL4.3Vpu I17V 5'-GCAATAGTAGCATTAGTAGTAGCAATAGTA
ATAGCAATAGTTGTGTGGTCCATAG- 3'    
NL4.3Vpu V26I 5'-GCAATAATAATAGCAATAGTTGTGTGGTCC
ATAATAATCATAGAATATAGGAAAATATTAAG- 
3'   
NL4.3Vpu 49V 5'-GGTTAATTGATAGACTAATAGAAAGAGTAG
AAGACAGTGGCAATGAGAGTGAAGG- 3' 
NL4.3Vpu 77H 5'-GGCACCATGCTCCTTGGCATGTTGATGATC
TG- 3'   
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Table 3-2: List of reverse primers for mutagenesis from NL4.3 Vpu to MEF 
NL4.3 Vpu I17V 
 
5'-CTATGGACCACACAACTATTGCTATTACTATTGCTAC
TACTAATGCTACTATTGC- 3'  
NL4.3 Vpu V26I 
 
5'-CTTAATATTTTCCTATATTCTATGATTATTATGGACCA
CACAACTATTGCTATTATTATTGC- 3'   
NL4.3 Vpu A49V 
 
5'-CCTTCACTCTCATTGCCACTGTCTTCTACTCTTTCTA
TTAGTCTATCAATTAACC- 3'   
NL4.3 Vpu D77H 5'-CAGATCATCAACATGCCAAGGAGCATGGTGCC- 3' 
Table 4-1: List of forward primers for mutagenesis MEF to NL4.3 Vpu  
MEF V17I 5'-GCAATAGTAGCATTAGTAGTAGCAGCAATACTAGCA
ATAGTTGTGTGGTCCATAATAC- 3' 
MEF I26V 5'-GCAGCAGTACTAGCAATAGTTGTGTGGTCCATAGTA
CTCATAGAATATAGGAAAATATTAAG- 3' 
MEF V49A 
 
5'-GATTGATAGAATAGCAGAAAGAGCAGAAGACAGTG
GCAATGAGAG- 3' 
MEF D77H 5'-GGCATGATGCTCCTTGGGATGTTAATGATCTGGATC
C- 3' 
Table 4-2: List of reverse primers for mutagenesis from MEF to NL4.3 Vpu  
MEF V17I 
 
5'-GTATTATGGACCACACAACTATTGCTAGTATTGCTGC
TACTACTAATGCTACTATTGC- 3' 
MEF I26V 
 
5'-CTTAATATTTTCCTATATTCTATGAGTACTATGGACCA
CACAACTATTGCTAGTACTGCTGC- 3' 
MEF V49A 
 
5'-CTCTCATTGCCACTGTCTTCTGCTCTTTCTGCTATTCT
ATCAATC- 3' 
MEF D77H 5'-GGATCCAGATCATTAACATCCCAAGGAGCATCATGC
C- 3' 
 
4.1.5 Reagents 
Enzymes and Buffers for Molecular Cloning  
Pfu polymerase/10× Pfu buffer New England Biolabs 
Endonuclease / the digest buffer New England Biolabs 
T4 ligase/ligation buffer New England Biolabs 
Kits for Molecular Cloning 
NucleoBond AX 100 Kit   Macherey-Nagel 
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NucleoSpin Extract II Kit Macherey-Nagel 
PCR Purification Kit Macherey-Nagel 
Plasmid Miniprep/Max-prep Macherey-Nagel 
Markers 
Protein Standards, pre-stained   New England Biolabs 
DNA molecular marker, 1kb DNA ladder  MBI Fermentas, St. Leon-Roth 
Inhibitors and Drugs 
MG-132  Sigma 
Protease Inhibitor Cocktail  Sigma 
Recombinant Human TNF-α Peprotech 
Antibodies for Western Blotting, Fluorescence-activated Cell Sorting (FACS) and 
Immunology Fluorescence Microscopy 
Table 5-1: List of primary antibodies 
Antibodies Usage/Dilution Source 
Rabbit-anti-Vpu         WB 1:1000 Vpu-101AP; FabGennix Inc.        
Mouse-anti-GFP         WB 1:1000 G6539; Sigma                  
Rat-anti-GFP            WB 1:1000 3H9 a-GFP; Chromotek            
Sheep-anti-HIV-1capsid WB 1:5000 Babara Müller, Uni. Heidelberg 
Mouse-anti-CD317       FACS 1: 500 Clone 26F8; BD Bioscience         
CD4-APC         FACS 1: 20 RPA-T4; BD Bioscience      
MHC-I-APC            FACS 1: 20 555555; BD Bioscience            
Mouse-anti-NTB-A       FACs 3μg/ml  MAB19081; R&D        
594 WGA IF 10 μg/μl Invitrogen 
Mouse-anti-Tfr WB 1:1000 Zymed Laboratories 
Tfr: Transferrin receptor 
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Table 5-2 List of secondary antibodies 
4.1.6 Plasmids 
pEGFP N1   
Origin: Clontech 
Descritption: It is used for the expression of enhanced green fluorescent protein 
(eGPF) in mammalian cell lines under the Cytomegalovirus (CMV) promoter. 
Usage: Construction of the expression plasmids for non-codon optimized natural vpu 
alleles and reference NL4.3 vpu. The vpu gene with the restriction cites (EcoRI and 
BamHI) was inserted into upstream of the eGFP sequence. Vpu was expressed as a 
fusion to the N-terminus of GFP tag. 
pIRESGFP   
Origin: Clontech 
Descritption: It contains the internal ribosome entry site (IRES) of the 
encephalomyocarditis virus (ECMV) between the multiple cloning sites (MCS) and 
the GFP coding region. This permits both the gene of interest (cloned into the MCS) 
and the EGFP gene to be translated simultaneously from a single bicistronic mRNA. 
Usage: Construction of the expression plasmids for non-codon optimized natural vpu 
alleles and reference NL4.3 vpu. The vpu gene with the restriction cites (EcoRI and 
BamHI) was inserted into upstream of the eGFP sequence. Vpu was expressed as a 
fusion to the N-terminus of GFP tag. 
pcDNA-SynVpu 
Descritption: It contains a codon-optimized HIV-1 NL4.3 vpu. It was from Klaus 
Strebel (Nguyen, llano et al. 2004). 
Antibodies Usage/Dilution Source 
Mouse-APC       FACS 1: 200 Jackson ImmunoResearch  
Goat-anti-mouse peroxidase  WB 1:5 000 Dianova 
Goat-anti-rat peroxidase     WB 1:5 000 Dianova 
Goat-anti-rabbit peroxidase  WB 1:5 000 Dianova 
Duck-anti-sheep peroxidase  WB 1:5 000 Dianova 
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Usage: Served as a positive control for the infectivity assay in the pre-test. 
pNL4.3 VpuEGFP, pNL4.3 VpuIRESGFP and pNL4.3 VpuS/A IRESGFP 
They were constructed as the same procedure with natural vpu alleles described in 4.2. 
pNL4.3VpuS/AIRESGFP was generated by site-directed mutagenesis from 
pNL4.3VpuIRESGFP. pNL4.3VpuS/AIRESGFP encodes for the Vpu protein 
containing two serine mutations at the amino acids of 52 and 56. They all served as 
controls for the functional analysis of natural vpu alleles. 
pHIV-1NL4.3 wt (BH10 Env) 
Origin: Valerie Bosch (DKFZ, Germany)  
Descritption: provirus plasmids (Bosch and Pawlita 1990) 
Usage: Infectivity assay 
pHIV-1 NL4.3ΔVpu (BH10 Env) 
Origin: Valerie Bosch (DKFZ, Germany)  
Descritption: Based on pHIV-1NL4.3 wt (BH10 Env), Vpu expression was abolished 
by mutating the vpu initiation codon to ATT (Pfeiffer, Pisch et al. 2006). 
Usage: Infectivity assay 
 
The following plasmids were from Daniel Sauter (Ulm University, Germany). The 
related experiments were performed by his group. 
pCG-WITO Vpu 
Description: It is derived from a transmitted/founder subtype B HIV-1 group M strain 
and it is highly active for CD4 downregulation and CD317/tetherin counteraction(Li, 
Gao et al. 2005) (Doehle, Chang et al. 2012) 
Usage: Positive control for the inhibition of NF-κB activation  
pCG-human tetherin IRES DsRed2 
Description: Human CD317/Tetherin was cloned into the CMV promoter-based pCG 
expression vector co-expressing DsRed2 as previously described (Sauter, Schindler et 
al. 2009). 
Usage: activation of NF-ƙB signalling. 
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pNF-ƙB(3x)-Firefly Luciferase 
Description: It contains three NF-κB binding sites kindly provided by Bernd 
Baumann. 
Usage: NF-κB reporter plasmid 
pTAL-Gaussia Luciferase 
Description: It contains the minimal promoter-TATA-like promoter (pTAL) region 
from the Herpes simplex virus thymidine kinase (HSV-TK) that is not responsive to 
NF-κB (Sauter, Hotter et al. 2013). 
Usage: The internal control for transfection efficiency, that is, used for the 
normalization of the NF-ƙB-induced expression of firefly luciferase. 
pTAL-Firefly Luciferase 
Description: The gaussia luciferase in pTAL-Gaussia Luciferase constructwas 
replaced by firefly luciferase (Sauter, Hotter et al. 2013) 
Usage: The negative control for the NF-κB reporter plasmid 
IKKβ 
Description: constitutively active mutant 
Usage: activation of NF-ƙB signalling. 
4.1.7 Eukaryotic Cell Lines  
HEK293T  
Origin: Human Embryonic Kidney cell line expressing the large T antigen of SV40  
Cell culture medium: DMEM (high) 
Usage: Check the expression of Vpu alleles 
A3.01  
Origin: Human T cell line, CD4 and CD8 double positive 
Cell culture medium: RPMI1640 complete 
Usage: CD4/CD317/MHC-I/NTB-A downregulation 
TZM-bl 
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Origin: Hela cell lines introduced separate integrated copies of the luciferase and 
ß-galactosidase genes under control of the HIV-1 promoter. The TZM-bl cell line is 
highly sensitive to infection with diverse isolates of HIV-1. 
Cell culture medium: DMEM (high) 
Usage: Check the expression of Vpu alleles; downregulation of CD4/CD317; 
infectivity assay 
Freezing medium: 90% (v/v) heat inactivated fetal calve serum supplemented with 
10% (v/v) DMSO 
Trypsin/EDTA: 10% (v/v) trypsin/EDTA (10×, Biochrom), 90% PBS 
 
4.1.8 Bacterial strains 
DH5α  
Origin: Invitrogin 
Genotype: F- φ80lacZΔM15 Δ(lacZYA-argF)U169 recA1 endA1 hsdR17(rk-, mk+) 
phoA supE44 thi-1 gyrA96 relA1 λ- 
Usage: Amplification of plasmids DNA 
Stab II 
Origin: Invitrogin 
Genotype: F- mcrA Δ(mcrBC-hsdRMS-mrr) recA1 endA1lon gyrA96 thi supE44 
relA1 λ- Δ(lac-proAB) 
Usage: Amplification of HIV-1 proviral plasmids  
4.1.9 Buffers and Solutions 
DNA loading Buffer  
Tris HCl (pH7.5)       50mM 
EDTA                   50mM 
Glycerol                  50% (v/v) 
Bromphenol blue                  0.25% 
Paraformaldehyde (PFA) pH7.3  
Paraformaldehyde                 3% (v/v) in PBS 
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PBS pH7.4  
Sodium Chloride (NaCl)                 96mM 
Sodium potassium phosphate (Na2HPO4)    10mM 
Monosodium phosphate (NaH2PO4 )          2.3mM 
PBS-T  
Sodium Chloride (NaCl)                 96mM 
Sodium potassium phosphate (Na2HPO4)    10mM 
Monosodium phosphate (NaH2PO4 )          2.3mM 
Tween 20                               1mM 
Luria Bertani (LB) Medium pH7.5  
Tryptone                             1% (w/v) 
Yeast extract                          0.5% (w/v) 
Sodium chloride (NaCl)                 170mM 
NaOH                               5mM 
Autoclaved at 121°C for 20 min  
SDS-PAGE Running gel  
30% acrylamide (0.8% bisacrylamide)      2.5 ml 
1.88 M Tris/HCL, pH 8.8                1.2 ml 
0.5% SDS                            1.2 ml 
Water                                1.1 ml 
APS 10%                              30 μl 
TEMED                                5 μl 
SDS-PAGE Stacking gel  
30% acrylamide (0.8% bisacrylamide)       330 μl 
0.625 M Tris/HCL, pH 6.8                400 μl 
0.5% SDS                             400 μl 
Water                                 870 μl 
APS 10%                               10 μl 
TEMED                                2 μl 
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2× SDS Sample Buffer  
Tris-HCl (pH6.8)                        130mM 
β-Mercaptoethanol                       10% (v/v) 
Glycerol                              10% (v/v) 
SDS                                  6% (w/v) 
Bromphenol  blue tip of a spatula 
6× SDS Sample Buffer  
Tris-HCl (pH6.8)                        390mM 
β-Mercaptoethanol                       30% (v/v) 
Glycerol                               30% (v/v) 
SDS                                  10% (w/v) 
Bromphenol blue                        blue tip of a spatula 
50× TAE Buffer  
Tris-acetic acid, pH7.8                    2M 
Sodium acetate                          250mM 
EDTA                                 500μM 
Tris-buffered Saline (TBS)  
Tris-HCl (pH7.6)                         20mM 
NaCl                                   140mM 
TBS-T  
Tris-HCl (pH7.6)                         20mM 
NaCl                                   140mM 
Tween 20                               1mM 
Transfer Blotting Buffer  
Tris.HCl, pH8.8                          25mM 
Glycine                                192mM 
Methanol                               20% (v/v) 
SDS                                   0.05%(w/v) 
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4.1.10 Lab Equipments, Chemicals and Consumption Items 
Table 6-1: List of Lab Equipment. 
Equipment Source 
Balance Ohaus Explorer, Germany 
Centrifuge Megafuge 1.0R                  Heraeus 
Centrifuge Biofuge fresco                   Heraeus 
Electroporator GenePulser X Cell TM           BioRad, USA 
Electrophoresis Power Supply                Amersham Biosciences 
Flow cytometer FACScalibur                BD, Germany 
Fluorescence Microscopy IX70               Olympus, Japan 
Microscopy Olympus CK2                  Olympus, Japan 
Freezer -80°C                            Thermo Scientific, USA 
LIEBHERR refrigerator and Freezer          LIEBHERR, UK 
Hera cell 150i CO2 incubator                Thermo Scientific, Germany 
Incubator Infors HT                        Infors, Bottmingen, Switzerland 
LSM510 confocal Microscopy               Zeiss, Germany 
Microplate Luminometer        Thermo Scientific, Germany 
Multi Channel Pipettes                     Thermo Scientific, Germany 
Minigel Twin (SDS PAGE) Biometra, Germany 
Nanophotometer   IMPLEN, Germany 
Odyssey Infrared Imaging System            Li-cor Biosciences, USA 
pH meter                                Knick, Germany 
Pipettes Labmate                          Abimed, Germany      
PCR Thermocycler                        Biometra, Germany      
Power PAC 200                           Bio-Rad, USA              
Srerile Hood  The Baker Company, USA 
UV Transilluminatoren                     INTAS, Germany 
 
Table 6-2: List of Chemicals and Consumption Items. 
Acrylamide bis aqueous solution 40 (29:1) Roth, Karlsruhe 
Acetone         Zentralbereich INF, Heidelberg 
Ammonium chloride (APS)                  Bio-Rad; München 
Blotting paper (Whatman)                   Schleicher&Schuell; Dassel 
Dishes/bottles/tube for cell culture            Neolab; Heidelberg 
Agar                                    BD falcon, Heidelberg 
Agarose NEEO Ultra quality                 Roth, Karlsruhe 
Ampicillin   Roth, Karlsruhe               
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Coverslips (12mm)                        Marienfeld 
DMEM/OptiMEM/RPMI1640               Invitrogen 
Electroporation cuvettes (4 mm gap)          Invitrogen, Karlsruhe 
Ethanol 100% (v/v)                        JT Baker, Deventer, Netherlands 
Ethidium bromide                         Merck, Darmstadt 
Fetal calf serum (FCS)                     Invitrogen 
Glycerol Zentralbereich INF, Heidelberg 
Isopropanol   Zentralbereich INF, Heidelberg 
Kanamycin Roth, Karlsruhe               
Lipofectamine 2000 Invitrogen, Karlsruhe 
Metafectene Biontex, Martinsried 
Milk powder                             Roth, Karlsruhe 
Mowoil Calbiochem 
β-Mercaptoethanol                         Sigma- Aldrich, München 
Nitrocellulose, Protran Transfer Membrane     Schleicher&Schuell, Dassel 
Penicillin/Streptomycin Sigma-Aldrich, München 
Protease inhibitor Mix                      Sigma-Aldrich, München 
Sodium acetate (NaCH3CO2)                Grüssing, Filsum 
Sodium chloride (NaCl)                    AppliChem; Darmstadt 
Sodium dodecyl sulfate (SDS)               Serva; Heidelberg 
Sodium hydroxide(NaOH)                  Merck; Darmstadt 
Sodium pyruvate                          Invitrogen; Karlsruhe 
Tris (hydroxymethyl aminomethane)          Roth; Karlsruhe 
Triton X-100                            Pharmacia Biotech; Erlangen 
Trypsin-EDTA                            Biochrom; Berlin 
TEMED Roth; Karlsruhe 
Trypan Blue                              Invitrogen; Karlsruhe 
Tween-20                               Roth; Karlsruhe 
Cell Culture Lysis Reagent (5×) Promega, Wisconsin, USA 
Luciferase assay Substrate Promega, Wisconsin, USA 
White polystyrene (Luc. Assay)              Corning, New York, USA 
Plastic materials for cell culture              Costar 
Penicillin and Streptomycin (50U/ml)          Invitrogen 
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4.2 Methods 
4.2.1 Cloning and Analysis of vpu genes from RT-PCR Products 
To amply the vpu gene sequences, polymerase chain reaction (PCR) was performed to 
amply the region of vpu gene from the RT-PCR samples with specific primers listed in 
Table 2-1 and 2-2. The amplified PCR fragments were digested with EcoRI and 
BamHI and then ligated into the vector pEGFP-N1 which was digested with the same 
enzymes. The PCR reaction system, PCR procedure, enzyme restriction digestion of 
PCR products/vector plasmids were as follows. 
PCR Reaction System 
Components           Ultimate concentration Volume (50.0μl) 
Templates (RT-PCR)  0.1μg/μl                 1.0 μl 
Forward primer         0.5 μM                 1.5 μl 
Reverse primer         0.5 μM                 1.5 μl 
dNTPs                10mM     1.0 μl 
Pfu                   0.2 U/μl                 1.0 μl 
10×Pfu buffer          1×                     5.0 μl 
H2O                   39.0 μl 
PCR procedure 
                     Cycles Temperature  Time 
Initial denaturation      1   98 °C         30 seconds 
Denaturation           30   98 °C         10 seconds 
Annealing             30 58 °C         30 seconds 
Elongation            30 72 °C         15 seconds 
Final elongation        1     72 °C         10 minutes 
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Restriction Endonuclease Digest of vpu PCR products/vector plasimds 
The reaction system was as follows and incubated at 37°C for 60-90 minutes. Then it 
was stopped by addition of 6× DNA loading buffer for further electrophoresis and 
purification. 
PCR products/Plasmids           10.0 μl/3.0 μl 
EcoR I                         2.0 μl (2.0 units) 
BamH I                        2.0 μl (2.0 units) 
NEB Buffer 4                   5.0 μl 10.0× 
Add H2O  to total volume         50.0 μl 
Gel Electrophoresis and Purification of PCR Products 
To purify the restriction-endonucleases-digested PCR fragments and vectors, they 
were separated by the agarose gels consisting of 1.5% (w/v) agarose and 0.7 μg/ml 
ethidium bromide in TAE buffer for 20-30 minutes, with the voltage of 85V 
electricity. The gels were then visualized under UV light. The bands at the indicated 
size were sliced and purified by NucleoSpin Extract II kit according to the 
manufacturer’s protocol. In the end, the purified products were dissolved in H2O. 
Ligation of pEGFP and Vpu Fragments  
Vpu gene were introduced into pEGFP N1 vector by the ligation of vpu PCR products 
and pEGFP N1 plasmid via their complementary base pairs in the ends which were 
generated from the endonuclease (EcoR I/BamH I) restriction digest as described 
above. The ligation mixture contained a molar ratio of 1:3 pEGFP N1 to vpu and 
catalysed by 2 units of T4 ligase (1.0 unit/μl). As a control, the vector fragments were 
incubated with no vpu insertion to estimate the percentage of ligated vector fragments. 
The ligation mixture was incubated at room temperature for 2 hours or 4°C for 
overnight. Then 10.0 μl of the ligation mixture was further performed for 
transformation described as below. 
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Heat Shock Transformation 
To amplify the ligated pVpuEGFP products or other plasmids, they were transformed 
into bacterial competent cells DH5α or StabII. The experimental procedure was as 
follows: 
① Took competent cells DH5α 50.0 μl or StabII 50.0 μl (for provirus plasmids 
production) from -80°C freezer, incubated on ice for thaw the competent cells 
② Added ligation reaction mixture 10.0 μl or plasmids 1.0 μl (1.0 μl/μg) 
③ Incubated the mixture of competent cells and DNA for 20-30 minutes on ice 
④ Heat shock the reaction in water bath at 42°C for 90 seconds to  
⑤ Incubate the reaction on ice for 2 minutes to reduce damage to cells 
⑥ Added 1.0 ml of LB (with no antibiotic) to the mixture and then incubated the for 
1 hour at 37°C 
⑦ Evenly plated 100 μl of the resulting culture on LB plates (with appropriate 
antibiotic added – usually ampicillin or kanamycin). Incubated at 37°C overnight. 
⑧ Picked colonies about 12-16 hours post transformation 
Plasmid DNA Isolation (Mini-prep) 
To identify the resulted natural vpu clones from the former steps or other DNA 
plasmids from the single clone, DNA plasmids need to be isolated. The DNA plasmids 
preparation was based on the manufactory’s protocols. 
①  Grew bacterial (DH5α or StabII) culture in LB medium with appropriate 
antibiotics at 37 °C overnight with shaking in 4.0 ml medium.  
② Harvest the bacterial culture into 1.5ml tube, spinning at maximum speed for 20 
seconds, then discarded the supernatant. 
③ Suspended the bacterial cells pellets with 300 μl of ice cold solution 1 (50 mM  
Tris-HCl, 10 mM EDTA, 100 μg/mL RNase A, pH 8.0).  
④ Lysed the bacterial cells with 300 μl of solution 2 (200 mM NaOH, 1%SDS) at 
room temperature (RT). Mixed the solutions by inverting them a few times gently, 
leaving the mixture at RT for less than 5 minutes. 
⑤ For neutralization, 300 μl of ice-cold solution 3 (2.8 M potassium acetate, pH 5.1), 
was added, leaving the mixture on ice for 5 minutes. 
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⑥ After spinning the mixture at maximum speed for 10 minutes, the supernatant was 
transferred to a new 1.5 ml tube, around 900 μl. 
⑦ After another spinning, 600μl isopropanol was added to the 900 μl supernatant to 
precipitate the DNA nucleic acids. 
⑧ Spin at maximum speed for 10 minutes in cold centrifuge, harvest the plasmids 
DNA pellets and discarded the supernatant. 
⑨ Plasmids DNA pellet was washed with 75% ethanol. Dry the plasmid DNA pellet 
at room temperature. 
⑩ Plasmid DNA was dissolved with 50 μl brown water. 
Quality Control of Plasmid DNA 
Before sending the isolated plasmids to sequence or performing further experiments, 
the plasmid DNA was first evaluated by the endonuclease restriction digest agarose 
gel (1.5%) electrophoresis (as described above) to see whether the plasmid showed 
the right bands and whether the target gene was in the right size. 
Sequencing  
Five vpu single clones derived from one patient were picked up for mini-prep. The 
isolated DNA plasmids were fist restricted by endonuclease digest (EcoR I/BamH I) 
as described above. The clones showing the right insertion were sent to GATC biotech 
for sequencing via the primer for pEGFP N1 promoter CMV provided by the 
company. The homepage is referred to http://www.gatc-biotech.com/en/home.html. 
Plasmid DNA Isolation (Max-prep) 
To extract DNA plasmids in a large scale, the NucleoBond A× 500 kit, which empolys 
a modified alkaline /SDS lysis procedure to prepare the bacterial cell pellet for plasmid 
purification, was used according to the manufacture’s protocol. The NucleoBond PC 
500 column was used for the purification of plasmid DNA, the basic principle is The 
experimental procedure was as follows: 
①  Grew bacterial (DH5α or StabII) culture in LB medium with appropriate 
antibiotics at 37 °C overnight with shaking in 400 ml medium.  
② Harvest of the bacterial cells and successional treatments with solution 1/2/3 (12 
ml of each solution per one extraction) were identical with the mini-prep. 
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③ Resulted bacterial lysate was centrifuged 4000 rpm for 10 minutes for clearing the 
lysate. At this period, equilibrated DNA binding column (NucleoBond PC 500) with 
the equilibration buffer N2 (100 mM Tris, 15% ethanol, 900 mM KCl, 0.15% Triton 
X-100, adjusted to pH6.3 with H3PO4) 6 ml.  
④ The cleared lysate was applied to the equilibrated NucleoBond Column PC500 
through a wet folded filter in order to remove remaining particles before loading the 
column. The plasmid DNA is bound to the anion-exchange resin. 
⑤ The column was washed with buffer N3 (100 mM Tris, 15 % ethanol, 1.15 M KCl, 
adjusted to pH 6.3 with H3PO4) 
⑥ Plasmid DNA was eluted from the column into a new 50 ml tube with 15ml 
elution buffer (100 mM Tris, 15 % ethanol, 1 M KCl, adjusted to pH 8.5 with H3PO4). 
⑦  Plasmid DNA was precipitated by the adding 15 ml of room temperature 
isopropanol to to avoid spontaneous co-precipitation of salt. 
⑧ After centrifugation at 4000rpm for 45 minutes at 4°C, the plasmid DNA was 
pelleted. It was washed with 75% ethanol and dried at RT. 
⑨ Plasmid DNA was dissolved within 300 μl Braun water. 
Measurement of DNA Concentration and Purity 
The concentration and purity of plasmid DNA solution were determined by measuring 
absorbance (optical density (OD)) at the absorbance at 260 nm and 280 nm 
respectively using NanoDrop™ spectrophotometer. The ration of OD260/OD280 within 
the range of 1.8-2.0 was considered as quality plasmid for further application. 
4.2.2 Home-made Site-directed Mutagenesis 
Primer Phosphorylation 
5’ end of the primers need to be phosphorylated. The reaction system is as follows: 
Primer 5.0 µl 
MgSO4 100mM 0.5 µl 
ATP 10mM 10.0 µl 
T4-PNK (5U) 0.5 µl 
10× Kinase Buffer A 5.0 µl 
Add water to  50.0 µl 
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The mixture was incubated at 37°C for 60 min, then heat inactivated and stored in 
-20°C. The PCR reaction system was the same principle described in 4.2.1. The thermo 
cycling procedure is different with normal PCR amplification. The annealing 
temperature was 55°C, and elongation time at 72°C was 10 min. The cycling was 
shortened to 18 (Laible and Boonrod 2009). 
DpnI digestion 
To get rid of the background, DpnI.restriction endonuclease was used to digest the 
methylated template plasmid before tansformation. For each reaction, 2U of DpnI was 
incubated with the PCR products at 37°C for 2 hours. Transformation was described 
in 4.2.1. 
 
4.2.3 Analysis of Vpu sequences 
Validation of Vpu Sequences  
More than one vpu allele is circulating in HIV-1 infected patient, and the 
contamination was a major concern for the cloning procedure. To exclude the 
contamination and pick up the predominant vpu allele circulation in each patient, the 
phylogenetic tree was generated based on the primary sequences in the databse and 
clonal vpu sequences (GATC sequencing results of pVpuEGFP plasmids) by using of 
the maximum-likelihood method (DNAml, PHYLIP), which was performed by our 
colleagues Takamasa Ueno group (Center for AIDS Research, Kumamoto University, 
Japan). The clonal vpu alleles, which assembled the primary sequences, were selected 
for functional analysis. And also, the intact enzyme restriction sites, open reading 
frame and the GFP tag for each construct were checked by using the software Clone 
Manager. 
Multiple Sequence Alignment 
All the validated vpu alleles, the sequences of their encoding amino acid were aligned 
against NL4.3 Vpu by using ClustalW2 from EMBL-EBI. The home page is referred 
to http://www.ebi.ac.uk/Tools/msa/clustalw2/. 
Mutation Frequency of Candidate Amino Acids  
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The candidate amino acids, which were suspected to be critical for Vpu functions, 
were determined by calculating the mutation frequencies out of all HIV-1 clade B 
subtype Vpu proteins extracted from Los Alamos National Laboratories 
(http://www.hiv.lanl.gov). The amino acids with mutation frequency lower than 0.1% 
were arbitrarily selected for further site-mutagenesis and functional analysis. 
4.2.4 Delivery of Plasmid DNA to Mammalian Cells 
Distinct methods were applied to deliver plasmid DNA into mammalian cells 
depending on cell lines and size of plasmid DNA. A3.01 cells, derived from human T 
lymphoblast, were transfected with vpu allele plasmids by electroporation. The 
delivery of provirus plasmids were mediated by lipofectamine 2000. 
Polyethylenimine (PEI) and metafectene were also used for the transfection of 
TZM-bl and 293T cells respectively. The methods and protocols used in this study 
were described as follows. 
Transfection of HEK 293T Cells  
The expression of natural vpu alleles was first evaluated in HEK 293T cells. 
Metafectene was used to transfect HEK 293T cells with pVpuEGFP plasmids.  
① One day prior to transfection, cells were seeded in 6 well-plate, 5×105 cells/well. 
② To remove the cell debris in old culture medium, fresh DMEM complete medium 
were added to the cells. 
③ The following solutions were prepared in EP tubes: Solution A: 3 μg of expression 
plasmid in 100 μl Opti-MEM medium. Solution B: 6 μl metafectene100 μl Opti-MEM 
medium. The solutions were gently mixed. 
④ The solutions were then combined with no mixture procedure, and then incubated 
the complex at room temperature for 25 minutes. 
⑤ The complex was then drop gently to the cells with gently swirling afterwards. 
Incubate at 37°C in a CO2 incubator.  
⑥ 24 hours post transfection, the cells were harvested for evaluating the expression 
of Vpu alleles. 
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Electroporation of A3.01 Cells  
① One day prior to electroporation, A3.01 cells were cultured in fresh medium. 
② 8×106 cells per one electroporation, the cells were harvested by centrifugation and 
dissolved in 500 µl pre-warmed RPMI1640 medium with no supplements of FCS and 
antibiotics. 
③ The suspended cells were transferred to the 4.0 mm cuvelte and added 30μg 
pVpuEGFP or pVpuIRESGFP plasmid. 
④  Electroporation was performed by using the Bio-Rad Genepulser under the 
procedure: voltage: 250 volts, capacitance: 950 microfarads (µF). 
⑤ Electroporated A3.01 cells were cultured in 4.0 ml RPMI1640 complete medium. 
Incubate at 37°C in a CO2 incubator.  
⑥ 24 or 48 hours post electroporation, cells were harvested for further analysis. 
Transfection of TZM-bl Cells by PEI  
① One day prior to transfection, TZM-bl cells were seeded in 12 well-plate, 7×104 
cells/well. 
② To remove the cell debris in old culture medium, fresh DMEM complete medium 
were added to the cells. 
③ 3 μg of expression plasmids were first added to a 1.5 ml EP tube with 100 μl 
Opti-MEM medium, briefly vortex the mixture, then 9 μl PEI was added, gently 
mixing and leaving the mixture at room temperature for 35-50 minutes 
④ DNA/PEI mixture was then transferred to cells, with gently swirl afterwards. 
Incubate at 37°C in a CO2 incubator.  
⑤ 24 hours post transfection, harvest the cells were harvested for further analysis. 
Transfection of TZM-bl Cells with Provirus Plasmids by Lipofectamine 2000  
PEI is widely used for the transfection of mammalian cells. However, it did not 
mediate the delivery of provirus plasmids in my hands (data not show). Then 
lipofectamine 2000 was used to co-transfect the TZM-bl cells with provirus and vpu 
expression plasmids for the infectivity assay, which was described in 4.2.7. 
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4.2.5 Confocal Microscopy 
A3.01 T cells adhered to poly-lysine coated coverslips were fixed with 3% PFA. 
Coverslips were mounted with mowiol medium and analysed with a Zeiss LSM510 
confocal microscope with a 100x PLAN-APO objective lens. Images were recorded 
with the Zeiss proprietary software LSM5 and processed with Adobe Photoshop 4.0.  
 
4.2.6 Biochemical Assays 
Preparation of Cell lysates 
For the separation and detection of target proteins, the transfected cells were lysed 
using SDS sample buffer or KEB lysis buffer in this study. Briefly, cells were washed 
and subjected to ice-cold KEB buffer (100 μl for 8×106 cells) followed by swirling at 
4°C. After centrifugation (10 min at 12,000 rpm at 4°C), supernatants were transferred 
into a new tube, stored at -20°C or immediately subjected to the applications such as 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). 
Discontinuous SDS-PAGE 
Cell lysates were denatured by treating with 2× SDS sample buffer and heating (95°C 
for 5 min). The proteins were separated by discontinuous SDS-PAGE. Equal amounts 
of cell lysates were loaded into the polyacrylamide gel and first run in the stacking gel 
(4.0% polyacrylamide), and then the stacked proteins were separated in the resolving 
gel (12.5% polyacrylamide) according to their relative molecular mass. The 
electrophoresis ran at 25 milliamps (mA), with the indication of a pre-stained protein 
marker ranging from 6 to175 kDa. Gels were subsequently applied to western 
blotting. 
Western Blotting 
After electrophoretic separation of proteins, gels were performed semi-dry proteins 
blotting to transfer the proteins to a nitrocellulose membrane according to the standard 
blotting flow. The nitrocellulose membrane, filter paper (Whatman blotting paper) and 
gel were soaked in the transfer blotting buffer and then assembled in a strict order to 
set the gel was close to cathode (-) and the membrane was close to anode (+). The gel 
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and membrane were sandwiched by the soaked blotting paper, then the whole 
component ran for electronic transfer under the current of 100 mA per Gel for 45-60 
minutes. 
The nitrocellulose membrane, with blotted proteins, was then detected for the 
expression of proteins by using antibodies and the reporter enzyme, horseradish 
peroxidase (HRP) in this study. The experimental procedure was described below. 
① Membranes were incubated with 5% milk to block unspecific binding sites. 
② Membrane were incubated with primary antibody overnight at 4°C after washing 
with PBST. 
③ To remove the unbinding primary antibody, membranes were washed for three 
times wash with PBST (15 min per time). 
④ The respective secondary antibody conjugated with HRP (diluted in 5% milk) was 
then added to membranes and incubated for 1 hour at RT. For the detection of proteins 
by LiCor Odyssey, the secondary antibody coupled with Alexa 700 (dilution of 
1:10,000 in 2% BSA) was added to the membrane and incubated in dark for 1 hour. 
Afterwards, the membrane was washed to remove the remaining secondary antibody 
and milk. 
⑤ The expression of target proteins was evaluated by enhanced chemiluminescent 
substrate (ECL) (Pierce), which was reflected on a photosensitive film. Membranes 
incubated with Alexa 700 conjugated antibody were scanned on Licor Odyssey with a 
wavelength of 700 nm. The quantification was assessed using Licor Odyssey 
software. 
 
4.2.7 Fluorescence-Activated Cell Sorting (FACS) 
To evaluate the surface level of CD4, CD317, MHC-1, NTB-A molecules in cells 
expressing Vpu alleles, FACS analysis was performed as the following steps: 
① A3.01 or TZM-bl cells were transfected with plasmid DNA in a 6-well plate or 
12-well plate scale as described in 4.2.4. Untransfected cells from the same batch 
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were served as control for FACS settings. They were harvest and suspended at 48 
hours or 24 hours post transfection. 
② All samples were divided to 4 aliquots, each aliquot of cells were stained with 100 
µl of diluted CD4-APC, CD317-APC, MHC-I-APC or NTB-A –APC respectively 
listed in Table 6, then were incubated in dark and on ice for 45 min. 
③ After staining, the cells were washed with PBS (3000rpm, 5 minutes, 4°C), and 
the pellets were suspended with 150 μl-300 μl PBS in each tube for performing FACS 
analysis. 
④The FACS analysis procedure was: firstly, untransfected and unstained sample was 
used to define the population of living cells; then, transfected but unstained control 
sample, together with transfected and stained sample, was used to adjust the detectors; 
finally, run samples after setting gates for GFP positive and negative cells to 
determine the CD4, CD317, MHC-I or NTB-A surface level in those two population 
of cells. 
4.2.8 Infectivity Assay 
Vpu has no effect on HIV-1 infectivity in cell culture system. Vpu-mediated virus 
release enhancement was evaluated by infectivity assay in TZM-bl cells. 
Transfection of TZM-bl Cells by Lipofectamine 2000  
① One day prior to transfection, TZM-bl cells were seeded in 12 well-plate, 7×104 
cells/well. 
② To remove the cell debris in old culture medium, fresh DMEM medium with no 
serum and antibiotics were added to the cells. 
③ The following solutions were prepared in EP tubes: Solution A: 2.7 µg of provirus 
and pVpuIRESGFP or pIRESGFP plasmids in 50 μl Opti-MEM medium. The amount 
of plasmids was shown below. Solution B: 2.7 μl lipofectamine 2000 in 50 μl 
Opti-MEM medium. The solutions were gently mixed. Triplicates were performed for 
each transfection. 
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Table 7: Co-transfection of TZM-bl cells with proviral plasmid and Vpu 
construct or empty vector. 
HIV-NL4.3 wt 1.2 μg  pIRESGFP  1.5 μg 
HIV-1 NL4.3 ΔVpu 1.2 μg  pIRESGFP  1.5 μg 
HIV-1 NL4.3 ΔVpu 1.2 μg  pVpuS/AIRESGFP  1.5 μg 
HIV-1 NL4.3 ΔVpu 1.2 μg  pVpuIRESGFP  1.5 μg 
HIV-1 NL4.3 ΔVpu 1.2 μg  EC and CP pVpuIRESGFP alleles 1.5 μg 
④ The solutions were then combined with no mixture procedure, and then incubated 
the complex at room temperature for 25 minutes. 
⑤ The complex was then drop gently to the cells with gently swirling afterwards. 
Incubate at 37°C in a CO2 incubator.  
⑥ The plates were then transferred to P3 lab and was changed to the fresh DMEM 
complete medium. 
⑦ 48 hours post transfection, the cell culture supernatant was harvested for the 
infection of newly-seeded TZM-bl cells which were then used for infectivity assay. 
The transfected cells were lysed and subjected to Western blotting for the evaluating 
the expression of Vpu or GFP, viral capsid p24 and p55. To detect the real expression 
level of those proteins in one single transfection, we avoided to detach the TZM-bl 
cells by trypsin/EDTA, which could break the syncytia cells or fragile cells then 
consequently loss proteins. The 2× SDS sample buffer was directly added into two of 
the triplicates for each sample and the cells were harvested by scrapping. TZM-bl 
cells in one of the triplicates were detached by by trypsin/EDTA, washed with PBS 
and then fixed with 3% PFA for 1 hour at room temperature, and the fixed cells were 
performed FACS analysis for determining the surface level of CD317. Infection of 
new TZM-bl cells, harvest and fixation of transfected cells were done in P3 lab. 
Western blotting and FACS analysis were done in P2 lab, and the procedures were the 
same as described in 4.2.7 and 4.2.8 respectively. 
Infectivity Assay 
① Prior one day of infection, TZM-bl cells were seeded in 96-well plates, 5×103 
cells/well. 
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② 50 μl the cell culture supernatant was added to the fresh TZM-bl cells, and 
incubated the infected cells for 72 hours. 
③ The infected cells were harvested with 40 μl cell lysis buffer (1:5 diluted in H2O) 
per well.  
④ The cell lysate was transferred to a new 96-well plates and brought to P2 lab. 
⑤ Transfer 10μl cell lysis to white plate, add 50 μl luciferin substrate per 10 μl cell 
lysis sample 
⑥ Measure the luciferase units in luminoskan ascent. 
 
4.2.9 Software 
Table 8: List of software used in this study. 
Software Version Source 
Adobe Illustrator  CS4 Adobe System 
Clone Manager Professional suite 8 Sci-Ed Software 
CellQuestPro 4.0.2 BD Biosciences 
Cyflogic 1.2.1 http://www.cyflogic.com/ 
Endnote  X5.0 Thomson  Reuters 
GraphPad Prism  5.0 GraphPad Software 
Image J ̶ http://imagej.nih.gov/ij/ 
LSM Image Browser LSM 5 http://www.zeiss.com/ 
 
4.2.10 Statistical Evaluation  
All statistical analysis were evaluated using GraphPad Prism 5 and statistical 
significance was determined using the Mann-Whitney U test (* p ≤ 0.05, ** p ≤ 0.01). 
Correlations between data sets were evaluated by applying Spearman’s or Pearson 
coefficient analysis (* p ≤ 0.05, ** p ≤ 0.01; *** p ≤ 0.001).  
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5 Results 
5.1 Validation of Patient-derived Vpu Genes 
All vpu alleles were amplified from the RT-PCR products provided by Takamasa 
Ueno (Center for AIDS Research, Kumamoto University, Japan). The acquisition of 
the RT-PCR products from the plasma HIV-1 isolates were previously described 
(Fellay, Shianna et al. 2007) (Miura, Brockman et al. 2008. Patient-derived Gag, Env, 
and Nef from the same EC and CP cohorts were characterized {Miura, 2009 #25) 
(Brumme, Li et al. 2011) (Mwimanzi, Markle et al. 2013). To evaluate the properties 
of the vpu alleles, the amplicons were cloned into pEGFP N1 expression vectors 
respectively. Five Vpu clones per patient were sequenced and then validated by 
maximum-likelihood phylogenetic tree to exclude the contamination. A single colone 
that closely resembled the original primary sequence in the database was picked up 
for further functional analysis. Genbank accession numbers for primary Vpu 
sequences are EU517721- EU873004 (EC) and FJ469688-FJ469764 (CP). 
Altogether 15 EC and 16 CP Vpu alleles were selected based on the validated 
sequences and comparable expression levels. All the sequences were assembled into a 
maximum likelihood phylogenetic tree (Figure 8). As shown, each representative 
patient Vpu allele has unique sequence, and all EC and CP Vpu sequences distributed 
equally to the reference NL4.3 Vpu, which indicated that there is no correlation 
between Vpu sequence diversity and disease progression. Clonal Vpu sequences from 
EC showed no evidence of gross defects or recent shared ancestry, which is consistent 
with previous analyses of bulk plasma HIV RNA sequences from our EC cohort 
(Miura, Brockman et al. 2008).  
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Figure 8: Maximum-likelihood phylogenetic tree of plasma HIV RNA-derived 
vpu clonal sequences. EC-derived Vpus are red, CP-derived Vpus are blue, and 
control strain NL4.3 Vpu is black. (This figure was performed by Takamasa Ueno, 
Center for AIDS Research, Kumamoto University, Japan) 
 
5.2 Alignment and Sequence analysis of Vpu Alleles 
With the validated Vpu alleles, we aligned and analyzed their amino acid sequences. 
Sequence variations for both groups were in the range of 16% to 24% (calculated by 
the software Clone Manager), which is similar to another study showing that the 
diversity of intra-patient Vpu alleles was around 20% (Pickering, Hue et al. 2014). 
Even though the representative Vpu sequences were highly variable, the documented 
critical motifs for CD4 downregulation and CD317 antagonism were principally 
conserved (Figure 9). Strikingly, no natural mutation occurred in the DSxxES motif, 
which is the target for CK-II phosphorylation and essential for CD4 degradation and 
CD317/tetherin antagonism (Margottin, Bour et al. 1998) (Goffinet, Allespach et al. 
2009) (Mangeat, Gers-Huber et al. 2009). In the transmembrane domain, the indicated 
determinants for CD317/tetherin counteraction were well conserved, especially the 
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central ones A10/A14/A18/W22 for CD317/tetherin contact (Vigan and Neil 2010), in 
addition, I4/A7 showing conservation to a slightly less extent. Two positively charged 
residues 30R and 31K critical for trans-Golgi network localization, located in the 
hinge region between the TM domain and the cytoplasmic domain, together with the 
residues V25/Y29 crucial for lipid raft association (Fritz, Tibroni et al. 2012) (Dube, 
Roy et al. 2009), were highly conserved. In the C-terminal domain, the trafficking 
motif ExxxLV displayed mild diversity. For example, MEF and E00452 showed 
insertion or deletion at the last amino acid, and the mutations at the variable xxx sites 
also gave rise to relatively higher diversity in the C-terminal domain. The recently 
identified 76W residue, which was shown unique importance for virion release 
enhancement (Jafari, Guatelli et al. 2014), was conserved among both group Vpus, 
except for E00452 with 76R. Enrichment of KIR2DL2-adapted polymorphism at 
71M/74H in EC Vpus was a striking property. Only 3 of 15 EC Vpus, including 
CTR183, MEF and FW048, displayed mutation of 74R/D/L, whereas, 11 of 16 CP 
Vpus showed 74R/D/L. The CTL targeting epitope EYRKILRQR was highly 
conserved. However, the other one HAPWDVNDL showed high variations in the first 
amino acid and flanking amino acids, such as E00449 and E00452. Last but not least, 
61S for Vpu stability (Estrabaud, Le Rouzic et al. 2007), was principally conserved, 
except for FW048 and E00468 with the mutation of K and A respectively. Altogether, 
the key functional motifs were generally preserved, the sequence variations mainly 
come from the N-terminal and C-terminal (Figure 9). 
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Figure 9: Sequence alignment and analysis of patient-derived Vpu alleles. Amino 
acid sequence alignment of the Vpu proteins analyzed generated using Clustal Omega 
(EMBL-EBI). HIV-1 NL4.3 Vpu on the top serves as reference sequence. Boxes 
indicate the position of functionally relevant residues and motifs. Different colours 
present the properties of the amino acid: red colours for small side chains and 
aromatic Y, blue for acidic residues, green for hydroxyl, sulfhydryl, amine groups and 
G, magenta for basic-H bonding or positive charged groups.  
 
 
5.3 Expression and Detection of Natural Vpu Alleles 
Besides the representative Vpu sequence for each patient, the following limited steps 
for further functional analysis are whether the expression of the non-codon-optimized 
Vpu clonal constructs can be detected and whether they express on the comparable 
level. We first checked the expression and detection of all generated pVpu.GFP 
constructs in 293T cells (data not shown), together with the sequence information, a 
set of 31 constructs is confirmed for further analysis. Then we evaluated the 
expression of the 15 EC and 16 CP vpu alleles in more relevant cell lines. Briefly, 
A301 cells transfected with pVpu.GFP or TZM-bl cells transfected with 
pVpuIRESGFP were collected and western blot analysis was performed. The 
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transferin receptor showed equal loading (Figure 10A, B; lower panel). As non-fusion 
proteins, the similar intensity of GFP bands reflected comparable transfection 
efficiency and comparable Vpu expression level for each allele (Figure 10B; middle 
panel). Whereas, Vpu probe showed more variant bands in fusion and non-fusion 
version of Vpu alleles by using the rabbit polyclonal Vpu antibody (Figure 10A, B; 
upper panel). This antibody was generated against a peptide encompassing amino 
acids 58-80 (EGD QEE LSA LME MGH HAP WNV ND). The failure of detection by 
Vpu antibody mainly resulted from the mutation from H to R/D/L at the position 74 
which is one of KIR2DL2 footprints. CP Vpus showed more sequence diversity at this 
position compared with EC Vpus, which was reflected by the more frequent detection  
 
 
 
Figure 10: Expression and detection of non-codon-optimized vpu alleles. A: A301 
cells were electroporated with Vpu.GFP plasmids (30 μg). B: TZM-bl cells were 
transfected with VpuIRESGFP plasmids (3 μg). 24 hours post-transfection cells were 
harvested and the cell lysates were analyzed by immunoblotting for Vpu, GFP, and 
transferin receptor. 
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of EC Vpus (Figure 10A, B; Upper panel). In addition, the insertion of HHA at 
C-terminal for E00449 and insertion of NII at N-terminal for E00456 could be the 
reasons for the poor detection or expression (Figure 2, 3). CTR183, E00452, E00462 
and E00466 showed less pronounced bands as fusion proteins. Nevertheless, they 
displayed similar bands as non-fusion proteins (Figure 2A). Overall, the expression 
levels of all alleles as fusion protein were comparable, which made us move on the 
further analysis. 
 
5.4 Subcellular Localization Patterns of Natural Vpu Alleles 
The subcellular distribution of Vpu in ER and TGN are essential for Vpu-induced 
CD4 degradation and virion release enhancement (Dube, Roy et al. 2009) (Vigan and 
Neil 2011). We analyzed the subcellular localization in A301 cells expressed with 
Vpu.GFPs. The plasma membrane was defined by WGA594, localization of Vpu 
alleles was indicated by GFP. The control NL4.3 Vpu.GFP was accumulated in the 
cellular compartment(s) (Figure 11). The majority of the EC and CP Vpus shown the 
similar cellular accumulation pattern as the reference NL4.3 Vpu.GFP, but CTR112 
from EC group displayed plasma membrane patches (Figure 11). Based on the 
comparable expression levels and localization in relevant cell lines, we investigated 
the functional analysis of the patient-derived Vpu alleles. 
 
5.5 Conservation of CD4 and CD317 Modulation Activities 
5.5.1 Surface Modulation of CD4 and CD317 by Vpu.GFPs 
We first analyzed the downregulation of CD4 and CD317 molecules from the surface 
of A301 cells. Vpu.GFPs were transiently expressed in A301 cells, and cell surface 
levels of CD4 and CD317 were examined by FACS 48 hours post transfection. eGFP 
and NL4.3 Vpu.GFP were set as negative and positive controls respectively. The y 
axis showed the mean fluorescence intensity (MFI) of CD4-APC or CD317-APC, and 
x axis represented GFP expression level (Figure 12A, 13A). MFI ratio of GFP positive  
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Figure 11: Subcellular localization of Vpu alleles. A3.01 cells were electroporated 
with Vpu.GFP expression constructs, harvested and fixed on coverslips after 24 hours. 
The plasma membrane was defined by WGA-594. Coverslips were analyzed with a 
Zeiss LSM510 confocal microscope with a 100x PLAN-APO objective lens. Images 
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were recorded with the Zeiss proprietary software LSM5 and processed with Adobe 
Photoshop 4.0. Scale bar: 10 μm. 
 
 
cells/MFI of GFP negative cells was first subtracted from the background of eGFP 
and the resulted value for each Vpu was further normalized to NL4.3 Vpu that was 
then arbitrarily set as 100% (Figure 12B, 13B). The ability to reduce surface levels of 
CD4 was conserved among the majority of analysed Vpus, except CTR183 and MEF 
from EC group, which showed obvious impairment, less than 50% of the NL4.3 Vpu 
(Figure 12B). Median with interquartile range (IQR) was evaluated to compare the 
downregulation potency of both groups. EC Vpus displayed lower capacity (median 
116.0 [IQR 77.0–129.0]%) to decrease the surface expression level of HIV-1 receptor 
CD4 molecules than CP Vpus (median 135.0 [IQR 119.0–149.8]%) (p< 0.01; Figure 
12 C).  
Downregulation of CD317 was analysed as the same procedure described before with 
the same batch of transfected cells. The positive control NL4.3 Vpu removed around 
80% of CD317 from the cell surface (Figure 13A). CP Vpus showed comparable 
activity with NL4.3 Vpu. However, EC Vpus had more impaired alleles, such as 
CTR183 and 8227 with lower than 50% of NL4.3 Vpu ability (Figure 13 B). 
Statistically, EC Vpus displayed lower capacity (median 76.7 [IQR 65.2–82.4]%) to 
decrease the surface expression level of HIV-1 receptor CD317 molecules than CP 
Vpus (median 97.4 [IQR 84.8–97.1]%) (p< 0.01; Figure 13C). It indicated that CD4 
and CD317 downregulation activities of patient-derived Vpu alleles are principally 
conserved with few impaired ones in EC group. And the statistical differences resulted 
from the higher frequencies of alleles with reduced ability in EC Vpus. 
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Figure 12: CD4 downregulation activity of Vpu.GFP alleles. A3.01 cells were 
electroporated with Vpu.GFP expression constructs, harvested after 48 hrs, and 
stained for cell surface CD4. A: Flow cytometry plots of eGFP and NL4.3 Vpu.GFP: 
CD4-APC (y-axis) vs. GFP (x-axis). Downregulation activity (R3/R2 ratio) was 
normalized to NL4.3 Vpu that was arbitrarily set to 100%. B: Graph showing the CD4 
downregulation activity of patient derived Vpu alleles relative to NL4.3 Vpu. Shown 
are mean values of triplicate transfections with the indicated standard deviation. The 
result is a representative of three independent experiments. C: Comparison of CD4 
downregulation activity of EC Vpus and CP Vpus. 
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Figure 13: CD317 downregulation activity of Vpu.GFP alleles. A3.01 cells were 
electroporated with Vpu.GFP expression constructs, harvested after 48 hrs, and 
stained for cell surface CD317. A: Flow cytometry plots of eGFP and NL4.3VpuGFP:  
CD317-APC (y-axis) vs. GFP (x-axis). Downregulation activity (R3/R2 ratio) was 
normalized to NL4.3 Vpu that was arbitrarily set to 100%. B: Graph showing the 
CD317 downregulation activity of patient derived Vpu alleles relative to NL4.3Vpu. 
Shown are mean values of triplicate transfections with the indicated standard 
deviation. The result is a representative of three independent experiments. C: 
Comparison of CD317 downregulation activity of EC Vpus and CP Vpus. 
 
5.5.2 Surface Modulation of CD4 and CD317 by VpuIRESGFPs 
We further evaluated the capacity of Vpu to modulate CD4 and CD317 in the 
non-fusion context. EC and CP VpuIRESGFPs were transiently expressed in TZM-bl 
cells. Surface CD4 and CD317 remaining levels were determined by FACS  
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Figure 14: CD4 downregulation activity of VpuIRESGFP alleles. TZM-bl cells 
were transfected with VpuIRESGFP constructs, harvested after 24 hours, and stained 
for cell surface CD4. A: Flow cytometry plots of IRESGFP and NL4.3 VpuIRESGFP: 
CD4-APC (y-axis) vs. GFP (x-axis). Downregulation activity (R3/R2 ratio) was 
normalized to NL4.3 Vpu that was arbitrarily set to 100%. B: Graph showing the CD4 
downregulation activity of patient derived Vpu alleles relative to NL4.3 Vpu. Shown 
are mean values of triplicate transfections with the indicated standard deviation. The 
result is representative of three independent experiments. C: Comparison of CD4 
downregulation activity of EC Vpus and CP derived Vpus. 
 
 
as described in 5.3.1. As shown in the primary data for controls, the reference NL4.3 
Vpu removed 80% of CD4 or CD317 from the surface (Figure 14A, 15A). The 
following evaluation showed that majority of patient-derived Vpus showed 
comparable potency to reduce CD4 surface levels as the reference strain NL4.3 Vpu  
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Figure 15: CD317 downregulation activity of VpuIRESGFPs alleles. TZM-bl cells 
were transfected with VpuIRESGFP constructs, harvested after 24 hours, and stained 
for cell surface CD317. A: Flow cytometry plots of IRESGFP and NL4.3 
VpuIRESGFP: CD317-APC (y-axis) VS. GFP (x-axis). Downregulation activity 
(R3/R2 ratio) was normalized to NL4.3 Vpu that was arbitrarily set to 100%. B: 
Graph showing the CD317 down-regulation activity of patient derived Vpu alleles 
relative to NL4.3 Vpu. Shown are mean values of triplicate transfections with the 
indicated standard deviation. The result is representative of three independent 
experiments. C: Comparison of and CD317 downregulation activity of Vpus and CP 
derived Vpus. 
 
 
(Figure 14B). Few alleles from EC group, such as CTR183, MEF and FW048, 
displayed lower than 80% of NL4.3 Vpu activity (Figure 14B). EC Vpus maintained 
significantly lower activity (median 94.5 [IQR 84.7–97.5]%) than CP Vpus (median 
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98.6 [IQR 95.2–101.6]%) (p< 0.05; Figure 14C). Similarly, majority of primary Vpus 
displayed potent abilities as reference NL4.3 Vpu to interfere with CD317 surface 
expression (Figure 15B). While unlike in the fusion version, EC Vpus showed similar 
CD317 downregulation activities (median 107.6 [IQR 93.2–112.7]%) as CP Vpus 
(median 102.4 [IQR 92.3–11.3]%). There was no statistically significant difference 
between these two groups (p˃ 0.05; Figure 15 C). The data generated in both fusion 
and non-fusion contexts showed the basic CD4 and CD317 downregulation activities 
were well conserved among all Vpus. 
 
5.6 EC Vpus Displayed Lower MHC-I and NTB-A Downregulation Activities 
5.6.1 Downregulation of MHC-I by Vpu.GFP and VpuIRESGFPs 
Vpu is one of the proteins that HIV-1 exploits to modulate the surface level of antigen 
presenting molecules MHC-I (Petersen, Morris et al. 2003). Downregulation of 
MHC-I by HIV-1 Nef was one of the strategies that HIV-1 escapes CTL killing 
(Collins, Chen et al. 1998) (Kirchhoff, Schindler et al. 2008). EC Nefs showed 
attenuated MHC-I downregulation activities compared with CP Nefs (Mwimanzi, 
Markle et al. 2013). Up-to-data, MHC-I reduction mediated by patient-derived Vpu 
alleles has not been investigated yet. We evaluated surface modulation of MHC-I in 
A301 cells transiently expressed fusion or non-fusion Vpu proteins. The experimental 
procedure and data analysis were the same with 5.3.1. Since the expression level of 
MHC-I and NTB-A on TZM-bl cells were low (data not shown). The data in this 
section were generated in A301 cells. NL4.3 Vpu removed 30%～40% of MHC-I 
from the cell surface level as fusion or non-fusion protein (Figure 16A, 17A). The 
majority of CP Vpus alleles showed comparable abilities as NL4.3 Vpu to reduce 
MHC-I molecules (median 98.2 [IQR 88.2–106.3]%) or (median 87.4 [IQR 
77.9–110.0]%) as fusion or non-fusion proteins (Figure 16A, 17A). However, EC  
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Figure 16: MHC-I downregulation activity of Vpu.GFP alleles. A301 cells were 
electroporated with Vpu.GFP expression constructs, harvested after 48 hours, and 
stained for cell surface MHC-I. A: Flow cytometry plots of GFP and NL4.3Vpu.GFP: 
MHC-I-APC (y-axis) vs. GFP (x-axis). Downregulation activity (R3/R2 ratio) was 
normalized to NL4.3Vpu that was arbitrarily set to 100%. B: Graph showing the 
MHC-I downregulation activity of patient derived Vpu alleles relative to NL4.3Vpu. 
Shown are mean values of triplicate transfections with the indicated standard 
deviation. The result is representative of two independent experiments. C: 
Comparison of MHC-I activity of EC Vpus and CP Vpus.  
 
 
Vpus displayed more variable and attenuated MHC-I reduction activity (median 
67.1[IQR 45.5–96.2]%) or (median 65.4 [IQR 52.7–90.4]%) (Figure 16B, 17B). The 
different patterns for EC and CP groups were reflected in the t test. There was 
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statistically significant difference between EC and CP Vpu alleles as fusion or 
non-fusion proteins (p< 0.05; Figure 16C, 17C). 
 
 
 
Figure 17: MHC-I downregulation activity of VpuIRESGFP alleles. A301 cells 
were electroporated with VpuIRESGFP expression constructs, harvested after 48 
hours, and stained for cell surface MHC-I. A: Flow cytometry plots of GFP and 
NL4.3Vpu.GFP: MHC-I-APC (y-axis) vs. GFP (x-axis). Downregulation activity 
(R3/R2 ratio) was normalized to NL4.3Vpu that was arbitrarily set to 100%. B: Graph 
showing the MHC-I downregulation activity of patient derived Vpu alleles relative to 
NL4.3Vpu. Shown are mean values of triplicate transfections with the indicated 
standard deviation. The result is representative of two independent experiments. C: 
Comparison of MHC-I activity of EC Vpus and CP Vpus. 
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5.6.2 Downregulation of NTB-A by Vpu.GFP alleles 
NTB-A is a co-activating ligand for NK cell activation and degranulation. Vpu is the 
only protein that HIV-1 utilizes to decrease NTB-A cell surface levels and 
consequently avoid the recognition of NK cells (Shah, Sowrirajan et al. 2010). It is 
unknown whether this activity of Vpu is conserved among natural Vpu alleles and 
whether there is any systematic difference between EC and CP Vpus. We analysed the 
NTB-A surface modulation activity mediated by patient-derived-Vpu alleles in A301 
cells as fusion and non-fusion proteins. Our positive control NL4.3Vpu decreased 
NTB-A surface expression by about 40% (Figure18A), which confirmed the previous 
result (Shah, Sowrirajan et al. 2010) (Bolduan, Hubel et al. 2013). Among both EC 
and CP Vpu alleles, NTB-A downregulation activity showed high degree of variation 
compared with CD4 and CD317 downregulation activity. In EC groups, there were 
more impaired ones again, such as 53, CTR112, CTR149, CTR183 and MEF showing 
around 25% of NL4.3 activity (Figure18A). Overall, the EC Vpus showed more lower 
NTB-A downregulation activity (median 60.7 [IQR 28.4–78.8]%) than CP Vpus 
(median 98.6 [IQR 57.5–109.4]%) (p< 0.01; Figure 18C). All non-fusion constructs, 
including our positive control NL4.3 Vpu, could only remove up to 10% of NTB-A 
from the A301 cell (data not shown). 
 
5.7 Vpu-mediated Enhancement of HIV-1 Virion Release  
5.7.1 Defect of GFP fused Vpu Proteins to Enhance HIV-1 Virion Release 
Vpu was shown to promote HIV-1 virion release by antagonizing the restriction of 
CD317/tetherin (Neil, Eastman et al. 2006). We evaluated the virion release 
enhancement mediated by Vpu alleles in TZM-bl cells which are introduced in 
integrated copies of luciferase genes under control of the HIV-1 promoter and 
sensitive to HIV-1 infection. Briefly, TZM-bl cells were co-transfected with HIV-1 
NL4.3 ΔVpu proviral plasmids and indicated Vpu alleles, empty vector or negative 
control VpuS/A mutant. The resulting supernatant was used to infect newly-seeded 
TZM-bl cells. The transfected cells were harvested for GFP, p24 and p55 immunology  
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Figure 18: NTB-A downregulation activity of Vpu.GFP alleles. A301 cells were 
electroporated with Vpu.GFP expression constructs, harvested after 48 hours, and 
stained for cell surface NTB-A. A: Flow cytometry plots of GFP and NL4.3Vpu.GFP: 
NTB-A-APC (y-axis) vs. GFP (x-axis). Downregulation activity (R3/R2 ratio) was 
normalized to NL4.3Vpu that was arbitrarily set to 100%. B: Graph showing the 
NTB-A downregulation activity of patient derived Vpu alleles relative to NL4.3Vpu. 
Shown are mean values of triplicate transfections with the indicated standard 
deviation. The result is representative of two independent experiments. C: 
Comparison of NTB-A activity of EC Vpus and CP Vpus. 
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blotting. The infected cells lysate was assayed for luciferase units which was the 
readout of the quantity of the infectious virions in the supernatant. Vpu was shown no 
effect on the infectivity of released HIV-1 virions, so quantity of the infectious virions 
in the supernatant indicated the quantity of the released virions. We first tested this 
activity of NL4.3 Vpu.GFP at a series of concentrations. The 0.8 μg non-codon 
optimized NL4.3 Vpu.GFP was expressed at the comparable level of the positive 
control 0.1μg of codon-optimized SynVpu. NL4.3 Vpu.GFP could not promote virion 
release but the non-fusion Vpu protein was able to enhance the virion release at 
proper concentration (Figure 19). This directed us to go for non-fusion Vpu proteins 
for the full panel of virion release evaluation. 
 
 
 
Figure 19: Virion release enhancement mediated by Vpu as fusion and 
non-fusion protein. TZM-bl cells were transiently transfected with HIV-1NL4.3 
ΔVpu provirus plasmid and the indicated Vpu allele. NL4.3 BH10 served as one 
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positive control. 48 hours post transfection, the cell supernatants containing viral 
particles were assayed for infectivity on TZM-bl reporter cells to determine the 
amount of infectious virions produced. TZM-bl cell lysates were subjected to Western 
blot detection. 
 
 
5.7.2 Virion Release Enhancement is Conserved among Patient-derived Vpus  
To examine whether patient-derived Vpus are able to enhance HIV-1 particle release 
or not, all indicated individual VpuIRESGFPs, together with HIV-1 NL4.3 ΔVpu 
proviral plasmids, were co-transfected TZM-bl cells and then processed for infectivity 
assay, western blotting and downregulation of CD317/tetherin as described in 5.7.1. 
Most of EC and CP Vpus displayed well-conserved abilities to enhance virion particle 
release similar to NL4.3 Vpu, with the exception of impaired EC 8227 and CP 
E00456. (Figure 20a, upper bars). To preclude the possibility of different levels of 
virion production and Vpu expression among different transfections, we analysed 
GFP, p24 and p55 levels in the transfected cells. The p24 and p55 antigen in the lysate 
from transfected cells from each Vpu allele were identical, which reflected similar 
virion production for each transfection of HIV-1 NL4.3 ΔVpu proviral plasmids 
(Figure 20a, lower panel); the expression levels of GFP were similar to each other 
(Figure 20a, upper panel), and this was used to define expression levels of Vpus as the 
Vpu antibody displayed different degree of affinity towards the Vpus (Figure 10). EC 
Vpus displayed a lower trend of virion release enhancement activity (median 4.6 [IQR 
[3.2–6.6] fold of HIV-1 NL4.3 ΔVpu) than CP Vpus (median 6.7 [IQR [5.2–13.3] fold 
of HIV-1 NL4.3 ΔVpu), but the statistic evaluation showed no significant different 
between these two groups (Figure 20a B; p=0.07). The activity to enhance HIV-1 
release was well conserved in both EC and CP Vpus and showed no systematic 
difference. 
84 
 
 
 
Figure 20a: Rescue of HIV-1 particle release by patient-derived Vpu alleles. 
TZM-bl cells were transiently transfected with HIV-1NL4.3 ΔVpu provirus plasmid 
and the indicated Vpu allele or control. 48 hours post transfection the cell 
supernatants containing viral particles were assayed for infectivity on TZM-bl 
indicator cells to determine the amount of infectious virions produced. TZM-bl cell 
lysates from one replicate of the assay were subjected to Western blot analysis. 
TZM-bl cells from the same replicate were harvested and assayed for cell-surface 
level of CD317. A: The yield of infectious HIV-1 in the supernatant and 
cell-associated levels of GFP, p24CA, and p55Gag were analyzed. HIV-1 particle 
release in the supernatant was assessed by measuring the induction of Luciferase units 
(top) in infected TZM-bl cells. Values (y axis) are normalized to that of control 
NL4.3ΔVpu, which was set to 1, error bars are standard error of the mean (SEM) for 
three independent experiments. Western blot results show the expression level of GFP, 
p24, and p55 in one representative experiment. B: Comparison of enhancement of 
virion release mediated by EC and CP Vpu alleles. Statistical significance was 
assessed using two-tailed Mann–Whitney U-Test (p= 0.07), bars represent median and 
inter-quartile ranges. 
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Figure 20b: CD317 cell surface downregulation by patient Vpu in the context of 
infection. TZM-bl cells transfected with HIV-1 NL4.3 ΔVpu and the indicated 
VpuIRESGFP plasmids were harvested 48 hrs post-transfection and CD317 cell 
surface levels quantified by flow cytometry. A: Flow cytometry plots of IRESGFP 
and NL4.3 VpuIRESGFP: CD317-APC (y-axis) VS. GFP (x-axis). Downregulation 
activity (R3/R2 ratio) was normalized to HIV-1 NL4.3 ΔVpu that was arbitrarily set to 
100%. B: The y-axis represents the relative CD317 cell surface levels remaining 
normalized to control cells transfected with NL4.3ΔVpu and IRESGFP (set to 100%). 
Shown are mean values of triplicate transfections with the indicated standard 
deviation. The result is representative of three independent experiments. C: 
Comparison of CD317 cell surface levels in TZM-bl cells producing viral particles 
and expressing EC or CP Vpu alleles. Statistical significance was assessed using 
two-tailed Mann–Whitney U-Test (p= 0.29), bars represent median and inter-quartile 
ranges.  
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5.7.3 Correlation of Vpu-mediated Virion release Enhancement and 
CD317/tetherin Surface Downregulation 
Vpu expression ultimately leads to the surface reduction of CD317/tetherin, while 
whether the removal of CD317/tetherin from an infected cell surface is required for 
overcoming the barrier of the virion release is contradictory from the reports of 
different groups (Strebel 2014). We investigated the surface level of CD317 in the 
presence of HIV-1 proviral constructs and individual Vpu alleles. In our system, 
reference NL4.3 Vpu reduced about 35% of CD317/tetherin from the cell surface in 
the presence of proviral HIV-1 plasmids (Figure 20b, A), the negative control NL4.3 
VpuS/A, with two serine mutations in DSGxxS motif, was shown activity to 
downregulate surface CD317/tetherin molecules but inactive to enhance virion release 
(Figure 20a, 20b). Analysis for patient-derived Vpus showed that Vpu-mediated 
surface reduction of CD317/tetherin was not strongly correlated with Vpu-mediated 
enhancement of virion release in our system (Figure 20a, 20b). First of all, E00450, 
CTR185 and FW048 showed the evidence high level of virion release did not require 
stronger CD317/tetherin downregulation activities. CTR123 and 8227, which showed 
very slight removal of CD317/tetherin, promoted virion release to a moderate extent. 
Overall, majority of EC and CP Vpus could reduce the cell surface level of 
CD317/tetherin in the presence of HIV-1 proviral constructs with no systematic 
difference (Figure 20b C; p=0.29), and the trend was similar in the absence of HIV-1 
proviral constructs (Figure 13, 14). 
 
5.8 Vpu Antagonizes NF-ƙB Activation 
5.8.1 Equal Efficiency to Inhibit CD317/tetherin-induced NF-ƙB Activation 
Prior to the identification of a host restriction factor to retain viral particles at the 
plasma membrane, CD317/tetherin was shown to activate the central transcriptional 
factor NF-ƙB in a cDNA screening (Matsuda, Suzuki et al. 2003). Recently the role of 
CD317/tetherin sensing virions and stimulating NF-ƙB activation was described. Vpu, 
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as the specific antagonist, could counteract the induction of NF-ƙB by CD317/tetherin 
(Galao, Le Tortorec et al. 2012) (Tokarev, Suarez et al. 2013).  
 
 
Figure 21: Antagonism of CD317-induced NF-kB signaling. A: Inhibition of 
CD317-induced NF-ƙB activation by Vpu alleles. Luciferase activity of the NF-ƙB 
reporter was determined 40 hours post transfection of HEK293T cells with expression 
plasmids for CD317 or filler, the indicated VpuIRESGFP expression plasmids and 
luciferase reporter plasmids. HIV-1 NL4.3 Vpu and HIV-1 M WITO Vpu served as 
controls. Mean values of 6-9 transfections are shown with the indicated standard 
deviation. B: Effect of EC and CP Vpu alleles on CD317-induced NF-ƙB activation. 
Statistical significance was assessed using two-tailed Mann–Whitney U-Test (p= 
0.29), bars represent median and interquartile ranges. C: Correlation of Vpu-mediated 
block of CD317-induced NF-ƙB activity and Vpu-mediated release of infectious 
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virions. Statistical analyses were done using Spearman’s correlation. (Data generated 
by Daniel Sauter, Ulm University) 
 
 
Inhibition of CD317/tetherin-induced NF-ƙB activation by Vpu was assessed in a 
reporter system in which the expression of firefly luciferase is driven by a promoter 
response to NF-κB. The transient expression of CD317 in HEK293T cells, which lack 
endogenous CD317, induced NF-κB activity up to 6 fold compared to the negative 
control in the absence of CD317 as shown by the white bars (Figure 21A). Expression 
of NL4.3 Vpu and also another more active WITO Vpu from founder HIV-1 virus 
could inhibit the CD317/tetherin-induced NF-ƙB activation. This inhibition activity 
does not differ between the EC and CP Vpus, with around 50% of them in each group 
able to suppress the CD317/tetherin-induced NF-ƙB activation in both groups (Figure 
21B). There was very mild correlation between Vpu-mediated virion release 
enhancement and NF-ƙB activation measuring the Spearman R (Figure 21C; R= 
-0.41, p=0.02). We suspect that other host factors may be involved in Vpu-mediated 
inhibition of CD317-induced NF-ƙB activation and Vpu-mediated recovery of virion 
release.  
 
5.8.2 Majority of Vpus Failed to Inhibit IKKβ-induced Activation of NF-kB 
NF-ƙB activation could also be initiated by the stimulation of catalytic unit IKKβ, 
which is critical for the phosphorylation and subsequent degradation of the inhibitor 
of NF-ƙB (IkB) by β-TrCP E3 ubiquitin ligases (Perkins 2007). Vpu could interfere 
with this NF-ƙB signalling pathway via competing the binding with β-TrCP (Bour, 
Perrin et al. 2001). We investigated whether the Vpus were able to inhibit 
IKKβ-induced activation of NF-ƙB in the similar reporter system used in 5.8.1. 
NF-ƙB was activated in the presence of IKKβ, as shown in white bars (Figure 22A). 
The pCG-WITO Vpu was set as a further positive control, in contrast to WITO Vpu, 
reference NL4-3 Vpu was inactive in this experiment and even enhanced NF-ƙB 
activation. This is in agreement with previous experiments using expression vectors  
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Figure 22: Antagonism of IKKβ-induced NF-kB signaling. A: Effect of EC and CP 
Vpu alleles on IKKβ-induced NF-ƙB activation. Luciferase activity of the NF-ƙB 
reporter was determined 40 hours post transfection of 293T cells with expression 
plasmids for IKKβ or filler, the indicated VpuIRESGFP expression plasmids and 
luciferase reporter plasmids. HIV-1 M WITO Vpu served as positive control. B: 
Comparison of inhibition IKKβ-induced NF-ƙB activation mediated by EC and CP 
Vpu alleles. Statistical significance was assessed using two-tailed Mann–Whitney 
U-Test (p= 0.27), bars represent median and interquartile ranges. C: Correlation of the 
Vpu-mediated block of CD317-induced NF-ƙB activity and IKK-ß-induced NF-ƙB 
activity among all Vpu alleles analysed. Statistical analyses were done using 
Spearman’s correlation. (Data generated by Daniel Sauter, Ulm University) 
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driven CMV promoter (Jafari, Guatelli et al. 2014). Only few of the alleles, including 
CTR29, CTR123, CTR185 and 8227 from EC group, as well as E00436, E00440, 
E00454, E00463, E00466, E00468, displayed slight inhibitory activities (Fig. 15 A). 
There was no significant difference between EC and CP Vpus (Figure 22B). 
Vpu-mediated inhibition of CD317/tetherin-induced NF-ƙB and IKKβ-induced NF-ƙB 
activation was not conserved among primary Vpus, while these two inhibitory 
functions of Vpu were well correlated (Figure 22C; R= 0.61, p=0.02), which suggest 
the two pathways may be integrated at some point. 
 
5.9 Scanning of Novel Functional Determinants of Vpu 
Loss of function for some alleles can be explained by lack of motifs, for some alleles. 
The assignment was not possible, indicating the existence of important yet  
un-characterized motifs of Vpu. Based on the results of functional analyses and 
natural amino acid variants, MEF allele from EC group interested us as its ability to 
modulate CD4, MHC-I, and NTB-A cell surface levels was significantly impaired, 
while MEF displayed full activity for CD317 downregulation and virion release 
enhancement. We first compared its expression level with NL4.3 Vpu to preclude the 
possibility that impaired activities did not result from the expression level. The 
expression of NL4.3 Vpu and MEF were comparable (Figure 23A), so the functional 
differences come from the inherent properties existing in the amino acid sequence. 
Since all described motifs critical for Vpu functions are conserved in MEF (Figure 9), 
we first aligned MEF and NL4.3 Vpu sequences. The variable regions or single amino 
acid were marked in red, then we referred to all the HIV-1 M group Vpu sequences in 
Los alamos national laboratory database (http://www.hiv.lanl.gov/content/index) and 
checked the mutation frequencies for these variable regions. The amino acids marked 
in the green box showed rare mutation frequencies, and were collected for further 
analysis (Figure 23B). 
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Figure 23: Identification of critical amino acids for full functionality. A: 
Validation of comparable expression level of NL4.3 Vpu and MEF. A301 cells were 
transfected with non-code optimized NL4.3 Vpu.GFP and MEF.GFP plasmids (30 
μg). 24 hours post-transfection cells were harvested and the cell lysates were analyzed 
by immunoblotting for Vpu and transferin. B: Sequence alignment and mutation 
frequency calculation. The potential amino acids in red were compared with all HIV-1 
clade B sequences in HIV-1 database (http://www.hiv.lanl.gov/content/index). 
 
We constructed a set of MEF alleles with single or grouped amino acid mutations, as 
well as a corresponding set of NL4.3 Vpu mutants by site-directed mutagenesis. 
Downregulation of CD4 and MHC-I was assessed by FACs. For NL4.3 Vpu, V25I 
and A49V impaired the CD4 downregulation activity, but I16V and D77H had no 
effect (Figure 24A). Single substitute of V17I, I26V and V50A increased rescued CD4 
downregulation activity of MEF, especially V50A almost making MEF as active as 
NL4.3 Vpu (Figure 24A). Interestingly, All the single mutants displayed impaired 
MHC-I downmodulation, whereas, the corresponding mutants V17I, I26V and V50A 
MEF did not rescue this ability, except H78D showing mild effect (Figure 24B). 
Within the grouped mutations, all listed single amino acids are required for optimal 
CD4 downregulation activity in the context of NL4.3 and MEF (Figure 24B). The 
grouped NL4.3 Vpu mutant showed almost comparable potency as a wild type to 
reduce MHC-I cell surface level. However, the MEF IVA rescued its ability while the  
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Figure 24: CD4 and MHC-I downregulation activity of mutated NL4.3 Vpu and 
MEF. A3.01 cells were electroporated with the indicated Vpu.GFP expression 
constructs, harvested after 48hrs, and stained for cell surface CD4 and MHC-I.  
Downregulation activity was normalized to eGFP that was set to 100%. A, C: Graphs 
showing the CD4 downregulation activity of Vpu alleles relative to eGFP. Shown are 
mean values of triplicate transfections with the indicated standard deviation. B, D: 
Graphs showing the MHC-I downregulation activity of Vpu alleles relative to eGFP. 
Shown are mean values of triplicate transfections with the indicated standard 
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deviation. E: A301 cells were transfected the indicated Vpu.GFP alleles (30 μg). 24 
hours post-transfection, The GFP positive cells were isolated, and the cell lysates were 
analyzed by immunoblotting for Vpu, and transferin. 
 
 
single mutant MEF V50A did not. Moreover, the full grouped mutant MEF IVAD 
completely recovered this activity (Figure 24D). To summarize, all listed single amino 
acids are required for optimal CD4 downregualtion, especially, 25V and 49A. While 
for MHC-I downmodulation, the grouped mutant MEF IVAD totally recovered for its 
activity, but the corresponding NL4.3 Vpu VIVH only showed little effect. The 
preliminary western blotting data showed the grouped mutants expressed at similar 
levels (Figure 24E). While the mechanism by which the listed amino acids affect 
Vpu’s activity in different alleles need to be further elucidated. 
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5.10 Summary of the Results 
The results were summarized in the following Table. Downregulation of CD4 and 
antagonism of CD317/tetherin were well conserved among EC and CP Vpus. IN 
contrast, inhibition of NF-ƙB signalling was not conserved in both patients. More EC 
Vpus showed impaired activity to modulate MHCI and NTB-A. 
C 1 C 2 7 1M 7 4 H
C TR 2 9 ＋ ＋ ＋ /－ ＋ /－ ＋  ＋  ＋ C 0 4 0 1  C 17 0 1 －
C TR 5 3 ＋ ＋ － － ＋ － － C 0 2 0 2  C 0 7 0 1 u.d .
C TR 112 ＋ ＋ － － ＋ － － C 0 7 0 1 C 0 6 0 2 －
C TR 12 3 ＋ ＋ /－ ＋ ＋ /－ ＋  ＋  ＋ C 0 3 0 4   C 12 0 2 ＋
C TR 14 9 ＋ ＋ ＋ /－ － ＋ － － C 0 3 0 4  C 0 6 0 2 －
C TR 18 3 ＋ /－ ＋ － － ＋ － － C 0 4 0 1  C 14 0 2 7 1M 7 4 R u.d .
C TR 18 5 ＋ ＋ ＋ ＋ ＋＋  ＋  ＋ C 0 2 0 2  C 12 0 3 －
M EF ＋ /－ ＋ － － ＋ － － C 0 2 0 5  C 0 3 0 3 7 1M 7 4 D u.d .
J LS ＋ ＋ ＋ ＋ ＋  ＋  － C 0 4  C 12 ＋
F W0 4 1 ＋ ＋ ＋ ＋ ＋  ＋  － C 16 0 1  C 16 0 1 u.d .
F W0 4 8 ＋ /－ ＋ ＋ ＋ /－ ＋＋ － － C 0 7 0 2  C 0 4 0 1 7 1M 7 4 D ＋
F W0 5 7 ＋ ＋ ＋ － ＋ － － C 0 10 2  C 0 6 0 2 u.d .
8 2 2 7 ＋ ＋ /－ － － －  ＋  － C 14 0 2  C 18 0 1 u.d .
8 2 5 2 ＋ ＋ ＋ /－ ＋ /－ ＋ － － C 0 4 0 1 C 0 7 0 1 u.d .
8 2 6 0 ＋ ＋ ＋ ＋ ＋ － － C 0 8 0 2  C 16 0 1 u.d .
C P
 E0 0 4 3 6 ＋ ＋ ＋ /－ ＋ /－ ＋ － ＋ C 0 3  C 0 8 7 1M 7 4 L ＋
 E0 0 4 3 8 ＋ ＋ ＋ ＋ ＋＋ ＋ － C 0 4  C 0 7 7 1R 7 4 L u.d .
 E0 0 4 3 9 ＋ ＋ ＋ － ＋ － － C 0 5  C 15 u.d .
 E0 0 4 4 0 ＋ ＋ ＋ ＋ ＋ ＋ ＋ C 0 7  C 0 7 7 1M 7 4 L u.d .
E0 0 4 4 2 ＋ ＋ ＋ /－ ＋ ＋ － － C 0 3  C 0 4 －
E0 0 4 4 4 ＋ ＋ ＋ － ＋ ＋ － C 0 2 0 2  C 0 6 7 1M 7 4 D u.d .
E0 0 4 4 9 ＋ ＋ ＋ ＋ ＋ ＋ － C 0 4  C 0 5 －
E0 0 4 5 0 ＋ ＋ ＋ ＋ /－ ＋＋ ＋ － C 0 1  C 0 7 7 1M 7 4 D u.d .
E0 0 4 5 2 ＋ ＋ /－ ＋ ＋ ＋ － － C 0 4  C 0 7 7 1M 7 4 L ＋
E0 0 4 5 4 ＋ ＋ ＋ ＋ /－ ＋ ＋ －  C 0 2  C 12 7 1M 7 4 D －
E0 0 4 5 5 ＋ ＋ ＋ ＋ ＋ － － C 0 7  C 0 8 7 1M 7 4 D －
E0 0 4 5 6 ＋ ＋ ＋ ＋ － － － C 0 2  C 0 4 －
E0 0 4 6 2 ＋ ＋ ＋ ＋ ＋ ＋ － C 0 2  C 0 4 7 1R 7 4 L u.d .
E0 0 4 6 3 ＋ ＋ ＋ ＋ /－ ＋＋ ＋ ＋ C 0 4  C 0 7 7 1M 7 4 D u.d .
E0 0 4 6 6 ＋ ＋ ＋ ＋ ＋ ＋ ＋ C 0 6  C 0 7 u.d .
E0 0 4 6 8 ＋ ＋ ＋ ＋ ＋ ＋ ＋ C 0 7  C 0 7 7 1R 7 4 L u.d .
N TB -A ↓ R e le a s e  a s s a y
 N F -ƙB  
C D 3 17  
 N F -ƙB  
IKKβ KIR 2 D L2
KIR -a s s o c ia te d  po lym o rphis m
EC C D 4  ↓ C D 3 17 ↓ M HC -1↓ HLA  C
 
Table 10: Summary of Vpu alleles function, HLA background and HLA or KIR 
associated amino acid polymorphisms. The activity of patient derived vpu alleles 
was rated relative to that of NL4.3 Vpu and the following activity classes were 
defined: CD4 and CD317: ＋: more than 80% of NL4.3 Vpu activity, +/－: 50% - 
80% of NL4.3 Vpu activity, －:  lower than 50% activity of NL4.3 Vpu. MHC-I and 
NTB-A downregulation: ＋: more than 75% activity of NL4.3 Vpu, ＋/－: 75% - 
50% of NL4.3 Vpu activity, －: lower than 50% activity of NL4.3 Vpu. Virion 
release: ＋＋ : fold increase over NL4.3vpu ˃ 12, ＋ : fold increase over 
NL4.3vpu ˃ 3, －: fold increase over NL4.3vpu < 3. Interference with NF-kB 
activation by CD317: ＋: equally or more active than NL4.3 Vpu (significant 
difference to IRESGFP), p ˃ 0.001, －: inactive (not different from IRESGFP, p˃ 
0.01. Interference with NF-kB activation by IKKβ: ＋: significant reduction relative 
to IRESGFP, p< 0.01, －: no significant reduction relative to IRESGFP, p˃ 0.01. n.d., 
not determined. 
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6 Discussion 
The aim of this study was to assess whether there are systematic differences between 
Vpu alleles derived from EC and CP HIV-1 infected individuals, and further evaluate 
whether variation of Vpu functions could contribute to host control of virus 
replication and thus disease progression in EC HIV patients (see summary of all 
results in Table 10). 
We assessed the surface downmodulation of CD4, CD317, MHC-I and NTB-A, as 
well as enhancement of virion particle release and antagonism of NF-кB signalling by 
using clonal plasma HIV RNA sequences from 15 EC and 16 CP in the in vitro 
system. We observed that all Vpu alleles were generally functional for the most 
characteristic activities of CD4/CD317 downregulation and virion particle promotion. 
In contrast, inhibition of NF-кB signalling was not conserved and showed no 
significant difference between EC and and CP Vpus. It was the first time that 
downregulation of MHC-I and NTB-A by patient-derived Vpus was investigated. We 
showed that EC Vpus displayed higher frequencies of attenuated ones regarding these 
activities, resulting in significantly lower median activities of EC Vpus than those of 
CP Vpus. The enrichment of KIR2DL2 footprints in EC Vpus was the most 
significant sequence difference compared with CP Vpus. Whether the different 
frequencies of adaption to the KIR2DL2 receptor had an impact on the individual 
analysed functions or could have other possible but not-yet-studied effects will be 
discussed. Moreover, natural mutations in Vpus and the effect on functions, 
correlation of individual activities, and implications of conserved and un-conserved 
functions will be discussed in the following sections.  
 
6.1 Patient-derived Vpu alleles Displayed Comparable Activities as GFP fusion 
and non-fusion Proteins 
In the beginning, we constructed vpu gene to the expression vector pEGFP N1 as 
fusion aiming to facilitate detection of the expression and the subcellular localization 
of Vpus. As shown in Figure 19, Vpu.GFP protein was not functional for the virion 
release enhancement. As a commonly used tag, GFP-associated defects were observed 
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in actin-myosin interaction, NF-ƙB and JNK signalling (Agbulut, Coirault et al. 2006) 
(Baens, Noels et al. 2006). Very interestingly, one early report showed that 
actin-myosin interaction was involved in HIV-1 release (Sasaki, Nakamura et al. 
1995), which then could explain how the GFP tag disabled the Vpu-mediated virion 
particle release. From another point of view, GFP tag may affect this activity of Vpu 
by stimulating miss-folding or blocking the functional residues of its C-terminus. 
Indeed GFP tag is very close to the 76W residue which is required for the promotion 
of virion release. 
To evaluate the Vpu-mediated virion release enhancement, we constructed the vpu 
gene to the pIRESGFP expression vector which allows the simultaneous and separate 
expression of Vpu and GFP. With all pVpuIRESGFP constructs, we performed the 
analysis of all downregulation activities of Vpu as well. To assess whether the 
modulation abilities of Vpu alleles were disturbed by the GFP tag, we analysed the 
correlation for CD4, CD317 and MHC-I downregulation activities of our alleles as 
Vpu.GFP and VpuIRESGFP proteins. Pearson’s correlation (r) was measured for the 
two data sets of each activity. Both CD4 and CD317 downregulation by all primary 
Vpu alleles were highly correlated as fusion or non-fusion proteins. MHC-I 
downregulation showed moderate correlation efficiency (r=0.38, p< 0.05; Figure 25). 
Overall, the general trend of CD4, CD317 and MHC-I downregulation mediated by 
Vpus was similar as fusion or non-fusion proteins, which indicated that the different 
levels of a specific downregulation ability among Vpus resulted from the inherited 
property of Vpus. Moreover, this validation analysis supported that the functional 
comparison of EC and CP Vpus based on Vpu.GFP proteins was valid. 
 
6.2 The Effects of Natural Amino Acid Variations on Functions of Vpus 
As shown in Figure 9, sequence of patient-derived Vpus displayed high diversity, 
especially in the N- and C-terminus, which is identical with former reports  
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Figure 25: Comparison of CD4, CD317 and MHC-I downmodulation activities 
by Vpu.GFP and VpuIRESGFP. Pearson correlation coefficient between data sets of 
CD4, CD317, and MHC-I downregulation by Vpu.GFP (x-axis) and by VpuIRESGFP 
(y-axis) was calculated by GraphPad prism. 
 
 
(Pickering, Hue et al. 2014) (Jafari, Guatelli et al. 2014). The natural changes, 
occurring at the amino acids critical for its functions defined based on NL4.3 Vpu, 
had some effects on the loss or gain of functions. CTR123, with a mutation at the 
amino acid 18 from alanine (A) to asparagine (N), was impaired in reducing CD317 
surface levels and in enhancing virion particle release. This finding is consistent with 
former studies showing A18 was required for antagonism of CD317 (Vigan and Neil 
2010). An A14L mutation previously displayed impaired ability to antagonize CD317 
(Vigan and Neil 2010), while the substitution of A14V or A14G did not show negative 
effect for any of the functions, such as CTR185 and FW048. The mutations at the 
residue of A7 only occurred in CP Vpus including E00438, E00444, E00452, E00454, 
E00455 and E00456. The Neil group showed A7 was one of the residues to interact 
directly with CD317 (McNatt, Zang et al. 2013). The substitutions of A7 in E00438, 
E00444, E00454 and E00455 did not result in the loss of function in enhancing viral 
particle release (Figure 20a), and this may be because other variations in the Vpu 
protein could compensate the adverse effect. The impairment of E00452 in the 
promotion of virion release is very likely a result from the mutation of W76R which 
was identified recently (Jafari, Guatelli et al. 2014). For E00456, the reason is very 
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likely due to the insertion of three amino acids in N-terminus adjacent to the CD317 
interacting domain.  
Our results confirmed the role of recently-defined V25 for CD4 downregulation 
activity (Magadan and Bonifacino 2012). MEF, with a substitution of Isoleucine (I) at 
position 25, showed suboptimal activity to induce CD4 degradation (Figure 12). 
However, the replacement of Val by Ala had no effect on E00440. These two 
observations are consistent with a former study based on NL4.3 Vpu, which 
demonstrated that the mutation of Val to Iso impair the Vpu-mediated CD4 
downregulation by reducing the extent of Vpu-induced CD4 polyubiquitination which 
is essential for CD4 degradation (Magadan and Bonifacino 2012). We contributed one 
new residue A48 that is required for optimal CD4 and MHC-I downregulation but not 
for CD317 downregulation. A48 is located in the end of the first cytoplasmic α-helix 
responsible for the physical binding with CD4 and adjacent to the β-TrCP binding 
motif DSGxxS (Margottin, Bour et al. 1998) (Magadan, Perez-Victoria et al. 2010). 
The mutation at this residue could have an impact on the binding of CD4 or β-TrCP 
and therefore lead to the impairment of CD4 downregulation activity. 
Principally, our sequences and functional analysis confirmed the key residues for each 
of the Vpu activities. The compensation from other amino acids in a specific allele 
should be taken account into the overall effect.  
 
6.3 Enrichment of KIR2DL2 Footprints 71M/74H and the Implications 
Adaption to KIR2DL2 receptor on NK cells was shown in several regions of HIV-1 
genome, especially in the overlapped segment of vpu and env. The adaption of HIV-1 
to the inhibitory receptor KIR2DL2 could enhance the inhibitory ability of KIR2DL2+ 
NK cells and consequently escape the NK cell killing. In contrast, the viruses 
containing variations from these adaptions were strongly inhibited by KIR2DL2+ NK 
cells (Alter, Heckerman et al. 2011). The different frequencies of the adaption to NK 
cell receptors, together with the specific KIR genotype, are thus very likely to have 
different impact on the viral replication. However, the sequences and genetic 
99 
 
information in our hands do not support the specific association of KIR2DL2 and 
71M/74H as reported before. For example, the alleles derived from KIR2DL2 
negative patients, such as CTR29, CTR112, CTR149, E00449 and E00456, have the 
71M/74H polymorphisms. In contrast, FW048 and E00436, which were derived from 
KIR2DL2 positive patients, do not have the adapted 71M/74H footprints.  
The most striking difference of amino acid sequences was the higher frequency of 
KIR-associated polymorphisms at 71M/74H in EC Vpus (12 out of 15) than CP Vpus 
(5 out of 16) (Figure 9). To test whether the composition of the M/H determines the 
functional differences, all alleles were grouped according to their genotype. No 
significant difference was observed for any of the downregulation activities or the 
inhibition of NF-кB among the Vpus (p˃ 0.05; Figure 26A-E). However, Vpu 
71M/74H (+) alleles showed slightly lower activity to reduce CD317 cell surface 
levels and promote virion particle release than Vpu 71M/74H (-) alleles (p< 0.05; 
Figure 26F-G). Taken together, the 71M/74H polymorphisms generally did not cause 
loss of functions and do not explain the functional differences observed between EC 
and CP Vpus. With the genetic background information and data sets, we are not able 
to define the driving force responsible for the differences between EC and Vpus. 
In addition to the KIR-associated polymorphisms in Vpu sequence, they were also 
extensively found throughout the HIV-1 genome, such as the KIR2DL2-associated 
footprints in Nef 9S and Gag 138L (Alter, Heckerman et al. 2011). Similar with the 
effect of Vpu 71M/74H on NK cell recognition, the genotype of Nef 9S or Gag 138L, 
together with the presence of the KIR2DL2 receptor, could inhibit the killing of 
HIV-1 by NK cells (Alter, Heckerman et al. 2011). We analysed the available 
sequences of Nef and Gag proteins from the same two cohorts herein studied. The 
KIR2DL2 footprints Nef 9S and Gag 138L displayed higher frequencies in EC than in 
CP (Table 11). It seemed the accumulation of KIR2DL2-associated amino acids is a 
general property for HIV-1 isolates form EC cohort. Whether the different frequencies 
have an impact on different viral replication potency in more physiologic conditions 
need to be further elucidated. 
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Clinical cohorts Frequencies of KIR2DL2-associated footprints 
 Vpu 71M/74H Nef 9S Gag 138L 
Elite controllers 61% 78% 75% 
Chronic progressors 31% 57% 63% 
 
Table 11: Frequency of KIR2DL2-associated footprints in ECs and CPs proteins 
The ratio was calculated from the sequences with KIR2DL2-associated amino acid(s) 
out of all available sequences. (All sequences were provided by Takamasa Ueno 
(Center for AIDS Research, Kumamoto University, Japan) 
 
Even though the observed differences in the Vpu function is not a result from the 
71M/74H polymorphism, the different levels of 71M/74H conservation may have an 
impact on the efficiency of immune responses in EC and CP patients due to different 
levels of adaption to immune pressure(s). Among the Vpu alleles studied, the majority 
of the differences concerned H74, which is the first residue of the HLA-Cw1 
restricted epitope HL9 of Vpu (HAPWDVDDL) (Liu, McNevin et al. 2007) (Liu, 
McNevin et al. 2011). As known, HLA-Cw1 is the ligand of KIT2DL2 receptor of NK 
cells (Wagtmann, Rajagopalan et al. 1995) (Symons and Fuchs 2008) (Moesta, 
Norman et al. 2008) and HLA-C-presented peptides have an impact on the binding 
and stablization with the KIR2DL2 (Snyder, Brooks et al. 1999) (Blais, Dong et al. 
2011). In this scenario, the alteration at 74H may influence the interaction of 
HLA-Cw1 and KIR2DL2 and thus lead to the inhibition or the activation of NK cells, 
which needs to be further characterized. 
From another point of view, higher mutation frequency of CP 74H could just facilitate 
the escape of HLA-Cw1-mediated CTL killing, and this may contribute to the 
establishment of server HIV-1 infection in CP patients. Interestingly, H74 is highly 
enriched in transmission-founder viruses (present in 100% of founder virus sequences 
vs. 53% of subtype B sequences), indicating that the underlying selection pressures 
may be particularly relevant during the acute phase of HIV infection. 
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Figure 26: Comparison of activities mediated by Vpu 71M/74H positive and 
negative alleles. A-C, F: Comparison of CD4, MHC-I, NTB-A and 
CD317downregulation activities between Vpu 71M/74H positive and negative alleles. 
D, E, G: Comparison of inhibition of NF-кB signalling and enhancement of virion 
particle release mediated by Vpu 71M/74H positive and negative alleles. Statistical 
significance was assessed using two-tailed Mann–Whitney U-test, bars represent 
median and interquartile ranges. 
 
 
6.4 Moderate Association between Downregulation Activities of Aatient-derived 
Vpus 
For all the activities imposed by natural Vpus, we evaluated their correlation with 
each other by measuring the Spearman R. The correlation between activities of 
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CD317 and MHC-I downregulation was significant (R= 0.69, p< 0.0001; Figure 27E), 
which suggests that Vpu may use similar mechanisms to downmodulate these two 
molecules. Vpu reduces the cell surface levels of CD317 by perturbing anterograde 
transport of newly synthesized CD317 and retaining CD317 molecules in 
Golgi-apparatus(Schmidt, Fritz et al. 2011). The mechanism of Vpu-mediated MHC-I 
downregulation has not been elucidated yet, but it was hypothesized that Vpu acts on 
newly-synthesized MHC-I molecules in ER and directs them for proteasomal 
degradation as how Vpu induces CD4 surface downregulaton (Kerkau, Bacik et al. 
1997). While the correlation between CD4 and MHC-I downregulation was 
intermediate (R= 0.52, p=0.003; Figure 27B). Taken together, our data suggests that 
Vpu may interfere with the trafficking of MHC-I similarly with CD317 in 
Golgi-apparatus. 
There was mild correlation between CD4 and CD317 downregulation (R= 0.41, 
p=0.02; Figure 27A), which is reasonable and not surprising from the knowledge 
based on the studies of the lab-adapted NL4.3 Vpu. The mechanisms of Vpu-mediated 
CD4 and CD317 surface level reduction are different as described above, but some of 
the amino acids or motifs are required for both of the activities. The determinants 
located in Vpu TMD, such as W22, A14 and A18 are essential for the downregulation 
of CD4 and CD317. Our data generated from natural Vpus principally supports that 
these two activities of Vpu are separable. 
The correlation between NTB-A and MHC-I downregulation was significant (R= 
0.53, p=0.002; Figure 27F), which may reflect Vpu over-layered mechanisms for 
these two activities. Vpu was shown to slow down the anterograde transport of the 
NTB-A and retain it in the Golgi-apparatus, distinct from the block of anterograde 
transport of CD317 (Bolduan, Hubel et al. 2013). Our two sets of correlation analyses 
suggest Vpu  
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Figure 27 Correlation between different functions of patient-derived Vpus. 
Correlation of Vpu functions were assessed by the strength of the spearman R 
coefficient. A-C: Correlation of CD4 with CD317, MHC-I or NTB-A. D, E: 
Correlation of CD317with MHC-I or NTB-A. F: Correlation of MHC-I with NTB-A.  
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may also affect the trafficking of MHC-I molecules as it does for CD317 or NTB-A. 
While since Vpu-mediated MHC-I and NTB-A downregulation are not as potent as 
the other activities, the correlation between them could be simply from the narrow 
dynamic range. Interestingly, there was no or very mild correlation between NTB-A 
and CD4 or CD317 downregulation (Figure 27C, D), which reflects the distinct 
mechanisms as described above. All together, the varying degrees of correlation 
reflect that Vpu uses different structural and functional domains and mechanisms to 
modulate the surface levels of these molecules. 
 
6.5 Conservation and Variation of Functions Mediate by EC and CP Vpus 
6.5.1 Implications from Conservation of Vpu-mediated CD4 Degradation and 
Difference between EC and CP Vpus 
Both EC and CP Vpus had conserved abilities to down-regulate CD4 despite high 
sequences diversity (Figure 12, 14). The Neil group also showed the conservation of 
CD4 downreguation activities of Vpu alleles derived from different clinical stages of 
15 HIV-1 infected individuals including rapid progressors, normal progressors and 
long-term non-progressors at different stages (Pickering, Hue et al. 2014). Similar 
observations were made in a cohort of acutely infected patients (Jafari, Guatelli et al. 
2014). This conservation may reflect that surface removal of HIV-1 CD4 receptor is 
strictly required for the preservation and persistence of HIV-1 in the infected 
individuals and even in EC patients who can naturally control HIV-1 replication but 
not elimination. The importance of CD4 down-modulation for HIV-1 fitness in the in 
vivo environment is also reflected by the fact that HIV-1 utilizes a combination of 
three proteins Nef, Vpu and Env to diminish its primary receptor CD4 molecules, and 
each activity implies different relevance for HIV-1 survival according to their 
respective expression patterns (Chen, Gandhi et al. 1996) (Wildum, Schindler et al. 
2006). Vpu acts on newly-synthesized CD4 molecules in the relatively late stage of 
HIV-1 life cycle, which was proposed to be critical for liberating Env from the 
Env-CD4 complex in the ER and thus facilitating the Env processing and viral 
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production and infectivity (Willey, Maldarelli et al. 1992) (Lama, Mangasarian et al. 
1999) (Levesque, Zhao et al. 2003) (Gautam and Bhattacharya 2013). In contrast, Nef 
plays the major role on reducing CD4 surface level by enhancing CD4 internalization 
from the plasma membrane and subsequent degradation in the early phase of HIV-1 
infection (Piguet, Chen et al. 1998), which is important for effective viral replication 
by preventing superinfection (Wildum, Schindler et al. 2006).  
The evidences from cohorts studies showed that HIV-1 Nef alleles from long term 
non-progressors were attenuated in down-regulating CD4 molecules (Tobiume, 
Takahoko et al. 2002) (Mwimanzi, Markle et al. 2013). Moreover, the study 
performed on pig-tailed macaque showed that Vpu-mediated CD4 degradation is 
associated with pathogenesis of HIV-1 (Stephens, McCormick et al. 2002). Our EC 
Vpu alleles maintained lower ability to decay CD4 surface expression levels than CP 
Vpu alleles. With all these evidences, we could deduce that full CD4 down-regulation 
by Vpu is very likely to add the strength of HIV-1 to combat with the host, and the 
different potency to remove CD4 from the cell surface may cause different clinical 
outcomes.  
 
6.5.2 Benefits from the Conservation of CD317 Antagonism by Vpus 
Vpu is the only protein that HIV-1 exploits to antagonize the host restriction factor 
CD317 by reducing its surface expression or displacing it from nascent virion 
particles at the plasma membrane (Neil, Zang et al. 2008). Surface downregulation of 
CD317 and promotion of virion particles were well conserved among EC and CP 
alleles, which is again identical with other cohorts studies  (Pickering, Hue et al. 
2014) (Jafari, Guatelli et al. 2014). Our data suggest surface removal of CD317 was 
not strictly required for enhancing virion release (Figure 20a, 20b), which indicates 
that Vpu-mediated virion particle release and CD317 downregulation are separable 
activities. How HIV-1 could benefit from these two Vpu-mediated functions is 
unknown. Recent reports provide new interpretations for the functional relevance and 
importance of CD317 antagonism during HIV-1 infection. CD317 molecules could 
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provide a platform for host NK cells to recognize the retained HIV-1 virions from the 
infected cell surface and facilitate the recognition and killing by NK cells via ADCC 
(Arias, Heyer et al. 2014) (Pham, Lukhele et al. 2014).  
The in vivo relevance of virion release was puzzling in the beginning because cell-free 
virions are not the only way for HIV-1 spreading. It is even more efficient for HIV-1 
spreading from cell to cell via virological synapses (Chen 2012). However, it was 
elucidated later that the quantity of cell free virions were associated with the 
efficiency of virion distribution and expansion in a humanized mice model, by this 
way the virion propagation was boosted especially in the early phase (Sato, Misawa et 
al. 2012). All together, the conserved abilities of CD317 surface downregulation and 
virion release enhancement among Vpus derived from different clinical outcomes just 
implies the important role of these conserved activities in the establishment and 
persistence of HIV-1 infection.  
 
6.5.3 Vpu-mediated MHC-I Down-modulation and its Functional Consequences 
MHC-I is responsible for loading pathogen-derived peptides and presenting them to 
Cytotoxic T lymphocytes (CTLs). Interference with MHC-I antigen-presentation is a 
general strategy used by many viruses to escape the CTL killing, such as HIV-1, HCV 
and HSV (Yewdell and Bennink 1999). HIV-1 Nef-mediated MHC-I downregulation 
and its consequences were well studied. In the presence of HIV-1 Nef, CTL killing is 
inefficient due to reduced MHC-I surface expression levels (Collins, Chen et al. 1998) 
(Petersen, Morris et al. 2003). Furthermore, CP Nef alleles from the same cohort 
studied herein displayed significantly higher capacities to down-regulate MHC-I 
surface expression level than EC Nef alleles (Mwimanzi, Markle et al. 2013). No 
further studies were followed to elucidate the functional relevance and the mechanism 
since the first report about HIV-1 Vpu-mediated MHC-I downregulation (Kerkau, 
Bacik et al. 1997). Our data showed that most EC Vpus was attenuated in MHC-I 
downregulation compared with our reference NL4.3 Vpu or majority of CP Vpus 
(Figure 16, 17). The relatively stable and higher MHC-I level may be advantageous to 
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the control of HIV-1 because more viral peptides can be loaded and presented on the 
infected cells surface via MHC-I and should consequently lead to more efficient CTL 
responses. And indeed the antigen loading is associated with disease progression. 
From this point of view, the potent downregulation of MHC-I by CP Vpus may help 
HIV-1 infected cells to escape CTL surveillance and therefore allow disease 
progression. Whether the attenuated MHC-1 downregulation by EC Vpus is the 
consequence or one of the reasons for natural HIV-1 suppression or due to the 
interaction is complicated to be investigated. 
 
6.5.4 Modulation of NTB-A: Selection Pressure from Innate Immunity 
A listing of increasing evidences support that the accessory protein Vpu is widely 
involved in the interference with NK cells functioning during HIV-1 infection (Shah, 
Sowrirajan et al. 2010) (Matusali, Potesta et al. 2012) (Arias, Heyer et al. 2014) 
(Pham, Lukhele et al. 2014). Apart from the adaption to specific KIR receptors to 
avoid the recognition of NK cells, Vpu has the capacity to modulate NK cell ligands 
including NTB-A and PVR on the surface of HIV-1 infected cells and thus disturbs 
the recognition and killing by NK cells (Shah, Sowrirajan et al. 2010) (Matusali, 
Potesta et al. 2012). However, whether these two activities of Vpu are conserved 
among natural Vpu alleles has not been investigated before. In this study we assessed 
NTB-A modulation by patient-derived Vpu alleles. Our data displayed that 
down-modulation of NTB-A was not conserved among natural Vpu alleles. The 
majority of EC Vpu alleles were attenuated but most of the CP Vpu alleles still were 
shown optimal or suboptimal activity in modulating NTB-A molecules (Figure 18). It 
is unknown how the autologous NK cells will react to decreased surface levels of 
NTB-A ligands in HIV-1 infected cells. Very likely, CP Vpus may have stronger 
potency to inhibit the activation of NK cells than EC Vpus by suppressing the 
activating factor-NTB-A, which is logically right at the time point of sample 
collection when all patients had established infection status. 
The variations observed in NTB-A downregulation activity may also indicate that the 
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patient-derived Vpu alleles were undergone different degrees of immune pressure(s) 
imposed by NK cells. And indeed it was proposed that NK cells are involved in the 
immune control of HIV-1 infection (Iannello, Debbeche et al. 2008). NK cells may 
play a central role in the acute stage of the HIV-1 infection because the drop in the VL 
of patients occurs before the CTL response is fully activated (Alter, Teigen et al. 
2007), and HIV-1 has undergone selection pressure imposed NK cell at this stage 
prior to entering to the chronic phage when our samples were collected. The 
variations of Vpu-mediated NTB-A may just reflect the different potency of NK cells 
selection of each patient. Even though the phenotypic background of the NK cells in 
our cohorts is unknown, the attenuated NTB-A downregulation activities by EC Vpu 
alleles may be a result from strong NK cells pressures, and the impairment of Vpu in 
turn contributes to the suppression of HIV-1 infection.  
 
6.5.5 Vpu-mediated inhibition NF-ƙB activation: An agonist or antagonist? 
As a central transcriptional factor for regulation of a specific gene expression, NF-ƙB 
plays a pivotal and dynamic role in innate and adaptive immunity upon virus infection 
(Gilmore 2006) (Ghosh and Hayden 2012). Induction of NF-ƙB is a double-edged 
sword for it can enhance HIV-1 replication and also induce gene expression of 
antiviral factors (Hiscott, Kwon et al. 2001) (Chan and Greene 2012). The HIV-1 
infection can be sensed by a diversity array of pattern recognition receptors (PPRs) in 
the immune system, which leads to the activation of NF-ƙB (Hiscott, Kwon et al. 
2001). The virion release restriction factor CD317 can also serve as a PPR to 
stimulate NF-ƙB signalling and consequently induces the downstream 
proinflammatory responses (Galao, Le Tortorec et al. 2012) (Tokarev, Suarez et al. 
2013). Vpu-mediated surface downregulation and viral antagonism of CD317 were 
well conserved among natural alleles, while half of our Vpu alleles, no matter derived 
from ECs or CPs, lost the inhibitory effect on CD317-induced NF-ƙB activation 
(Figure 21). The variations of Vpu-mediated inhibition of CD317-induced NF-ƙB 
signalling were also observed from Vpu alleles collected from CPs and long-term 
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non-progressors (LNTP) from the point of initial infection to five years during HIV-1 
infection, which was reported by the Neil group (Pickering, Hue et al. 2014). Among 
the patients they studied, Vpus, derived from 3 out of 4 CPs and 3 out of 5 LTNPs, 
displayed significant decreasing capacities to inhibit NF-ƙB signalling. But there were 
also Vpu alleles derived from two patients showing increased activities to suppress 
NF-ƙB signalling. All these cohort studies indicate that inhibition of NF-ƙB signalling 
can be fine-turned depending on the stage of the infection and the micro-environment 
in a specific patient. 
Our Vpu alleles were inactivated to intercept IKKβ stimulated NF-ƙB activation. This 
might be due to the CMV promoter in our constructs, which was reported that the 
expression of constructs with CMV promoter was disturbed in the presence of 
interferon (Harms and Splitter 1995). In our system, the production of interferon can 
be triggered by the over-presence of IKK-β. 
Regarding the mechanisms, it was proposed that CD317-mediated restriction of virion 
release and stimulation of NF-ƙB signalling are separable activities because they 
require different structural domains of CD317 (Galao, Le Tortorec et al. 2012) 
(Tokarev, Suarez et al. 2013) (Sauter, Hotter et al. 2013). This fact adds the 
complexity of the mechanism of how Vpu antagonize CD317-induced NF-ƙB 
activation, which is not defined yet. The study from scanning the molecular 
determinants revealed that these two activities of Vpu are uncoupled (Pickering, Hue 
et al. 2014). The Neil group showed that the motif such as E29 required for the 
promotion of virion particle release was not needed for suppression of NF-ƙB 
activation, but the mutations at 59G and E62 were defect for inhibition of NF-ƙB 
activation but not enhancement of virion particle release. While both activities 
involved residue A18 located in TMD of Vpu. CTR123, with a substitution of 
asparagine (N) at 18, was inactive for the antagonism of CD317. For the rest of 
alleles, the molecular determinants rendering the loss of ability to suppress NF-ƙB 
activation need to be further identified. 
Overall, our result suggests that Vpu-mediated inhibition of NK-ƙB signalling is not a 
must for the persistence of the HIV-1 infection at the time point of sample collection. 
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However, this does not exclude the importance of Vpu-mediated inhibition of NF-ƙB 
signalling in the early stage of the HIV-1 infection. Since NF-ƙB activation could 
benefit both HIV-1 replication and host antiviral immune responses, it is not 
surprising that the inhibitory effect of Vpu alleles on NF-ƙB is quite various, which is 
probably dependent on the stage of the infection and the immune environment of the 
patient. The loss or gain of this function may be associated with the kinetics of HIV-1 
replication or host antiviral responses. 
 
6.6 EC Vpu alleles may be more conserved under CTL pressure  
Unlike HIV-1 accessory protein Nef, which has partially overlapped functions with 
Vpu and is intensively targeted by CTLs (Schmokel, Sauter et al. 2011) (Price, 
Goulder et al. 1997) (Leslie, Kavanagh et al. 2005). HIV-1 Vpu was rarely targeted by 
CTLs and the sequence diversity does not majorly result from the CTL-associated 
selective pressures (Addo, Yu et al. 2002) (Addo, Altfeld et al. 2002) (Altfeld, Addo et 
al. 2001) (Hasan, Carlson et al. 2012). However, at least four Vpu-derived epitopes, 
such as LAIVALVVA, EYRKILRQR, ALVEMGHHV and HAPWDVNDL, which are 
spanning from the transmembrane domain and the end of cytoplasmic tail (HIV lanl 
database), can be recognized by HIV-1 specific CD8+ T cells and elicit immune 
responses. Among them, the HLA-Cw0102 restricted CTL epitope HAPWNVND 
showed a significantly higher variation frequency in CP Vpus than EC Vpus (Figure 
9). Our data showed the variation in this epitope did not cause the loss of Vpu 
functions but rather slightly higher capacity to antagonize CD317 than the Vpu alleles 
with founder epitope, which is consistent with previous study that the epitope of 
HAPWNVND was undergone positive selection which is no cost for viral fitness and 
beneficial to HIV-1itself (Liu, McNevin et al. 2007) (Liu, McNevin et al. 2011). 
The dynamics of CTL responses and the evolution of this epitope were assessed over 
the first four years of HIV-1 infection in an ART-naïve patient. This founder epitope 
was undergone positive selections, and the CTL responses declined dramatically 
around 400 days post onset of the primary infection due to the epitope evolution (Liu, 
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McNevin et al. 2011). So the maintenance of this epitope keeps the consistent effect 
of initially developed CTLs which is critical for the control of HIV-1 infection. Under 
this scenario, frequent variations in this CTL recognition epitope may reduce the 
recognition of HIV-1 infected cells in CP patients. While the conservation of EC Vpus 
CTL epitope may facilitate the CTL responses and thus contribute to the undetectable 
viral loads status. 
   
In summary, functions of Vpu were generally conserved among all patient-derived 
alleles except for the antagonism of NF-ƙB activation. All of the experiment data sets 
and analysis showed slight systematic differences between EC and CP Vpu alleles 
regarding CD4, MHC-1 and NTB-A downregulation based on our rather small sample 
size. The driving force for these differences is undefined but not due to the KIR 
associated polymorphisms. The functional relevance of these differences needs to be 
elucidated in more relevant or physiological conditions. 
 
7 Perspectives  
To give more insight into the unsolved issue whether Vpu is a pathogenic factor of 
HIV-1 or not, we compared the sequences and functions of Vpu alleles derived from 
two distinct and treatment naïve HIV-1 clinical groups. Our results, together with the 
studies performed in the cell culture system, support that Vpu enhances the 
persistence and pathogenesis of HIV-1, even though it is not strictly required for the 
viral replication in vitro. Based on my knowledge, several aspects are proposed for 
further investigations into Vpu. 
7.1 Implications from the Studies of Animal Models 
Recently, the Bieniase group showed HIV-1 could establish AIDS like phenotype by 
successively passaging CCR5 strain HIV-1 in the pigtailed macaque and with the 
treatment of CD8 antibody during the acute infection, which has never been achieved 
previously. The adaption of Vpu to the macaque CD317/tetherin is one of the key 
factors to establish that phenotype (Hatziioannou, Del Prete et al. 2014). Their model 
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provides direct evidences that the viral adaption or genotype, as well as the 
immunological events during early infection, are crucial for the disease outcomes. In 
line with this, the role of HIV-1 genetics is proposed as important as host factors in 
the pathogenesis and virulence of HIV-1 (Fraser, Lythgoe et al. 2014).  
The TMD of Vpu is critical for the acquired ability to antagonize CD317/tetherin, as 
the Bieniase group observed. However, the DSGxxSG motif, which is essential for its 
functions, is not studied. It could be worthwhile to introduce the Vpu S/A mutant into 
the macaque-adapted HIV-1 strain to assess the significance of the DSGxxSG-related 
functions using their model. 
 
7.2 Biological and Clinical Relevance of KIR-associated Footprints in Vpu alleles 
The Vpu 71M/74H polymorphism has an effect on the NK cell killing through the 
interaction with specific type of KIRs. Based on our sequence information and data 
sets from all functional analysis, the 71M/74H footprints do not explain the impaired 
or optimal functions of Vpu alleles. To further look into the relevance of biological 
and clinical relevance of KIR-associated footprints in Vpus, we are trying to obtain 
the genetic information of each patient. First, it’s necessary to check if the adaption to 
KIR2DL2 is also true for our cohorts. In our EC cohort, not only for Vpu, but also in 
Gag and Nef, the frequency of adaption to a specific KIR receptor is generally lower 
compared with those from CP cohort (Table 8). If there is a strict adaption in our 
cohorts, then we could evaluate the possible consequences of the adaption in each 
patient. If the adaption to KIR2DL2 does not fit our cohorts, the higher frequency of 
Vpu with 71M/74H in EC might come from other immune selection pressures, which 
can only be elucidated by further epidemiological and experimental data. 
 
7.3 Critical Motifs of Vpu-mediated Inhibition of virion sensing 
Vpu is the only protein that HIV-1 exploits to antagonism CD317 which functions as 
both the restriction factor and virion sensor. These two activities of Vpu is not well 
correlated, and we can get some hints from our alleles. E00456, which is active for 
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CD317 surface downregulation but inactive for recovery of virion release 
enhancement and inhibition of NF-ƙB, has around three amino acid insertion in its 
N-terminal compared with clade B HIV-1 isolates. This insertion might be responsible 
for its inability for these two activities. Fw048 is a good example for the discrepancy 
of these two activities, which was active for recovery of virion release enhancement 
but inactive for inhibition of NF-ƙB signalling, the 61K could be one of the reasons. 
The two mentioned candidate motif, together with the relatively variable C-terminal, 
are potential determinants for inhibit NF-ƙB signalling in my opinion. Further study 
can be done to verify these motifs and the mechanism. 
 
7.4 Disability of NK cell Degranulation by EC and CP Vpus 
NK cell degranulation is triggered via the interactions of activation receptors and 
co-activation receptors with their specific ligands .This process releases cytotoxic 
granule contents towards the bounded target cells and is of central importance in NK 
cell-mediated killing. However, NK cell degranulation is compromised in HIV-1 
infection. The reason behind this is that Vpu blocks the transport of the co-activator 
NTB-A to surface of infected cells. Since the Vpu-mediated inhibition of NK cell 
degranulation and lysis is a prominent phenotype from lab-adapted Vpu, and there is a 
significant difference between EC and CP Vpu alles regarding this activity, it might be 
worthwhile to perform further functional assays to check: 1) Could all patient-derived 
Vpu alleles inhibit the NK cell killing? 2) If the Vpu-mediated inhibition of NK cell 
killing is associated with viral loads or other clinical parameter or patient genetic 
information or not? 3) Is the NTB-A down-modulation between EC and CP correlated 
with differentiated NK cell cytolytic ability?  
7.5 Interference of ADCC by Vpu: a Potential Candidate for Vaccine Design? 
As mentioned in the introduction, ADCC showed protection in macaques and in the 
Thai trail (Gomez-Roman, Patterson et al. 2005) (Florese, Demberg et al. 2009) 
(Haynes, Gilbert et al. 2012). The higher ADCC antibody titres and broader ADCC 
responses may partially contribute to the viral suppression in EC (Baum, Cassutt et al. 
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1996) (Lambotte, Ferrari et al. 2009). Vpu derived peptides were shown to induce 
IFN-γ expression of NK cells as well as Env-derived peptides (Stratov, Chung et al. 
2008) (Johansson, Rollman et al. 2011). And this property of Vpu may put it as a 
candidate for vaccine design. It would be very interesting to uncover the following 
issues: 1) Define the peptides eliciting ADCC antibodies in each individual Vpu 
alleles and compare whether there are amino acids different among the known 
peptides, especially in C-terminal 19mer one. It was shown even one single amino 
acid change in C-terminal of Vpu could totally abort NK cell-mediated ADCC 
responses (Stratov, Chung et al. 2008). 2) Evaluating the magnitude and breadth of 
ADCC response elicited by potential patient-derived Vpu peptides. 3) Systematically 
compare the difference between EC and CP groups regarding the peptides that can be 
recognized and evaluated the contribution of Vpu-elicited ADCC for viral control. 
 
115 
 
8 References 
Adamson, C. S. and E. O. Freed (2007). "Human immunodeficiency virus type 1 assembly, release, and 
maturation." Adv Pharmacol 55: 347-387. 
Addo, M. M., M. Altfeld, et al. (2002). "HIV-1 Vpu represents a minor target for cytotoxic T 
lymphocytes in HIV-1-infection." AIDS 16(7): 1071-1073. 
Addo, M. M., X. G. Yu, et al. (2002). "Cytotoxic T-lymphocyte (CTL) responses directed against 
regulatory and accessory proteins in HIV-1 infection." DNA Cell Biol 21(9): 671-678. 
Agbulut, O., C. Coirault, et al. (2006). "GFP expression in muscle cells impairs actin-myosin 
interactions: implications for cell therapy." Nat Methods 3(5): 331. 
Alter, G. and M. Altfeld (2009). "NK cells in HIV-1 infection: evidence for their role in the control of 
HIV-1 infection." J Intern Med 265(1): 29-42. 
Alter, G., D. Heckerman, et al. (2011). "HIV-1 adaptation to NK-cell-mediated immune pressure." 
Nature 476(7358): 96-100. 
Alter, G., N. Teigen, et al. (2007). "Evolution of innate and adaptive effector cell functions during acute 
HIV-1 infection." J Infect Dis 195(10): 1452-1460. 
Alter, G., N. Teigen, et al. (2005). "Sequential deregulation of NK cell subset distribution and function 
starting in acute HIV-1 infection." Blood 106(10): 3366-3369. 
Altfeld, M., M. M. Addo, et al. (2001). "Vpr is preferentially targeted by CTL during HIV-1 infection." 
J Immunol 167(5): 2743-2752. 
Andrew, A. J., E. Miyagi, et al. (2009). "The formation of cysteine-linked dimers of BST-2/tetherin is 
important for inhibition of HIV-1 virus release but not for sensitivity to Vpu." Retrovirology 6: 
80. 
Arhel, N. (2010). "Revisiting HIV-1 uncoating." Retrovirology 7: 96. 
Arias, J. F., L. N. Heyer, et al. (2014). "Tetherin antagonism by Vpu protects HIV-infected cells from 
antibody-dependent cell-mediated cytotoxicity." Proc Natl Acad Sci U S A 111(17): 
6425-6430. 
Arts, E. J. and D. J. Hazuda (2012). "HIV-1 antiretroviral drug therapy." Cold Spring Harb Perspect 
Med 2(4): a007161. 
Ayinde, D., N. Casartelli, et al. (2012). "Restricting HIV the SAMHD1 way: through nucleotide 
starvation." Nat Rev Microbiol 10(10): 675-680. 
Baens, M., H. Noels, et al. (2006). "The dark side of EGFP: defective polyubiquitination." PLoS One 1: 
e54. 
Bailey, J. R., K. G. Lassen, et al. (2006). "Neutralizing antibodies do not mediate suppression of human 
immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in 
patients on highly active antiretroviral therapy." J Virol 80(10): 4758-4770. 
Baum, L. L., K. J. Cassutt, et al. (1996). "HIV-1 gp120-specific antibody-dependent cell-mediated 
cytotoxicity correlates with rate of disease progression." J Immunol 157(5): 2168-2173. 
Bello, G., C. Casado, et al. (2005). "A subset of human immunodeficiency virus type 1 long-term 
non-progressors is characterized by the unique presence of ancestral sequences in the viral 
population." J Gen Virol 86(Pt 2): 355-364. 
Benson, R. E., A. Sanfridson, et al. (1993). "Downregulation of cell-surface CD4 expression by simian 
immunodeficiency virus Nef prevents viral super infection." J Exp Med 177(6): 1561-1566. 
116 
 
Berger, E. A. (1997). "HIV entry and tropism: the chemokine receptor connection." AIDS 11 Suppl A: 
S3-16. 
Berger, E. A., R. W. Doms, et al. (1998). "A new classification for HIV-1." Nature 391(6664): 240. 
Bieniasz, P. D. (2006). "Late budding domains and host proteins in enveloped virus release." Virology 
344(1): 55-63. 
Blais, M. E., T. Dong, et al. (2011). "HLA-C as a mediator of natural killer and T-cell activation: 
spectator or key player?" Immunology 133(1): 1-7. 
Bleul, C. C., L. Wu, et al. (1997). "The HIV coreceptors CXCR4 and CCR5 are differentially expressed 
and regulated on human T lymphocytes." Proc Natl Acad Sci U S A 94(5): 1925-1930. 
Boasso, A., A. W. Hardy, et al. (2008). "HIV-induced type I interferon and tryptophan catabolism drive 
T cell dysfunction despite phenotypic activation." PLoS One 3(8): e2961. 
Boasso, A. and G. M. Shearer (2008). "Chronic innate immune activation as a cause of HIV-1 
immunopathogenesis." Clin Immunol 126(3): 235-242. 
Bolduan, S., P. Hubel, et al. (2013). "HIV-1 Vpu affects the anterograde transport and the glycosylation 
pattern of NTB-A." Virology 440(2): 190-203. 
Bolinger, C. and K. Boris-Lawrie (2009). "Mechanisms employed by retroviruses to exploit host 
factors for translational control of a complicated proteome." Retrovirology 6: 8. 
Bosch, V. and M. Pawlita (1990). "Mutational analysis of the human immunodeficiency virus type 1 
env gene product proteolytic cleavage site." J Virol 64(5): 2337-2344. 
Bour, S., C. Perrin, et al. (2001). "The human immunodeficiency virus type 1 Vpu protein inhibits 
NF-kappa B activation by interfering with beta TrCP-mediated degradation of Ikappa B." J 
Biol Chem 276(19): 15920-15928. 
Bour, S., C. Perrin, et al. (1999). "Cell surface CD4 inhibits HIV-1 particle release by interfering with 
Vpu activity." J Biol Chem 274(47): 33800-33806. 
Bour, S., U. Schubert, et al. (1995). "The human immunodeficiency virus type 1 Vpu protein 
specifically binds to the cytoplasmic domain of CD4: implications for the mechanism of 
degradation." J Virol 69(3): 1510-1520. 
Brady, T., B. J. Kelly, et al. (2013). "Quantitation of HIV DNA integration: effects of differential 
integration site distributions on Alu-PCR assays." J Virol Methods 189(1): 53-57. 
Brakier-Gingras, L., J. Charbonneau, et al. (2012). "Targeting frameshifting in the human 
immunodeficiency virus." Expert Opin Ther Targets 16(3): 249-258. 
Brambilla, A., L. Turchetto, et al. (1999). "Defective nef alleles in a cohort of hemophiliacs with 
progressing and nonprogressing HIV-1 infection." Virology 259(2): 349-368. 
Bruce, E. A., T. E. Abbink, et al. (2012). "Release of filamentous and spherical influenza A virus is not 
restricted by tetherin." J Gen Virol 93(Pt 5): 963-969. 
Brugger, B., B. Glass, et al. (2006). "The HIV lipidome: a raft with an unusual composition." Proc Natl 
Acad Sci U S A 103(8): 2641-2646. 
Brumme, Z. L., C. Li, et al. (2011). "Reduced replication capacity of NL4-3 recombinant viruses 
encoding reverse transcriptase-integrase sequences from HIV-1 elite controllers." J Acquir 
Immune Defic Syndr 56(2): 100-108. 
Bukrinskaya, A., B. Brichacek, et al. (1998). "Establishment of a functional human immunodeficiency 
virus type 1 (HIV-1) reverse transcription complex involves the cytoskeleton." J Exp Med 
188(11): 2113-2125. 
117 
 
Buonocore, L. and J. K. Rose (1990). "Prevention of HIV-1 glycoprotein transport by soluble CD4 
retained in the endoplasmic reticulum." Nature 345(6276): 625-628. 
Burnett, J. C., K. Miller-Jensen, et al. (2009). "Control of stochastic gene expression by host factors at 
the HIV promoter." PLoS Pathog 5(1): e1000260. 
Butera, S. T. (2000). "Therapeutic targeting of human immunodeficiency virus type-1 latency: current 
clinical realities and future scientific possibilities." Antiviral Res 48(3): 143-176. 
Carrington, M., G. W. Nelson, et al. (1999). "HLA and HIV-1: heterozygote advantage and 
B*35-Cw*04 disadvantage." Science 283(5408): 1748-1752. 
Casado, C., S. Colombo, et al. (2010). "Host and viral genetic correlates of clinical definitions of HIV-1 
disease progression." PLoS One 5(6): e11079. 
Casartelli, N., G. Di Matteo, et al. (2003). "Structural defects and variations in the HIV-1 nef gene from 
rapid, slow and non-progressor children." AIDS 17(9): 1291-1301. 
Chamond, N., N. Locker, et al. (2010). "The different pathways of HIV genomic RNA translation." 
Biochem Soc Trans 38(6): 1548-1552. 
Chan, J. K. and W. C. Greene (2012). "Dynamic roles for NF-kappaB in HTLV-I and HIV-1 retroviral 
pathogenesis." Immunol Rev 246(1): 286-310. 
Chen, B. K. (2012). "T cell virological synapses and HIV-1 pathogenesis." Immunol Res 54(1-3): 
133-139. 
Chen, B. K., R. T. Gandhi, et al. (1996). "CD4 down-modulation during infection of human T cells with 
human immunodeficiency virus type 1 involves independent activities of vpu, env, and nef." J 
Virol 70(9): 6044-6053. 
Chen, H., Z. M. Ndhlovu, et al. (2012). "TCR clonotypes modulate the protective effect of HLA class I 
molecules in HIV-1 infection." Nat Immunol 13(7): 691-700. 
Chen, M. and J. L. Manley (2009). "Mechanisms of alternative splicing regulation: insights from 
molecular and genomics approaches." Nat Rev Mol Cell Biol 10(11): 741-754. 
Chevalier, M. F., B. Julg, et al. (2011). "HIV-1-specific interleukin-21+ CD4+ T cell responses 
contribute to durable viral control through the modulation of HIV-specific CD8+ T cell 
function." J Virol 85(2): 733-741. 
Chiang, C. C., S. M. Wang, et al. (2010). "A single amino acid substitution in HIV-1 reverse 
transcriptase significantly reduces virion release." J Virol 84(2): 976-982. 
Chiu, Y. L., C. K. Ho, et al. (2002). "Tat stimulates cotranscriptional capping of HIV mRNA." Mol Cell 
10(3): 585-597. 
Cohen, E. A., E. F. Terwilliger, et al. (1988). "Identification of a protein encoded by the vpu gene of 
HIV-1." Nature 334(6182): 532-534. 
Cohen, Y. Z. and R. Dolin (2013). "Novel HIV vaccine strategies: overview and perspective." Ther Adv 
Vaccines 1(3): 99-112. 
Collins, K. L., B. K. Chen, et al. (1998). "HIV-1 Nef protein protects infected primary cells against 
killing by cytotoxic T lymphocytes." Nature 391(6665): 397-401. 
Craigie, R. and F. D. Bushman (2012). "HIV DNA integration." Cold Spring Harb Perspect Med 2(7): 
a006890. 
Crise, B., L. Buonocore, et al. (1990). "CD4 is retained in the endoplasmic reticulum by the human 
immunodeficiency virus type 1 glycoprotein precursor." J Virol 64(11): 5585-5593. 
Cunningham, A. L., H. Donaghy, et al. (2010). "Manipulation of dendritic cell function by viruses." 
Curr Opin Microbiol 13(4): 524-529. 
118 
 
Dazza, M. C., M. Ekwalanga, et al. (2005). "Characterization of a novel vpu-harboring simian 
immunodeficiency virus from a Dent's Mona monkey (Cercopithecus mona denti)." J Virol 
79(13): 8560-8571. 
Deeks, S. G. and B. D. Walker (2007). "Human immunodeficiency virus controllers: mechanisms of 
durable virus control in the absence of antiretroviral therapy." Immunity 27(3): 406-416. 
DeGottardi, M. Q., A. Specht, et al. (2008). "Selective downregulation of rhesus macaque and sooty 
mangabey major histocompatibility complex class I molecules by Nef alleles of simian 
immunodeficiency virus and human immunodeficiency virus type 2." J Virol 82(6): 
3139-3146. 
Deng, H., R. Liu, et al. (1996). "Identification of a major co-receptor for primary isolates of HIV-1." 
Nature 381(6584): 661-666. 
Di Nunzio, F. (2013). "New insights in the role of nucleoporins: a bridge leading to concerted steps 
from HIV-1 nuclear entry until integration." Virus Res 178(2): 187-196. 
Doehle, B. P., K. Chang, et al. (2012). "Vpu-deficient HIV strains stimulate innate immune signaling 
responses in target cells." J Virol 86(16): 8499-8506. 
Doria-Rose, N. A., R. M. Klein, et al. (2010). "Breadth of human immunodeficiency virus-specific 
neutralizing activity in sera: clustering analysis and association with clinical variables." J Virol 
84(3): 1631-1636. 
Dube, M., B. B. Roy, et al. (2009). "Suppression of Tetherin-restricting activity upon human 
immunodeficiency virus type 1 particle release correlates with localization of Vpu in the 
trans-Golgi network." J Virol 83(9): 4574-4590. 
Engelman, A. and P. Cherepanov (2012). "The structural biology of HIV-1: mechanistic and therapeutic 
insights." Nat Rev Microbiol 10(4): 279-290. 
Erikson, E., T. Adam, et al. (2011). "In vivo expression profile of the antiviral restriction factor and 
tumor-targeting antigen CD317/BST-2/HM1.24/tetherin in humans." Proc Natl Acad Sci U S 
A 108(33): 13688-13693. 
Estrabaud, E., E. Le Rouzic, et al. (2007). "Regulated degradation of the HIV-1 Vpu protein through a 
betaTrCP-independent pathway limits the release of viral particles." PLoS Pathog 3(7): e104. 
Evans, D. T., R. Serra-Moreno, et al. (2010). "BST-2/tetherin: a new component of the innate immune 
response to enveloped viruses." Trends Microbiol 18(9): 388-396. 
Fauci, A. S., D. Mavilio, et al. (2005). "NK cells in HIV infection: paradigm for protection or targets 
for ambush." Nat Rev Immunol 5(11): 835-843. 
Fellay, J., K. V. Shianna, et al. (2007). "A whole-genome association study of major determinants for 
host control of HIV-1." Science 317(5840): 944-947. 
Feng, Y., C. C. Broder, et al. (1996). "HIV-1 entry cofactor: functional cDNA cloning of a 
seven-transmembrane, G protein-coupled receptor." Science 272(5263): 872-877. 
Flores-Villanueva, P. O., E. J. Yunis, et al. (2001). "Control of HIV-1 viremia and protection from AIDS 
are associated with HLA-Bw4 homozygosity." Proc Natl Acad Sci U S A 98(9): 5140-5145. 
Florese, R. H., T. Demberg, et al. (2009). "Contribution of nonneutralizing vaccine-elicited antibody 
activities to improved protective efficacy in rhesus macaques immunized with Tat/Env 
compared with multigenic vaccines." J Immunol 182(6): 3718-3727. 
Fogli, M., P. Costa, et al. (2004). "Significant NK cell activation associated with decreased cytolytic 
function in peripheral blood of HIV-1-infected patients." Eur J Immunol 34(8): 2313-2321. 
119 
 
Ford, E. S., C. E. Puronen, et al. (2009). "Immunopathogenesis of asymptomatic chronic HIV 
Infection: the calm before the storm." Curr Opin HIV AIDS 4(3): 206-214. 
Frankel, A. D. (1992). "Activation of HIV transcription by Tat." Curr Opin Genet Dev 2(2): 293-298. 
Frankel, A. D. and J. A. Young (1998). "HIV-1: fifteen proteins and an RNA." Annu Rev Biochem 67: 
1-25. 
Fraser, C., T. D. Hollingsworth, et al. (2007). "Variation in HIV-1 set-point viral load: epidemiological 
analysis and an evolutionary hypothesis." Proc Natl Acad Sci U S A 104(44): 17441-17446. 
Fraser, C., K. Lythgoe, et al. (2014). "Virulence and pathogenesis of HIV-1 infection: an evolutionary 
perspective." Science 343(6177): 1243727. 
Freed, E. O. (2001). "HIV-1 replication." Somat Cell Mol Genet 26(1-6): 13-33. 
Friedrich, B. M., N. Dziuba, et al. (2011). "Host factors mediating HIV-1 replication." Virus Res 
161(2): 101-114. 
Fritz, J. V., N. Tibroni, et al. (2012). "HIV-1 Vpu's lipid raft association is dispensable for counteraction 
of the particle release restriction imposed by CD317/Tetherin." Virology 424(1): 33-44. 
Galao, R. P., A. Le Tortorec, et al. (2012). "Innate sensing of HIV-1 assembly by Tetherin induces 
NFkappaB-dependent proinflammatory responses." Cell Host Microbe 12(5): 633-644. 
Ganser-Pornillos, B. K., M. Yeager, et al. (2008). "The structural biology of HIV assembly." Curr Opin 
Struct Biol 18(2): 203-217. 
Gao, X., G. W. Nelson, et al. (2001). "Effect of a single amino acid change in MHC class I molecules 
on the rate of progression to AIDS." N Engl J Med 344(22): 1668-1675. 
Gautam, A. and J. Bhattacharya (2013). "Evidence that Vpu modulates HIV-1 Gag-envelope interaction 
towards envelope incorporation and infectivity in a cell type dependent manner." PLoS One 
8(4): e61388. 
Geffin, R., D. Wolf, et al. (2000). "Functional and structural defects in HIV type 1 nef genes derived 
from pediatric long-term survivors." AIDS Res Hum Retroviruses 16(17): 1855-1868. 
Geraghty, R. J., K. J. Talbot, et al. (1994). "Cell type-dependence for Vpu function." J Med Primatol 
23(2-3): 146-150. 
Gheysen, D., E. Jacobs, et al. (1989). "Assembly and release of HIV-1 precursor Pr55gag virus-like 
particles from recombinant baculovirus-infected insect cells." Cell 59(1): 103-112. 
Ghosh, S. and M. S. Hayden (2012). "Celebrating 25 years of NF-kappaB research." Immunol Rev 
246(1): 5-13. 
Gilmore, T. D. (2006). "Introduction to NF-kappaB: players, pathways, perspectives." Oncogene 
25(51): 6680-6684. 
Giroud, C., N. Chazal, et al. (2013). "HIV-1-associated PKA acts as a cofactor for genome reverse 
transcription." Retrovirology 10: 157. 
Goffinet, C., I. Allespach, et al. (2009). "HIV-1 antagonism of CD317 is species specific and involves 
Vpu-mediated proteasomal degradation of the restriction factor." Cell Host Microbe 5(3): 
285-297. 
Goffinet, C., S. Homann, et al. (2010). "Antagonism of CD317 restriction of human immunodeficiency 
virus type 1 (HIV-1) particle release and depletion of CD317 are separable activities of HIV-1 
Vpu." J Virol 84(8): 4089-4094. 
Goila-Gaur, R. and K. Strebel (2008). "HIV-1 Vif, APOBEC, and intrinsic immunity." Retrovirology 5: 
51. 
120 
 
Gomez-Roman, V. R., L. J. Patterson, et al. (2005). "Vaccine-elicited antibodies mediate 
antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in 
rhesus macaques challenged with SIVmac251." J Immunol 174(4): 2185-2189. 
Goujard, C., M. Bonarek, et al. (2006). "CD4 cell count and HIV DNA level are independent predictors 
of disease progression after primary HIV type 1 infection in untreated patients." Clin Infect 
Dis 42(5): 709-715. 
Grossman, Z., M. Meier-Schellersheim, et al. (2006). "Pathogenesis of HIV infection: what the virus 
spares is as important as what it destroys." Nat Med 12(3): 289-295. 
Grossman, Z., M. Meier-Schellersheim, et al. (2002). "CD4+ T-cell depletion in HIV infection: are we 
closer to understanding the cause?" Nat Med 8(4): 319-323. 
Gupta, R. K., P. Mlcochova, et al. (2009). "Simian immunodeficiency virus envelope glycoprotein 
counteracts tetherin/BST-2/CD317 by intracellular sequestration." Proc Natl Acad Sci U S A 
106(49): 20889-20894. 
Harms, J. S. and G. A. Splitter (1995). "Interferon-gamma inhibits transgene expression driven by SV40 
or CMV promoters but augments expression driven by the mammalian MHC I promoter." 
Hum Gene Ther 6(10): 1291-1297. 
Hasan, Z., J. M. Carlson, et al. (2012). "Minor contribution of HLA class I-associated selective pressure 
to the variability of HIV-1 accessory protein Vpu." Biochem Biophys Res Commun 421(2): 
291-295. 
Hatziioannou, T., G. Q. Del Prete, et al. (2014). "HIV-1-induced AIDS in monkeys." Science 
344(6190): 1401-1405. 
Hauser, H., L. A. Lopez, et al. (2010). "HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by 
sequestration in a perinuclear compartment." Retrovirology 7: 51. 
Haynes, B. F., P. B. Gilbert, et al. (2012). "Immune-correlates analysis of an HIV-1 vaccine efficacy 
trial." N Engl J Med 366(14): 1275-1286. 
Hellen, C. U. and P. Sarnow (2001). "Internal ribosome entry sites in eukaryotic mRNA molecules." 
Genes Dev 15(13): 1593-1612. 
Hersperger, A. R., F. Pereyra, et al. (2010). "Perforin expression directly ex vivo by HIV-specific CD8 
T-cells is a correlate of HIV elite control." PLoS Pathog 6(5): e1000917. 
Hessol, N. A., A. R. Lifson, et al. (1989). "Natural history of human immunodeficiency virus infection 
and key predictors of HIV disease progression." AIDS Clin Rev: 69-93. 
Hiscott, J., H. Kwon, et al. (2001). "Hostile takeovers: viral appropriation of the NF-kappaB pathway." 
J Clin Invest 107(2): 143-151. 
Ho, D. D., A. U. Neumann, et al. (1995). "Rapid turnover of plasma virions and CD4 lymphocytes in 
HIV-1 infection." Nature 373(6510): 123-126. 
Hogg, R. S., B. Yip, et al. (2001). "Rates of disease progression by baseline CD4 cell count and viral 
load after initiating triple-drug therapy." JAMA 286(20): 2568-2577. 
Hu, W. S. and H. M. Temin (1990). "Retroviral recombination and reverse transcription." Science 
250(4985): 1227-1233. 
Huang, X., H. Chen, et al. (2012). "Precise determination of time to reach viral load set point after 
acute HIV-1 infection." J Acquir Immune Defic Syndr 61(4): 448-454. 
Hubert, J. B., M. Burgard, et al. (2000). "Natural history of serum HIV-1 RNA levels in 330 patients 
with a known date of infection. The SEROCO Study Group." AIDS 14(2): 123-131. 
121 
 
Hulme, A. E., O. Perez, et al. (2011). "Complementary assays reveal a relationship between HIV-1 
uncoating and reverse transcription." Proc Natl Acad Sci U S A 108(24): 9975-9980. 
Hunt, P. W. (2009). "Natural control of HIV-1 replication and long-term nonprogression: overlapping 
but distinct phenotypes." J Infect Dis 200(11): 1636-1638. 
Hussain, A., S. R. Das, et al. (2007). "Oligomerization of the human immunodeficiency virus type 1 
(HIV-1) Vpu protein--a genetic, biochemical and biophysical analysis." Virol J 4: 81. 
Huthoff, H. and G. J. Towers (2008). "Restriction of retroviral replication by APOBEC3G/F and 
TRIM5alpha." Trends Microbiol 16(12): 612-619. 
Iannello, A., O. Debbeche, et al. (2008). "Antiviral NK cell responses in HIV infection: II. viral 
strategies for evasion and lessons for immunotherapy and vaccination." J Leukoc Biol 84(1): 
27-49. 
International, H. I. V. C. S., F. Pereyra, et al. (2010). "The major genetic determinants of HIV-1 control 
affect HLA class I peptide presentation." Science 330(6010): 1551-1557. 
Ivanchenko, S., W. J. Godinez, et al. (2009). "Dynamics of HIV-1 assembly and release." PLoS Pathog 
5(11): e1000652. 
Jacque, J. M. and M. Stevenson (2006). "The inner-nuclear-envelope protein emerin regulates HIV-1 
infectivity." Nature 441(7093): 641-645. 
Jafari, M., J. Guatelli, et al. (2014). "Activities of transmitted/founder and chronic clade B HIV-1 Vpu 
and a C-terminal polymorphism specifically affecting virion release." J Virol 88(9): 
5062-5078. 
Jamieson, B. D., G. M. Aldrovandi, et al. (1996). "The SCID-hu mouse: an in-vivo model for HIV-1 
pathogenesis and stem cell gene therapy for AIDS." Semin Immunol 8(4): 215-221. 
Jia, B., R. Serra-Moreno, et al. (2009). "Species-specific activity of SIV Nef and HIV-1 Vpu in 
overcoming restriction by tetherin/BST2." PLoS Pathog 5(5): e1000429. 
Johansson, S. E., E. Rollman, et al. (2011). "NK cell function and antibodies mediating ADCC in 
HIV-1-infected viremic and controller patients." Viral Immunol 24(5): 359-368. 
Jordan, A., D. Bisgrove, et al. (2003). "HIV reproducibly establishes a latent infection after acute 
infection of T cells in vitro." EMBO J 22(8): 1868-1877. 
Jouvenet, N., S. J. Neil, et al. (2009). "Broad-spectrum inhibition of retroviral and filoviral particle 
release by tetherin." J Virol 83(4): 1837-1844. 
Karlsson Hedestam, G. B., R. A. Fouchier, et al. (2008). "The challenges of eliciting neutralizing 
antibodies to HIV-1 and to influenza virus." Nat Rev Microbiol 6(2): 143-155. 
Karn, J. and C. M. Stoltzfus (2012). "Transcriptional and posttranscriptional regulation of HIV-1 gene 
expression." Cold Spring Harb Perspect Med 2(2): a006916. 
Kawai, S., Y. Azuma, et al. (2008). "Interferon-alpha enhances CD317 expression and the antitumor 
activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models." 
Cancer Sci 99(12): 2461-2466. 
Kerkau, T., I. Bacik, et al. (1997). "The human immunodeficiency virus type 1 (HIV-1) Vpu protein 
interferes with an early step in the biosynthesis of major histocompatibility complex (MHC) 
class I molecules." J Exp Med 185(7): 1295-1305. 
Kim, H. and J. Yin (2005). "Effects of RNA splicing and post-transcriptional regulation on HIV-1 
growth: a quantitative and integrated perspective." Syst Biol (Stevenage) 152(3): 138-152. 
Kirchhoff, F., M. Schindler, et al. (2008). "Role of Nef in primate lentiviral immunopathogenesis." Cell 
Mol Life Sci 65(17): 2621-2636. 
122 
 
Klatt, N. R., F. Villinger, et al. (2008). "Availability of activated CD4+ T cells dictates the level of 
viremia in naturally SIV-infected sooty mangabeys." J Clin Invest 118(6): 2039-2049. 
Koenig, S., H. E. Gendelman, et al. (1986). "Detection of AIDS virus in macrophages in brain tissue 
from AIDS patients with encephalopathy." Science 233(4768): 1089-1093. 
Koppensteiner, H., R. Brack-Werner, et al. (2012). "Macrophages and their relevance in Human 
Immunodeficiency Virus Type I infection." Retrovirology 9: 82. 
Kozak, M. (1989). "The scanning model for translation: an update." J Cell Biol 108(2): 229-241. 
Krishnan, L. and A. Engelman (2012). "Retroviral integrase proteins and HIV-1 DNA integration." J 
Biol Chem 287(49): 40858-40866. 
Kueck, T. and S. J. Neil (2012). "A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of 
tetherin for endosomal degradation and counteracts interferon-induced restriction." PLoS 
Pathog 8(3): e1002609. 
Kupzig, S., V. Korolchuk, et al. (2003). "Bst-2/HM1.24 is a raft-associated apical membrane protein 
with an unusual topology." Traffic 4(10): 694-709. 
Kuri-Cervantes, L., G. S. de Oca, et al. (2014). "Activation of NK cells is associated with HIV-1 disease 
progression." J Leukoc Biol 96(1): 7-16. 
Kuritzkes, D. R. (2009). "HIV-1 entry inhibitors: an overview." Curr Opin HIV AIDS 4(2): 82-87. 
Lahouassa, H., W. Daddacha, et al. (2012). "SAMHD1 restricts the replication of human 
immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside 
triphosphates." Nat Immunol 13(3): 223-228. 
Laible, M. and K. Boonrod (2009). "Homemade site directed mutagenesis of whole plasmids." J Vis 
Exp(27). 
Lama, J., A. Mangasarian, et al. (1999). "Cell-surface expression of CD4 reduces HIV-1 infectivity by 
blocking Env incorporation in a Nef- and Vpu-inhibitable manner." Curr Biol 9(12): 622-631. 
Lambotte, O., G. Ferrari, et al. (2009). "Heterogeneous neutralizing antibody and antibody-dependent 
cell cytotoxicity responses in HIV-1 elite controllers." AIDS 23(8): 897-906. 
Lanchy, J. M., C. Isel, et al. (2000). "Dynamics of the HIV-1 reverse transcription complex during 
initiation of DNA synthesis." J Biol Chem 275(16): 12306-12312. 
Lane, H. C., H. Masur, et al. (1983). "Abnormalities of B-cell activation and immunoregulation in 
patients with the acquired immunodeficiency syndrome." N Engl J Med 309(8): 453-458. 
Langford, S. E., J. Ananworanich, et al. (2007). "Predictors of disease progression in HIV infection: a 
review." AIDS Res Ther 4: 11. 
Lanier, L. L. (2008). "Up on the tightrope: natural killer cell activation and inhibition." Nat Immunol 
9(5): 495-502. 
Leslie, A., D. Kavanagh, et al. (2005). "Transmission and accumulation of CTL escape variants drive 
negative associations between HIV polymorphisms and HLA." J Exp Med 201(6): 891-902. 
Levesque, K., Y. S. Zhao, et al. (2003). "Vpu exerts a positive effect on HIV-1 infectivity by 
down-modulating CD4 receptor molecules at the surface of HIV-1-producing cells." J Biol 
Chem 278(30): 28346-28353. 
Li, J. T., M. Halloran, et al. (1995). "Persistent infection of macaques with simian-human 
immunodeficiency viruses." J Virol 69(11): 7061-7067. 
Li, M. and R. Craigie (2006). "Virology: HIV goes nuclear." Nature 441(7093): 581-582. 
123 
 
Li, M., F. Gao, et al. (2005). "Human immunodeficiency virus type 1 env clones from acute and early 
subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies." 
J Virol 79(16): 10108-10125. 
Lichtfuss, G. F., W. J. Cheng, et al. (2012). "Virologically suppressed HIV patients show activation of 
NK cells and persistent innate immune activation." J Immunol 189(3): 1491-1499. 
Limou, S., S. Le Clerc, et al. (2009). "Genomewide association study of an AIDS-nonprogression 
cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 
02)." J Infect Dis 199(3): 419-426. 
Liu, Y., J. McNevin, et al. (2007). "Evolution of human immunodeficiency virus type 1 cytotoxic 
T-lymphocyte epitopes: fitness-balanced escape." J Virol 81(22): 12179-12188. 
Liu, Y., J. P. McNevin, et al. (2011). "Dynamics of viral evolution and CTL responses in HIV-1 
infection." PLoS One 6(1): e15639. 
Llano, M., D. T. Saenz, et al. (2006). "An essential role for LEDGF/p75 in HIV integration." Science 
314(5798): 461-464. 
Maddon, P. J., A. G. Dalgleish, et al. (1986). "The T4 gene encodes the AIDS virus receptor and is 
expressed in the immune system and the brain." Cell 47(3): 333-348. 
Magadan, J. G. and J. S. Bonifacino (2012). "Transmembrane domain determinants of CD4 
Downregulation by HIV-1 Vpu." J Virol 86(2): 757-772. 
Magadan, J. G., F. J. Perez-Victoria, et al. (2010). "Multilayered mechanism of CD4 downregulation by 
HIV-1 Vpu involving distinct ER retention and ERAD targeting steps." PLoS Pathog 6(4): 
e1000869. 
Mak, J. and L. Kleiman (1997). "Primer tRNAs for reverse transcription." J Virol 71(11): 8087-8095. 
Malim, M. H. and M. Emerman (2008). "HIV-1 accessory proteins--ensuring viral survival in a hostile 
environment." Cell Host Microbe 3(6): 388-398. 
Malim, M. H., J. Hauber, et al. (1989). "The HIV-1 rev trans-activator acts through a structured target 
sequence to activate nuclear export of unspliced viral mRNA." Nature 338(6212): 254-257. 
Mangeat, B., G. Gers-Huber, et al. (2009). "HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 
by binding it and directing its beta-TrCP2-dependent degradation." PLoS Pathog 5(9): 
e1000574. 
Mansky, L. M. (1998). "Retrovirus mutation rates and their role in genetic variation." J Gen Virol 79 ( 
Pt 6): 1337-1345. 
Marassi, F. M., C. Ma, et al. (1999). "Correlation of the structural and functional domains in the 
membrane protein Vpu from HIV-1." Proc Natl Acad Sci U S A 96(25): 14336-14341. 
Marchand, C., A. A. Johnson, et al. (2006). "Mechanisms and inhibition of HIV integration." Drug 
Discov Today Dis Mech 3(2): 253-260. 
Margottin, F., S. P. Bour, et al. (1998). "A novel human WD protein, h-beta TrCp, that interacts with 
HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif." Mol Cell 
1(4): 565-574. 
Marras, F., E. Nicco, et al. (2013). "Natural killer cells in HIV controller patients express an activated 
effector phenotype and do not up-regulate NKp44 on IL-2 stimulation." Proc Natl Acad Sci U 
S A 110(29): 11970-11975. 
Marshall, N. F. and D. H. Price (1995). "Purification of P-TEFb, a transcription factor required for the 
transition into productive elongation." J Biol Chem 270(21): 12335-12338. 
124 
 
Martin, M. P., X. Gao, et al. (2002). "Epistatic interaction between KIR3DS1 and HLA-B delays the 
progression to AIDS." Nat Genet 31(4): 429-434. 
Martinson, J. J., N. H. Chapman, et al. (1997). "Global distribution of the CCR5 gene 32-basepair 
deletion." Nat Genet 16(1): 100-103. 
Matsuda, A., Y. Suzuki, et al. (2003). "Large-scale identification and characterization of human genes 
that activate NF-kappaB and MAPK signaling pathways." Oncogene 22(21): 3307-3318. 
Matusali, G., M. Potesta, et al. (2012). "The human immunodeficiency virus type 1 Nef and Vpu 
proteins downregulate the natural killer cell-activating ligand PVR." J Virol 86(8): 4496-4504. 
Mavilio, D., J. Benjamin, et al. (2003). "Natural killer cells in HIV-1 infection: dichotomous effects of 
viremia on inhibitory and activating receptors and their functional correlates." Proc Natl Acad 
Sci U S A 100(25): 15011-15016. 
McMichael, A. J., P. Borrow, et al. (2010). "The immune response during acute HIV-1 infection: clues 
for vaccine development." Nat Rev Immunol 10(1): 11-23. 
McNatt, M. W., T. Zang, et al. (2013). "Vpu binds directly to tetherin and displaces it from nascent 
virions." PLoS Pathog 9(4): e1003299. 
Mellors, J. W., A. Munoz, et al. (1997). "Plasma viral load and CD4+ lymphocytes as prognostic 
markers of HIV-1 infection." Ann Intern Med 126(12): 946-954. 
Merrick, W. C. (2004). "Cap-dependent and cap-independent translation in eukaryotic systems." Gene 
332: 1-11. 
Migueles, S. A., C. M. Osborne, et al. (2008). "Lytic granule loading of CD8+ T cells is required for 
HIV-infected cell elimination associated with immune control." Immunity 29(6): 1009-1021. 
Milush, J. M., S. Lopez-Verges, et al. (2013). "CD56negCD16(+) NK cells are activated mature NK 
cells with impaired effector function during HIV-1 infection." Retrovirology 10: 158. 
Miura, T., M. A. Brockman, et al. (2008). "Genetic characterization of human immunodeficiency virus 
type 1 in elite controllers: lack of gross genetic defects or common amino acid changes." J 
Virol 82(17): 8422-8430. 
Miura, T., M. A. Brockman, et al. (2009). "HLA-associated alterations in replication capacity of 
chimeric NL4-3 viruses carrying gag-protease from elite controllers of human 
immunodeficiency virus type 1." J Virol 83(1): 140-149. 
Miyauchi, K., Y. Kim, et al. (2009). "HIV enters cells via endocytosis and dynamin-dependent fusion 
with endosomes." Cell 137(3): 433-444. 
Moesta, A. K., P. J. Norman, et al. (2008). "Synergistic polymorphism at two positions distal to the 
ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3." J 
Immunol 180(6): 3969-3979. 
Mogensen, T. H., J. Melchjorsen, et al. (2010). "Innate immune recognition and activation during HIV 
infection." Retrovirology 7: 54. 
Moir, S., A. Malaspina, et al. (2001). "HIV-1 induces phenotypic and functional perturbations of B cells 
in chronically infected individuals." Proc Natl Acad Sci U S A 98(18): 10362-10367. 
Morita, E., V. Sandrin, et al. (2007). "Human ESCRT and ALIX proteins interact with proteins of the 
midbody and function in cytokinesis." EMBO J 26(19): 4215-4227. 
Moutouh, L., J. Corbeil, et al. (1996). "Recombination leads to the rapid emergence of HIV-1 dually 
resistant mutants under selective drug pressure." Proc Natl Acad Sci U S A 93(12): 6106-6111. 
Mwimanzi, P., T. J. Markle, et al. (2013). "Attenuation of multiple Nef functions in HIV-1 elite 
controllers." Retrovirology 10: 1. 
125 
 
Naranbhai, V., M. Altfeld, et al. (2013). "Changes in Natural Killer cell activation and function during 
primary HIV-1 Infection." PLoS One 8(1): e53251. 
Neil, S. J., S. W. Eastman, et al. (2006). "HIV-1 Vpu promotes release and prevents endocytosis of 
nascent retrovirus particles from the plasma membrane." PLoS Pathog 2(5): e39. 
Neil, S. J., T. Zang, et al. (2008). "Tetherin inhibits retrovirus release and is antagonized by HIV-1 
Vpu." Nature 451(7177): 425-430. 
Nguyen, K. L., M. llano, et al. (2004). "Codon optimization of the HIV-1 vpu and vif genes stabilizes 
their mRNA and allows for highly efficient Rev-independent expression." Virology 319(2): 
163-175. 
O'Connell, K. A., J. R. Bailey, et al. (2009). "Elucidating the elite: mechanisms of control in HIV-1 
infection." Trends Pharmacol Sci 30(12): 631-637. 
O'Connell, K. A., Y. Han, et al. (2009). "Role of natural killer cells in a cohort of elite suppressors: low 
frequency of the protective KIR3DS1 allele and limited inhibition of human 
immunodeficiency virus type 1 replication in vitro." J Virol 83(10): 5028-5034. 
Ocwieja, K. E., S. Sherrill-Mix, et al. (2012). "Dynamic regulation of HIV-1 mRNA populations 
analyzed by single-molecule enrichment and long-read sequencing." Nucleic Acids Res 
40(20): 10345-10355. 
Oeckinghaus, A. and S. Ghosh (2009). "The NF-kappaB family of transcription factors and its 
regulation." Cold Spring Harb Perspect Biol 1(4): a000034. 
Ogg, G. S., X. Jin, et al. (1998). "Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma 
load of viral RNA." Science 279(5359): 2103-2106. 
Oxenius, A., D. A. Price, et al. (2004). "HIV-specific cellular immune response is inversely correlated 
with disease progression as defined by decline of CD4+ T cells in relation to HIV RNA load." 
J Infect Dis 189(7): 1199-1208. 
Pacyniak, E., M. L. Gomez, et al. (2005). "Identification of a region within the cytoplasmic domain of 
the subtype B Vpu protein of human immunodeficiency virus type 1 (HIV-1) that is 
responsible for retention in the golgi complex and its absence in the Vpu protein from a 
subtype C HIV-1." AIDS Res Hum Retroviruses 21(5): 379-394. 
Parkin, N. T., M. Chamorro, et al. (1992). "Human immunodeficiency virus type 1 gag-pol 
frameshifting is dependent on downstream mRNA secondary structure: demonstration by 
expression in vivo." J Virol 66(8): 5147-5151. 
Pelletier, J., G. Kaplan, et al. (1988). "Cap-independent translation of poliovirus mRNA is conferred by 
sequence elements within the 5' noncoding region." Mol Cell Biol 8(3): 1103-1112. 
Pereyra, F., M. M. Addo, et al. (2008). "Genetic and immunologic heterogeneity among persons who 
control HIV infection in the absence of therapy." J Infect Dis 197(4): 563-571. 
Perkins, N. D. (2007). "Integrating cell-signalling pathways with NF-kappaB and IKK function." Nat 
Rev Mol Cell Biol 8(1): 49-62. 
Perrin, L., L. Kaiser, et al. (2003). "Travel and the spread of HIV-1 genetic variants." Lancet Infect Dis 
3(1): 22-27. 
Petersen, J. L., C. R. Morris, et al. (2003). "Virus evasion of MHC class I molecule presentation." J 
Immunol 171(9): 4473-4478. 
Petit, S. J., C. Blondeau, et al. (2011). "Analysis of the human immunodeficiency virus type 1 M group 
Vpu domains involved in antagonizing tetherin." J Gen Virol 92(Pt 12): 2937-2948. 
126 
 
Pfeiffer, T., T. Pisch, et al. (2006). "Effects of signal peptide exchange on HIV-1 glycoprotein 
expression and viral infectivity in mammalian cells." FEBS Lett 580(15): 3775-3778. 
Pham, T. N., S. Lukhele, et al. (2014). "HIV Nef and Vpu protect HIV-infected CD4+ T cells from 
antibody-mediated cell lysis through down-modulation of CD4 and BST2." Retrovirology 11: 
15. 
Pickering, S., S. Hue, et al. (2014). "Preservation of tetherin and CD4 counter-activities in circulating 
Vpu alleles despite extensive sequence variation within HIV-1 infected individuals." PLoS 
Pathog 10(1): e1003895. 
Piguet, V., Y. L. Chen, et al. (1998). "Mechanism of Nef-induced CD4 endocytosis: Nef connects CD4 
with the mu chain of adaptor complexes." EMBO J 17(9): 2472-2481. 
Price, D. A., P. J. Goulder, et al. (1997). "Positive selection of HIV-1 cytotoxic T lymphocyte escape 
variants during primary infection." Proc Natl Acad Sci U S A 94(5): 1890-1895. 
Pritschet, K., N. Donhauser, et al. (2012). "CD4- and dynamin-dependent endocytosis of HIV-1 into 
plasmacytoid dendritic cells." Virology 423(2): 152-164. 
Purcell, D. F. and M. A. Martin (1993). "Alternative splicing of human immunodeficiency virus type 1 
mRNA modulates viral protein expression, replication, and infectivity." J Virol 67(11): 
6365-6378. 
Razzak, M. (2012). "Genetics: Schlafen 11 naturally blocks HIV." Nat Rev Urol 9(11): 605. 
Robertson, D. L., J. P. Anderson, et al. (2000). "HIV-1 nomenclature proposal." Science 288(5463): 
55-56. 
Robinson, H. L. (2002). "New hope for an AIDS vaccine." Nat Rev Immunol 2(4): 239-250. 
Sachsenberg, N., A. S. Perelson, et al. (1998). "Turnover of CD4+ and CD8+ T lymphocytes in HIV-1 
infection as measured by Ki-67 antigen." J Exp Med 187(8): 1295-1303. 
Santoro, M. M. and C. F. Perno (2013). "HIV-1 Genetic Variability and Clinical Implications." ISRN 
Microbiol 2013: 481314. 
Sasaki, H., M. Nakamura, et al. (1995). "Myosin-actin interaction plays an important role in human 
immunodeficiency virus type 1 release from host cells." Proc Natl Acad Sci U S A 92(6): 
2026-2030. 
Sato, K., N. Misawa, et al. (2012). "Vpu augments the initial burst phase of HIV-1 propagation and 
downregulates BST2 and CD4 in humanized mice." J Virol 86(9): 5000-5013. 
Sauter, D., D. Hotter, et al. (2013). "A rare missense variant abrogates the signaling activity of 
tetherin/BST-2 without affecting its effect on virus release." Retrovirology 10: 85. 
Sauter, D., M. Schindler, et al. (2009). "Tetherin-driven adaptation of Vpu and Nef function and the 
evolution of pandemic and nonpandemic HIV-1 strains." Cell Host Microbe 6(5): 409-421. 
Sauter, D., D. Unterweger, et al. (2012). "Human tetherin exerts strong selection pressure on the HIV-1 
group N Vpu protein." PLoS Pathog 8(12): e1003093. 
Schmidt, S., J. V. Fritz, et al. (2011). "HIV-1 Vpu blocks recycling and biosynthetic transport of the 
intrinsic immunity factor CD317/tetherin to overcome the virion release restriction." MBio 
2(3): e00036-00011. 
Schmokel, J., D. Sauter, et al. (2011). "The presence of a vpu gene and the lack of Nef-mediated 
downmodulation of T cell receptor-CD3 are not always linked in primate lentiviruses." J Virol 
85(2): 742-752. 
127 
 
Schubert, U., L. C. Anton, et al. (1998). "CD4 glycoprotein degradation induced by human 
immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the 
ubiquitin-conjugating pathway." J Virol 72(3): 2280-2288. 
Schubert, U., P. Henklein, et al. (1994). "The human immunodeficiency virus type 1 encoded Vpu 
protein is phosphorylated by casein kinase-2 (CK-2) at positions Ser52 and Ser56 within a 
predicted alpha-helix-turn-alpha-helix-motif." J Mol Biol 236(1): 16-25. 
Schwartz, S., B. K. Felber, et al. (1990). "Env and Vpu proteins of human immunodeficiency virus type 
1 are produced from multiple bicistronic mRNAs." J Virol 64(11): 5448-5456. 
Shah, A. H., B. Sowrirajan, et al. (2010). "Degranulation of natural killer cells following interaction 
with HIV-1-infected cells is hindered by downmodulation of NTB-A by Vpu." Cell Host 
Microbe 8(5): 397-409. 
Shankarappa, R., J. B. Margolick, et al. (1999). "Consistent viral evolutionary changes associated with 
the progression of human immunodeficiency virus type 1 infection." J Virol 73(12): 
10489-10502. 
Sheehy, A. M., N. C. Gaddis, et al. (2002). "Isolation of a human gene that inhibits HIV-1 infection and 
is suppressed by the viral Vif protein." Nature 418(6898): 646-650. 
Sherman, M. P., C. M. de Noronha, et al. (2003). "Nuclear export of Vpr is required for efficient 
replication of human immunodeficiency virus type 1 in tissue macrophages." J Virol 77(13): 
7582-7589. 
Shun, M. C., N. K. Raghavendra, et al. (2007). "LEDGF/p75 functions downstream from preintegration 
complex formation to effect gene-specific HIV-1 integration." Genes Dev 21(14): 1767-1778. 
Sierra, S., B. Kupfer, et al. (2005). "Basics of the virology of HIV-1 and its replication." J Clin Virol 
34(4): 233-244. 
Sloan, R. D. and M. A. Wainberg (2011). "The role of unintegrated DNA in HIV infection." 
Retrovirology 8: 52. 
Snyder, G. A., A. G. Brooks, et al. (1999). "Crystal structure of the HLA-Cw3 allotype-specific killer 
cell inhibitory receptor KIR2DL2." Proc Natl Acad Sci U S A 96(7): 3864-3869. 
Sodroski, J., W. C. Goh, et al. (1986). "A second post-transcriptional trans-activator gene required for 
HTLV-III replication." Nature 321(6068): 412-417. 
Spira, S., M. A. Wainberg, et al. (2003). "Impact of clade diversity on HIV-1 virulence, antiretroviral 
drug sensitivity and drug resistance." J Antimicrob Chemother 51(2): 229-240. 
Stephens, E. B., C. McCormick, et al. (2002). "Deletion of the vpu sequences prior to the env in a 
simian-human immunodeficiency virus results in enhanced Env precursor synthesis but is less 
pathogenic for pig-tailed macaques." Virology 293(2): 252-261. 
Stoltzfus, C. M. and J. M. Madsen (2006). "Role of viral splicing elements and cellular RNA binding 
proteins in regulation of HIV-1 alternative RNA splicing." Curr HIV Res 4(1): 43-55. 
Stratov, I., A. Chung, et al. (2008). "Robust NK cell-mediated human immunodeficiency virus 
(HIV)-specific antibody-dependent responses in HIV-infected subjects." J Virol 82(11): 
5450-5459. 
Strebel, K. (2013). "HIV accessory proteins versus host restriction factors." Curr Opin Virol 3(6): 
692-699. 
Strebel, K. (2014). "HIV-1 Vpu - an ion channel in search of a job." Biochim Biophys Acta 1838(4): 
1074-1081. 
128 
 
Strebel, K., T. Klimkait, et al. (1989). "Molecular and biochemical analyses of human 
immunodeficiency virus type 1 vpu protein." J Virol 63(9): 3784-3791. 
Strebel, K., T. Klimkait, et al. (1988). "A novel gene of HIV-1, vpu, and its 16-kilodalton product." 
Science 241(4870): 1221-1223. 
Stremlau, M., C. M. Owens, et al. (2004). "The cytoplasmic body component TRIM5alpha restricts 
HIV-1 infection in Old World monkeys." Nature 427(6977): 848-853. 
Sundquist, W. I. and H. G. Krausslich (2012). "HIV-1 assembly, budding, and maturation." Cold Spring 
Harb Perspect Med 2(7): a006924. 
Suzuki, Y., M. L. Chew, et al. (2012). "Role of host-encoded proteins in restriction of retroviral 
integration." Front Microbiol 3: 227. 
Suzuki, Y. and R. Craigie (2007). "The road to chromatin - nuclear entry of retroviruses." Nat Rev 
Microbiol 5(3): 187-196. 
Swann, S. A., M. Williams, et al. (2001). "HIV-1 Nef blocks transport of MHC class I molecules to the 
cell surface via a PI 3-kinase-dependent pathway." Virology 282(2): 267-277. 
Symons, H. J. and E. J. Fuchs (2008). "Hematopoietic SCT from partially HLA-mismatched 
(HLA-haploidentical) related donors." Bone Marrow Transplant 42(6): 365-377. 
Thomas, R., R. Apps, et al. (2009). "HLA-C cell surface expression and control of HIV/AIDS correlate 
with a variant upstream of HLA-C." Nat Genet 41(12): 1290-1294. 
Tobiume, M., M. Takahoko, et al. (2002). "Inefficient enhancement of viral infectivity and CD4 
downregulation by human immunodeficiency virus type 1 Nef from Japanese long-term 
nonprogressors." J Virol 76(12): 5959-5965. 
Tokarev, A., M. Suarez, et al. (2013). "Stimulation of NF-kappaB activity by the HIV restriction factor 
BST2." J Virol 87(4): 2046-2057. 
Turlure, F., E. Devroe, et al. (2004). "Human cell proteins and human immunodeficiency virus DNA 
integration." Front Biosci 9: 3187-3208. 
Vallari, A., V. Holzmayer, et al. (2011). "Confirmation of putative HIV-1 group P in Cameroon." J Virol 
85(3): 1403-1407. 
Van Cor-Hosmer, S. K., D. H. Kim, et al. (2013). "Restricted 5'-end gap repair of HIV-1 integration due 
to limited cellular dNTP concentrations in human primary macrophages." J Biol Chem 
288(46): 33253-33262. 
Van Engelenburg, S. B., G. Shtengel, et al. (2014). "Distribution of ESCRT machinery at HIV assembly 
sites reveals virus scaffolding of ESCRT subunits." Science 343(6171): 653-656. 
Venkatesh, S. and P. D. Bieniasz (2013). "Mechanism of HIV-1 virion entrapment by tetherin." PLoS 
Pathog 9(7): e1003483. 
Vergis, E. N. and J. W. Mellors (2000). "Natural history of HIV-1 infection." Infect Dis Clin North Am 
14(4): 809-825, v-vi. 
Vigan, R. and S. J. Neil (2010). "Determinants of tetherin antagonism in the transmembrane domain of 
the human immunodeficiency virus type 1 Vpu protein." J Virol 84(24): 12958-12970. 
Vigan, R. and S. J. Neil (2011). "Separable determinants of subcellular localization and interaction 
account for the inability of group O HIV-1 Vpu to counteract tetherin." J Virol 85(19): 
9737-9748. 
Wagtmann, N., S. Rajagopalan, et al. (1995). "Killer cell inhibitory receptors specific for HLA-C and 
HLA-B identified by direct binding and by functional transfer." Immunity 3(6): 801-809. 
129 
 
Wainberg, M. A. and B. G. Brenner (2012). "The Impact of HIV Genetic Polymorphisms and Subtype 
Differences on the Occurrence of Resistance to Antiretroviral Drugs." Mol Biol Int 2012: 
256982. 
Wakefield, J. K., A. G. Wolf, et al. (1995). "Human immunodeficiency virus type 1 can use different 
tRNAs as primers for reverse transcription but selectively maintains a primer binding site 
complementary to tRNA(3Lys)." J Virol 69(10): 6021-6029. 
Warren, K., D. Warrilow, et al. (2009). "Reverse Transcriptase and Cellular Factors: Regulators of 
HIV-1 Reverse Transcription." Viruses 1(3): 873-894. 
Warrilow, D., G. Tachedjian, et al. (2009). "Maturation of the HIV reverse transcription complex: 
putting the jigsaw together." Rev Med Virol 19(6): 324-337. 
Watts, J. M., K. K. Dang, et al. (2009). "Architecture and secondary structure of an entire HIV-1 RNA 
genome." Nature 460(7256): 711-716. 
Wildum, S., M. Schindler, et al. (2006). "Contribution of Vpu, Env, and Nef to CD4 down-modulation 
and resistance of human immunodeficiency virus type 1-infected T cells to superinfection." J 
Virol 80(16): 8047-8059. 
Wilen, C. B., J. C. Tilton, et al. (2012). "HIV: cell binding and entry." Cold Spring Harb Perspect Med 
2(8). 
Willey, R. L., F. Maldarelli, et al. (1992). "Human immunodeficiency virus type 1 Vpu protein induces 
rapid degradation of CD4." J Virol 66(12): 7193-7200. 
Wilusz, J. (2013). "Putting an 'End' to HIV mRNAs: capping and polyadenylation as potential 
therapeutic targets." AIDS Res Ther 10(1): 31. 
Wren, L. H., A. W. Chung, et al. (2013). "Specific antibody-dependent cellular cytotoxicity responses 
associated with slow progression of HIV infection." Immunology 138(2): 116-123. 
Yewdell, J. W. and J. R. Bennink (1992). "Cell biology of antigen processing and presentation to major 
histocompatibility complex class I molecule-restricted T lymphocytes." Adv Immunol 52: 
1-123. 
Yewdell, J. W. and J. R. Bennink (1999). "Mechanisms of viral interference with MHC class I antigen 
processing and presentation." Annu Rev Cell Dev Biol 15: 579-606. 
Yewdell, J. W. and A. B. Hill (2002). "Viral interference with antigen presentation." Nat Immunol 
3(11): 1019-1025. 
Zhang, Z. Q., S. W. Wietgrefe, et al. (2004). "Roles of substrate availability and infection of resting and 
activated CD4+ T cells in transmission and acute simian immunodeficiency virus infection." 
Proc Natl Acad Sci U S A 101(15): 5640-5645. 
 
 
 
 
 
 
 
 
130 
 
Acknowledgements 
This dissertation is dedicated to my work and the knowledge gained while studying at 
Heidelberg University. My four years at Heidelberg University has been a great and 
rememberable experience. Throughout the years I worked with my advisor and many 
great colleagues who are always ready to help and communicate. This dissertation is 
to study and explain in depth the effect of Vpu in HIV-1.  
First and foremost, I would like to thank my advisor, Professor Dr. Oliver T. Fackler. 
He helped and guided me to complete this study. He helped me throughout the years 
to perform successful experiments and gain more in-depth knowledge of my subject. 
Without his supervision this work would not have been possible.  
I would like to thank my colleagues for their help during my study at Heidelberg 
University. Claudia, Francois, Miriam, Nadine, and Andrea guided me to handle 
the lab equipment. Francios and Niko spent precious time in teaching me the 
professional software to create better figures. Johanna proposed smart ideas for the 
discussion on this study. This work is an achievement of excellent team work. 
I want to especially thank my parents, Liyin Chen and Liju Hu, and fiancé, Brian 
Haynes. Without their support, none of this dissertation would have been possible. 
My parents raised and guided me throughout my life. They did the best they could to 
allow me to reach my true potential. My fiancée never stopped keeping me motivated 
and believing in me. He was and is a shoulder I can lay on. I would never have been 
able to make it through this past year without the guidance and support of my loved 
ones.  
I would like to say thanks to my friend Hanse Pape. He spent tremendous time on 
correcting and refining my dissertation writing. 
I sincerely appreciate the Chinese Scholarship Council to support me for pursuing my 
PhD training in Germany. 
Last but not least, I would also like to thank my first supervisor in Germany: Prof. Dr. 
M. Alexander Schmidt. He and his wife always gave their hands when I needed help. 
They allowed me to progress onto a new topic of study.  
 
